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Under the Direction of Jenny. J. Yang, PhD

ABSTRACT
Liver metastases are often observed with primary cancers, including uveal melanoma
(UM), breast, ovarian, and colon cancer. Chemokine receptor 4 (CXCR4) is one of the major
chemokine receptors that overexpressed by cancers due to its role in tumor growth, migration, and
progression. Organs such as the liver, bone, and brain have an intrinsically high concentration of
CXCR4 ligand, C-X-C motif chemokine ligand 12 (CXCL12). As a result, CXCR4 is also often
expressed at metastases in these organs. There is an unmet medical need for noninvasively early
detecting, staging, and monitoring the prognosis of liver cancers and metastases as well as probing
tumor microenvironment for target therapy and drug. In this dissertation, we first report the
elevated expression of CXCR4 in the UM patients’ liver metastases and metastatic UM mouse

models and validate its role as an imaging biomarker for liver metastases. We then report our
achievement in the development of a CXCR4-targeted MRI contrast agent, ProCA32.CXCR4, for
sensitive detection of UM liver metastases using MRI. ProCA32.CXCR4 exhibits high relaxivities
(r1 = 30.9 mM-1 s-1, r2 = 43.2 mM-1 s-1, 1.5 T; r1 = 23.5 mM-1 s-1, r2 = 98.6 mM-1 s-1, 7.0 T), strong
CXCR4 binding affinity (Kd = 1.1  0.2 µM), and the capability of CXCR4 molecular imaging in
both metastatic and intrahepatic xenotransplantation UM mouse models. ProCA32.CXCR4
enables robust detection of UM metastases as small as 0.1 mm2 in the liver. CXCR4 receptor
blockage experiment proved the specific binding of ProCA32.CXCR4 to CXCR4. In addition, the
application of ProCA32.CXCR4 in primary liver cancer detection and treatment effect monitoring
are tested in hepatocellular carcinoma (HCC) mouse model. Except for gadolinium, we explored
the possibility of manganese-based protein contrast agent and proved manganese-based ProCA
exhibits high relaxivity and strong gadolinium binding affinity. We further designed and
characterized ProCA32.RGD for integrin v3 molecular imaging to reveal the tumor
microenvironment. ProCA32.RGD targeted imaging was achieved in a 4T1 breast cancer mouse
model. Further development of the biomarker targeted imaging agents is expected to have strong
translation potential for early detection, surveillance, and treatment stratification of cancer and
related diseases.

INDEX WORDS: MRI contrast agent, Gadolinium, Molecular imaging, CXCR4, Uveal
melanoma, Metastasis, Early detection, HCC, Integrin v3, Angiogenesis
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1.1

INTRODUCTION

Cancer as a metastatic disease
Cancer (Malignant Neoplasm) is a global public health issue and one of the leading causes

of death in the United States. Caused by uncontrollable cell division and proliferation, cancer cells
can invade locally (healthy tissues) and regionally (lymph nodes, tissue, and organs). Data from
2018 shows the estimated new cases of cancers in the United States is 1,735,350, and cancer causes
about 609,640 patient deaths in the United States (1). Cancer is the second leading cause of death
in all age groups after heart diseases (2).
Metastasis describes the invasion and colonization of tumor cells to tissues or organs that
are not directly connected with the primary cancer sites. Metastasis is the top cause of cancer
mortality and responsible for over 90 percent of cancer-related deaths. Most tumors metastasize
through the bloodstream. The vasculature metastasis dissemination involves multiple stepwise
processes that include local invasion, intravasation, subsistence in the circulation system,
extravasation, and finally colonization. First, cancer cells locally infiltrate and invade adjacent
tissue, and some of them break the basement membrane and leave primary tumor sites. Then,
tumor cells separate from the primary tumor sites and enter into the vasculature system; this
process called intravasation. After that, tumor cells migrate through vasculatures and find a way
of extravasation and form metastases in new locations (3). Although metastasis is an inefficient
process, it is still the primary cause of tumor-related death. Very few tumor cells can eventually
survive all the steps and develop metastases. A lot of complicated factors contribute to this whole
process: the initial mutation endows the tumor cells unlimited proliferation ability; the immune
tolerance of tumor cells and the tumor cell successfully colonize and take over a new organ.
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Organ-specific metastasis pattern is observed with various cancers, which means specific
cancer has preferred sites of metastasis. Breast cancer usually metastasizes to the liver, bones,
lungs, and brain. Colorectal and pancreatic cancer are more likely to metastasize to the liver and
lungs. A large portion of prostate cancer goes to the bones, and uveal melanoma almost exclusively
metastasizes to the liver (over 95%) (4). The reason for the organ-specific metastasis remains
unknown. Potentially, the expression of genes in primary tumors might provide markers that
facilitate the organ-specific metastasis.
The cellular mechanisms involved in metastasis are complicated. The factors of tumor
cells include expression of the genes that alter cell adhesion in the primary site (5, 6), strategies to
survival in the circulatory system (7, 8) and eventually colocalize secondary organ and forming
new blood supply for further proliferation (9, 10). Also, tumor microenvironment significantly
affects metastases progression. The various types of cells, such as cancer stem cells, immunerelated cells, stroma cells, and fibroblasts consisted of the microenvironment facilitate and promote
tumor progression (11). Understanding the mechanism of metastasis, monitoring the metastatic
progression, and revealing the local anatomical and biological information of cancer metastases
would be vitally crucial for tumor diagnosis, stratification of therapy and intervention.
As the improvement of the standard of care (SOC) during the past few decades, the cancerrelated death rate has been decreasing, and most cancers with initial diagnoses of the localized
disease have promising 5-year survival rates. However, for cancer patients with diagnoses of
metastatic diseases, it is still an indication of the terminal disease stage. In some metastatic cancer,
immunotherapy is proved to be able to improve the prognosis. For example, ipilimumab prolonged
the overall survival of metastatic melanoma (12), and enzalutamide (an androgen-receptorsignaling pathway inhibitor) can significantly extend the survival of men with metastatic prostate
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cancer (13). However, for the other types of cancer with metastases, such as breast cancer, gastric
cancer, and pancreatic cancer, the survival rates remain unoptimistic (14-16).
1.1.1 Cancer diagnosis technology and early detection of cancer
The diagnosis of cancer is essential before, during, and after the cancer treatment. The
common diagnostic tests include a review of health history, physical examinations, laboratory
examinations, biopsy, imaging tests (ultrasound, CT, MRI, PET/CT), and endoscopy, etc. The
major imaging modalities used in clinical settings are positron emission tomography (PET), singlephoton emission computed tomography (SPECT) and magnetic resonance imaging (MRI) (17, 18).
The modern technology allows genetic tests as well to provide more precise and further genetic
information of cancer that could further benefit the cancer treatment.
Statistic evidence shows that the early detection of cancer can efficiently improve cancer
prognosis. More than 90 percent of bowel cancer patients can survive the disease for more than
five years if diagnosed at the earliest stage. The five-year survival rate of breast cancer patients
diagnosed at the early stage is 90%; but for the women diagnosed at the most advanced stage, the
five-year survival rate is 15%. For ovarian cancer, the five-year survival rate drastically dropped
to 5% in patients diagnosed with the most advanced stage of the disease, compared to 90% of the
five-year survival rate in patients diagnosed at the earliest stage (19).
The early detection and staging of cancer are critically important for the diagnosis and
prognosis of cancer. The management of cancer becomes more precise and personalized, along
with a better understanding of cancer pathophysiology. Cancer immunotherapy and targeted
cancer therapy focus more on molecular and cellular levels than systemic levels. There are
approved agents to target human epidermal growth factor receptor 2 (HER2) for breast cancer,
epidermal growth factor receptor (EGFR) for non-small cell lung cancer (20, 21). Thus, knowing
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the molecular information of tumor cells and microenvironment with non-invasive imaging assays
becomes an unmet medical need which can be fulfilled by biomarker targeted molecular imaging.
Our knowledge for cancer biomarkers and imaging capability is essential for the success of early
detection.
1.2

Molecular imaging
“Molecular imaging is the in vivo visualization, characterization, and measurement of

biological processes at the molecular and cellular levels (22).” On top of the present imaging
assays, which rely on detecting the microscopical alteration of physiological status, molecular
imaging enables more specific and quantitative assessment of disease status. Molecular imaging
can non-invasively profiling the pathological characterizations of diseased tissues and enabling
early detection, personalizing treatment stratifications, and following up the treatment effect.
Histological analysis is the gold standard for analyzing the morphology and molecular signatures
of tissues. However, the prominent disadvantage of histological analysis is the reliance on biopsy
to collect tissue invasively and does not provide spatial information in the whole organ. The
advances in molecular and cellular technology, the availability of different animal models and
small animal scanners facilitate the development of molecular imaging. The rapid development of
the molecular imaging field promises the possibility of assessing the pathological process on a
molecular level with non-invasively imaging acquisitions.
The main deciding factors for molecular imaging, including biomarker, imaging sensitive
instrumentation, and probes. Molecular imaging development is rooted in nuclear medicine, which
has relatively higher sensitivity through the administration of radiolabeled tracers. Due to the
limitation of sensitivity, the major imaging modality in molecular imaging is PET, SPET, and
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Ultrasound. Recently, near IR fluorescence imaging probes have also been developed (23). For
MRI, there is no targeted probe has been approved.
The definition of a biomarker is proposed to be “A characteristic that is objectively
measured and evaluated as an indicator of normal biological processes, pathogenic processes, or
pharmacologic responses to a therapeutic intervention.” (24) Biomarkers are widely used in
disease screening and diagnosing, cancer staging, stratification of treatments. Biomarkers, a
parameter that considers the individual differences across the same disease, is crucial for cancer
diagnosis, prognosis prediction, and treatment stratification. For instance, HER2 is found to be
over-expressed and plays a vital role in breast cancer development. The HER2 status of breast
cancer patients is related to the prognosis and guides the decision- making regarding the choice of
using monoclonal antibody Trastuzumab (25, 26). Similarly, research of colorectal cancer shows
that colorectal patients with KRAS wild type tumors can benefit from treatment with a
combination of cetuximab and FOLFIRI when compared with FOLFIRI alone. Patients treated
with cetuximab plus FOLFIRI showed a reduced risk of progression and metastasis (27). The
selection of biomarker for cancer imaging is very challenging and requires careful validation of
patient samples. This dissertation will address the validation of CXCR4 as a biomarker for the
liver metastases. (Chapter 5)
1.3

Medical imaging modalities
PET imaging records the high-energy  rays emitted from the subject. A neutron-deficient,

positron emitted isotope was selected for labeling biomolecules as PET tracers. Positron emitted
isotopes that were frequently used for developing PET tracers are 15O, 13N, 11C, and 18F (18). The
PET radiotracers are made using either a cyclotron (28) or a generator. Fluorodeoxyglucose (FDG),
an analog of glucose, is the most commonly used biologically active tracer for PET imaging.
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FDG introduced to the subject, and the decay of
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F generates positron (e+) and an electron

neutrino (ve). After emission, the positron travels in the tissue and loses the energy until it
annihilates with an electron and emits two annihilation gamma rays in opposite directions (29)
(Figure 1.1). PET imaging has high sensitivity in the range of 10−11–10−12 mole/L and with no
depth limitation. As a result, PET imaging is a very robust imaging modality for clinical usage.

Figure 1.1 The principles of positron emission.
Positron emitted along with the decay of the neutron-deficient isotope, the detection of
annihilation photons within the time window.
Single-photon emission computed tomography (SPECT) is less sensitive than PET
imaging. However, SPECT has the advantage of allowing the usage of various isotopes with
different energy γ-rays, which enables the simultaneous detection of multiple events at the same
time.
Optical imaging as another approach to achieve molecular imaging has the advantage of
being economical and has the potential of achieving multichannel imaging by using optical probes
with different imaging spectra. Optical imaging, including bioluminescence imaging, fluorescence
imaging, has the advantage of being detected at a very low level due to the background-free nature
of the emitted light. The technical barrier of optical imaging is how to conquer the low light
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transmission efficiency and detect the light emitted within the living subjects, especially for bigger
animals.
Magnetic resonance imaging (MRI) obtains the three-dimensional imaging of the human
body without radiation involvement and has been widely used in clinic settings. This technique
has been rapidly developing, evolving, and deriving the different clinical applications due to its
high resolution and sensitivity to soft tissues. MRI has the potential for molecular imaging due to
its advantages of higher spatial resolution and non-radiation exposure. The sensitivity of current
MRI contrast agents limits its applications in molecular imaging. This dissertation aims to develop
novel biomarker targeted contrast agents to extent MRI application for molecular imaging.
1.4

Magnetic Resonance Imaging

1.4.1 Physics
The MRI technique builds on the basic principles of nuclear magnetic resonance and
generates imaging information of the anatomy, function, and metabolism of tissues without
causing ionizing irradiation. The nuclear magnetic resonance (NMR) phenomenon was described
by Bloch and Purcell in 1946 (30, 31). Damadian proposed in 1971 that relaxation time for two
solid malignant tumors, Walker sarcoma and Novikoff hepatoma are distinct from the healthy
tissues (32). This discovery ignited the hope of distinguishing benign and malignant tissue using
MRI. By detecting water relaxation in a strong magnetic field following a temporary pulse
sequence, MRI provides the internal picture of tissues and organs for diagnosis.
Atoms with an odd number of protons and/or an odd number of neutrons exhibit the
phenomenon of nuclear magnetic resonance because of the spin angular momentum they possess.
Of the atoms exhibiting this phenomenon, such as 1H, 31P, and 23Na, 1H is the most abundant in
the body and most practical for MRI imaging application. By applying a static magnetic field B0,
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all the 1H spins will align with the direction of B0 (z-direction) and produce a magnetization
moment M. While the proton spins aligned in the z-direction interact with the radiofrequency field
in the transverse direction, a torque will be induced, and the magnetization moment M will rotate
away in a procession motion from its equilibrium position along with z-axis. M will eventually go
back to the initial equilibrium position along with z after being excited by a radiofrequency field.
In the process, the transverse component of M, Mxy decays while the longitudinal component Mz
grows. Two parameters, T1 and T2, are introduced to characterize the return of different
components of M. Introduced contrast agents alter the relaxation time constant and provide signal
enhancement on imaging.
1.4.2 MRI contrast agents
Although MRI is a non-radiation, high-resolution imaging modality, the sensitivity of MRI
is limited by the water background. To resolve this issue, MRI contrast agents have been applied
to increase the contrast of imaging results by Lauterbur PC (33) for the first time in 1983. Since
then, the MRI contrast agents have become an indispensable element of the MR imaging
technique. Based on the bio-distribution preference of different contrast agents, they can be
grouped to intravenous contrast agents, intravascular contrast agents, and hepatobiliary contrast
agents such as gadobenate dimeglumine (Gd-BOPTA), gadoxetic acid (Gd-EOB-DTPA) and
mangafodipir trisodium (Mn-DPDP). The gadolinium-based contrast agents are the most
commonly used in medical applications since been first described as a potential NMR agent (34).
Nine of these agents are commercialized for different imaging purposes.
MRI contrast between tissues in the image differentiates different tissues and local
environment and reflects as the different intensity on MRI images. The MRI contrast arises from
and is affected by multiple factors: proton density, innate T1 and T2 of tissue, perfusion, and

9

diffusion of local water molecules. The MRI contrast agents aim to alter the T1 and T2 of the tissue
at their presence and enhance the contrast of images. All contrast agents shorten both T1 and T2.
However, based on the predominant influence on T1 or T2, MRI contrast agents can be divided
into T1 contrast agents and T2 contrast agents. More specifically, when a contrast agent alters
longitudinal relaxation rate (1/T1) and transverse relaxation rate (1/T2) in a similar level, the
contrast agents are T1 weighted contrast agent, because the intrinsic faster T2 of tissue contrasts
enhance dominantly on T1 in a percentage base (35). If a contrast agent alters transverse relaxation
more predominantly than longitudinal relaxation, the contrast agent is a T2 weighted contrast agent.
The most commonly used MRI contrast agents, gadolinium-based contrast agents (GBCA), are T1
contrast agents for the significant influence on T1. There are very few exceptions of the application
of GBCA that use the T2 effect. The T2 effect of gadolinium-based contrast agents reflects as
darkening the signal on MRI images, and it only shows up when the contrast agent concentration
is in mM range. For imaging purposes, the contrast agent concentration is usually much lower
than one mM (36, 37). The T2 effect of gadolinium contrast agents is limited by the increased risk
of toxicity at a higher dosage.
Superparamagnetic iron oxide is T2 weighted contrast agents because they affect the T2
relaxation and show a darkening enhancement on T2 weighted images (38). Transitional metal ion
manganese (II) has five unpaired electrons that possess T1 property and weak T2 property, and
attempts of using manganese-based contrast agents for enhancement have been made (33, 39, 40).
The gadolinium-based MRI contrast agents in clinical use are formulated with a chelator
to protect the dissociation of free Gd3+, which potentially causes toxicity (41). Due to the seven
unpaired electrons, gadolinium possesses paramagnetic properties. Current GBCAs can be divided
into linear and macrocyclic based on the structure of chelating ligands (42, 43). According to their
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charges, they can be further divided into sub-categories of ionic and non-ionic ones. In general,
macrocyclic contrast agents are more stable than the linear “open chain” ones, for the reason that
the previous ones form a structure that cages the gadolinium ion. Ionic contrast agents are more
stable than non-ionic ones for the stronger electrostatic interactions between Gd3+ and the donor
groups (44, 45).
There are fundamental features that researchers are trying to look for in the design of
gadolinium-based contrast agents, including high relaxivity, high stability, low toxicity, tissue
specificity, or even biomarker specificity. Relaxivity (r1 and r2) is the capability of contrast agents
shorten T1 and T2 and provides contrast enhancement on images. The higher relaxivity of contrast
agents enables the same signal intensity by less concentration or increases the signal intensity by
equivalent dosage. Developing MRI contrast agents with higher relaxivity increases the imaging
sensitivity and reduces the contrast agent’s toxicity potentially. High stability contrast agents are
considerably safer. The linear contrast agents are less stable than macrocyclic contrast agents.
Additionally, the majority of reported nephrogenic systemic fibrosis (NSF) cases were associated
with the administration of the non-ionic, linear contrast agent Omniscan (46). Tissue specificity
enables the contrast enhancement in a specific tissue and expands the application of the contrast
agent. For example, the hepatocytes-specific contrast agents can be specifically uptake by
hepatocytes and assist in the differentiating diagnosis of hepatocellular carcinoma. Biomarkerspecific contrast agents that target specific biomarkers, especially cancer biomarkers, arise from
the development of molecular imaging. Biomarker-targeted MRI contrast agents are expected to
improve the understanding of diseases at a molecular level and help to make decisions regarding
diagnosis and therapeutic stratification.
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1.4.3 MRI contrast agents for molecular imaging
An important factor in achieving molecular imaging with MRI is to improve the relaxivity
of contrast agents. MR imaging has lower sensitivity compared with nuclear medicine imaging
approaches such as PET. As a result, MRI contrast agents must reach specific local concentrations
to achieve imaging enhancement of biomarkers. The relaxation time of tissues is various. Taking
tissue relaxation time measurement under 3.0 T as an example, the T1 of gray matter is 1460 ± 33
ms (47), white matter is 840 ± 50 ms (48), the liver is 840 ± 50 ms (49). Assuming relaxation time
of specific tissue is 1000 ms, in order to achieve an observable robust change (0.5 s-1) on MR
contrast enhancement with current gadolinium-based MRI contrast agents, a minimum
concentration of 100 µM is required (calculation based on r1 equal to 5 mM-1 s-1 and binding with
biomolecule in a 1:1 stoichiometry) (35). Such a concentration of contrast agent cannot be
achieved in vivo considering the biomarkers present in 10-6 -10-10 concentration in tissue (50) and
the fast elimination of small molecule contrast agent.
Attempts have been made to achieve molecular MR imaging. One of the early approaches
is to label monoclonal antibodies with Gd-DTPA. Matsumura A et al. use monoclonal antibodies
against 9L glioma cells to conjugate Gd-DTPA and achieve tissue-specific enhancement of mouse
brain tumors (51). Melanoma-specific enhancement was reported using monoclonal antibodies
against melanoma conjugated with Gd-DTPA (52). Another example is the alphaVbeta3-targeted
MRI contrast agent, which is reported to achieve molecular imaging through alphaVbeta3 and
show the angiogenic 'hot spots' with magnetic resonance imaging (53). The robust enhancement
of biomarkers requires higher relaxivity contrast agents with targeting capability.
Various factors attribute to the relaxivity of contrast agents. The rotational motion of
contrast agents is decisive for the relaxivity. To achieve catalytical relax of bulky water, the
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gadolinium should efficiently relax the water and the relaxed water can be exchanged quickly with
the unrelaxed ones. For small molecules, the rotational rate is majorly decided by the relaxation
efficiency. However, when the rotational motion becomes slower, the water exchange rate
becomes a predominant factor. This phenomenon has been described with the relaxivity
measurement of MS-325 and the analog MS-325-BMA. The relaxivity of both contrast agents in
PBS buffer is similar. However, the relaxivity of MS-325 is significantly higher than MS-325BMA in the human serum albumin solution (35). Once the agents were bound with human serum
albumin, the rotational motion of both contrast agents slowed down, and the water exchange rate
of MS-325-BMA is slower than MS-325 (54). One approach to improve the relaxivity of
gadolinium contrast agents is to link multiple gadolinium in one molecule. This can improve the
concentration of gadolinium in the target region and increase the contrast of images (55, 56).
Another approach is to locate gadolinium in the center of the molecule and form more rigid local
structures. In this case, the local motion of gadolinium is restricted and changes the factors
governing the relaxivity to achieve significantly higher relaxivity (57, 58). Alternatively, the lipid
platform for MRI contrast agents’ construction and MRI has been reported to target the fibrin and
detect thrombus in vivo (59, 60).
Hydration number q refers to the water molecule directly bound to the gadolinium in the
inner coordination sphere. The water molecules in the second and outer coordination spheres
contribute to the relaxivity as well. With more water molecules coordinating in the inner sphere,
gadolinium contrast agents generate higher relaxivity (61). However, the tradeoff would be that
the stability becomes less because the introduction of more coordination sites for the ligands
decreases the thermodynamic stability of contrast agents.
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Outer sphere

Figure 1.2 Physical parameters affect the relaxation of gadolinium-based MRI contrast
agents.

1.4.4 Protein-based MRI contrast agents
Designing the MRI contrast agents with higher relaxivity need to consider multiple factors
including hydration number q, second sphere and outer coordination sphere, rotational correlation
time (τR), and water exchange rate. We designed a serious of protein-based Gd3+ MRI contrast
agents (ProCAs) (62) which chelating the gadolinium (III) ion using the interaction between side
chains of residues and gadolinium (III) ion, instead of linking the Gd-chelator with protein through
covalent and noncovalent interaction. This allows optimizing the relaxivity related factors such as
water number, rotational correlation time and second correlation sphere. We reported a novel MR
contrast agent ProCA32 that has unprecedented liver imaging capability (63). ProCA32 is derived
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from a parvalbumin scaffold with two gadolinium binding sites. ProCA32 possesses slower
rotational correlation time (τR) than small molecules such as Gd-DTPA and exhibits a much higher
relaxivity (both r1 and r2) when compared with current commercially available contrast agent.
ProCA32 can image small metastases in millimeter-scale (63) whereas imaging capability of small
chelator MR contrast agents usually limited to a centimeter scale. In addition, ProCAs allows the
linkage of targeting moieties specific for biomarkers and achieve related biomarker molecular
imaging. GRPR, PSMA, and HER2 specific imaging can be achieved by the administration of
corresponding contrast agents (64-66).
An ideal protein-based MRI contrast agent should satisfy several criteria: high r1 and r2
relaxivity, strong Gd3+ binding affinity, low toxicity, high stability and solubility, suitable PK/PD
properties, no interaction with other proteins, and low cost of production. This dissertation is
focused on the development of CXCR4 targeted contrast agent, ProCA32.CXCR4.
ProCA32.CXCR4 based on the ProCA32 structure and targeting CXCR4 with targeting moiety at
the C terminus.
1.5

Chemokine receptor 4 (CXCR4)

The chemokines are a family of small, pro-inflammatory cytokines secreted by immunerelated cells, which mediate chemotaxis of cells through the interaction with chemokine receptors.
Interleukin 8 is the first chemokine been identified and characterized (67). Since then, more and
more chemokines have been identified, until today, there are over 50 ligands identified in humans
and mice (68). Chemokines are first appreciated as a chemoattractant for innate immune cells (69).

The chemokines achieve their biological roles by interaction with the chemokine receptors
that expressed on the target cells. Chemokine receptors belong to the family of G protein-coupled
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receptors (GPCR) that have seven transmembrane domains connected by three extra-membrane
loops (70). Chemokine receptors can be divided into G-protein coupled chemokine receptors and
atypical chemokine receptors based on their signaling (68). According to the positioning of the
first two cysteines, chemokine receptors can be classified into four groups (CXC, CC, C, and
CX3C) (71). Chemokine receptors were first appreciated as the mediators of leukocyte- trafficking
in acute inflammation and then found to be involved in other biological processes such as T helper
cell differentiation, angiogenesis, and co-entry of HIV. (72, 73)
Chemokine receptor 4 (CXCR4), also known as CD184 or “fusion”, is the chemokine
receptor for stromal-derived factor 1(SDF-1, renamed as CXCL12). Chemokine receptor 4 is a
rhodopsin-like receptor encoded on chromosome 2. CXCR4 is widely expressed on many
different types of cells such as leukocytes, progenitor, stem cells, endothelial, epithelial, and
stromal cells. CXCL12 is the established natural ligand of CXCR4 since 1996 (74). In 2005, Burns
et al. (75) reported chemokine receptor 7 (CCR7) is another receptor for CXCL12. CXCL12 is
ubiquitously expressed in human tissue and has high expression levels in the liver, kidney, lungs,
and bone marrow (76, 77). The CXCR4/CXCL12 axis mediates physiological and pathological
processes such as cell migration, metastatic malignancy, vascularization, and organ homeostasis
(78, 79). The biological effect of CXCR4 is achieved by binding the nature ligand CXCL12, to
activate the downstream protein kinase to trigger the signaling pathway (Figure 1.3). Upon the
activation of CXCR4 by interacting with CXCL12, the downstream signaling pathway is initiated
by dissociation of βγ subunit and α subunit. A series of complex signal pathways transduction were
achieved by activation of IP3 (Inositol triphosphate), ERK1/2 (extracellular signal-regulated
kinases1/2), PI3K (phosphoinositide 3-kinases), JAK and calcium release to mediate a series of
biological incidences including cell migration, proliferation, survival and gene transcription.
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Figure 1.3 Chemokine receptor 4(CXCR4) mediated cellular pathways.

Chemokine receptor 4 has been found as co-receptor for HIV entry in 1996 (74). Since
then, the focus of the CXCR4 study broadened from mere chemoattractant (80) to cell migration
and cancer metastasis. CXCR4/CXCL12 axis regulates leukocytes trafficking (80), HIV infection
(74), cell migration, and cancer metastasis (81). CXCR4 has a universal expression in different
tissues and organs. Both the HPA and GTEx datasets showed that the RNA tissue category is
expressed in all tissues that been studied (human protein atlas). It has a high expression level in
immune-related tissues such as bone marrow, spleen, and lymph nodes (82). Functional CXCR4
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protein is found on human epithelial cells (83, 84), endothelial cells (85), mast cells (86), and
dendritic cells (87). CXCL12 chemoattracts cells that express CXCR4 along with the CXCL12
concentration gradients and play a pivotal role in a variety of physiological and pathological
processes such as embryonic development, hematopoiesis, vascularization, inflammation, immune
surveillance and cancer metastasis (79, 88). CXCR4 knockout mice exhibit hematopoietic and
cardiac defects and fetal cerebellar development (89).
CXCR4 is the chemokine receptor that involves in the complex network of inflammation,
wound healing, and cancer development. The network parallel with each other and well connected.
As a result, CXCR4 participates and mediates various directional cell recruitment and triggers
downstream signaling.
1.5.1 The significance of CXCR4 in cancer cells
Chemokine receptors are extensively expressed in the tumor cells and direct the tumor cells
migration through the interaction with their ligands (90-92). CXCR4 is the major chemokine
receptor expressed on tumor cells. CXCR4 was found to be expressed by over 23 types of cancer,
including melanoma, breast cancer, and ovarian cancer (93). The expression levels are different
between vary tumor types, primary tumor, and metastases and even different subpopulations of
cells. The expression level of CXCR4 indicates cancer prognosis. Breast cancer is the most
prevalent invasive cancer for women and comprises 16% of female cancer. Take breast cancer as
an example; most breast tumor cells exhibit an elevated CXCR4 expression, whereas CXCR4
barely expressed in normal breast tissue. Xu et al. reported in 2013 that the overall survival and
disease-free survival are negatively related to the CXCR4 expression level (94). Over 75% of
triple-negative breast cancer patients have a high expression level of CXCR4 (95), and over-
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expression of CXCR4 at primary tumor sites positively correlates the lymph mode metastasis and
lower survival rates (96).

Figure 1.4 The roles of CXCR4 in cancer development.
Figure adapted from reference (90).

CXCR4 contributes to tumor immune suppression. One study shows that malignant human
ovarian epithelial tumor cells have the high-level expression of stromal-derived factor-1and
through the interaction with CXCR4, plasmacytoid DCs precursor chemotaxis, and
adhesion/transmigration was activated. This protects plasmacytoid DCs precursor from tumor
macrophage interleukin-10–induced apoptosis. (97) CXCR4 facilitates tumor growth. In human
ovarian tumor cell line IGROV that has a high expression level of CXCR4, CXCL12 can stimulate
cell growth in vitro (98).
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CXCR4 expression levels vary from low to high in AML patients cells and is an
independent prognostic marker in acute myelogenous leukemia (99). In multiple myeloma (MM),
CXCR4 has been shown to involve in cancer homing and migration. The cancerous B-cells are
attracted to bone marrow, where the stromal-cell secrets high level of CXCL12 (100). In acute
myelogenous leukemia, the CXCR4/CXCL12 axis directs AML cells that express CXCR4 in the
same fashion with directing normal hematopoietic stem cells migrate along with the CXCL12
gradient (101). Marrow stromal cells constitutively secrete CXCL12. Thus, the marrow niche
provides a primary residual environment after chemotherapy. Specific aiming at mobilizing HSCs
into the peripheral circulation, AMD 3100 as a potent, selective CXCR4 antagonist can antagonize
CXCL12 binds to CXCR4 and interrupt the homing of AML cells to bone marrow stromal. By
mobilization of AML cells into the peripheral circulation, AMD 3100 effectively sensitizing the
AML cells to chemotherapy (101).
CXCR4/CXCL12 axis is found to be crucial for organ-specific metastasis, supported by
the most common metastatic sites for CXCR4 positive cancer are those organs have high CXCL12
concentrations such as liver, lungs and bone marrow (102). Functional CXCR4 is expressed on
breast tumor cells, breast tumor cells only metastasis to the organs and tissues strongly express the
CXCR4 ligand, CXCL12, and the metastasis can be partially blocked by CXCR4 antibody (103).
The majority of prostate cancer patients eventually develop metastases in the bone, which has a
high CXCL12 level. It suggests that CXCR4/CXCL12 interaction plays an important role in
prostate cancer metastasis (104). Therefore, the CXCR4 expression level is proposed to be a
prognostic factor and therapeutic target for prostate cancer (105). The CXCL12 signaling study of
human prostate cancer cell line-PC3 study by Fernandis, A.Z. proved that CXCL12 activates
MEK/ERK signaling and NF-κB, which play an important role in cancerous cell survival (106).
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CXCR4 inhibitors, including antibodies, peptides, and small molecules can reduce metastasis
burden of prostate cancer cells in PCa mouse model studies (105, 107). CXCR4/CXCL12 axis also
involved in regulating the metastasis in non-small cell lung cancer (108).

Figure 1.5 The role of CXCR4/SDF-1α axis in various diseases.
Figure adapted from reference (109).
1.5.2 CXCL12 in the cancer microenvironment
To date, numerous researches proved that tumor microenvironment (TME) provides
habitat that favoring tumor proliferation, migration, and invasion. Carcinoma-associated
fibroblasts (CAF) is one of the major cell types discovered in different tumors; CAF promotes
tumorigenesis instead of suppressing tumor growth as normal fibroblasts do (110). CAF secret
CXCL12 and stimulate breast cancer growth through the CXCL12 and CXCR4 interaction (111).
CXCL12 promotes the expression of integrin and cancer cell adhesion in small cell lung cancer
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(SCLC); 2, 4, 5 and 1 integrin mediates the adhesion of SCLC cells to fibronectin and
collagen upon CXCL12 activation (112). A similar phenomenon is observed in prostate cancer
PC3 study; CXCL12 treatment promotes the adhesion of PC3 cells to fibronectin (113).
Angiogenesis is another critical step for cancer progression; new forming vasculature
guaranteed the nutrient supply for tumor growth. CXCL12 is proved to promote endothelial cell
tube formation and angiogenesis (114, 115). In vivo study proved that the presence of CXCL12 is
essential in blood vessel formation through a heme-oxygenase 1 dependent mechanism (116). Also,
the CXCL12 level in plasma is related to bone marrow angiogenesis in multiple myeloma patients
(117).
CXCL12 presented in the tumor microenvironment can also promote tumor cell
proliferation and survival. In human glioblastoma cell lines study, CXCL12 treatment showed the
ability to stimulate tumor cell growth; the CXCL12 dependent proliferation is correlated with
phosphorylation and activation of pathways ERK (extracellular signal-regulated kinases) 1/2 and
Ark (118).
1.5.3

CXCR4 as a therapeutic target
The critical role of the CXCR4-CXCL12 axis in various diseases and different stages of

inflammation, cancers, and infectious diseases makes CXCR4 targeted therapy has strong
translational potential. Intensive study on the structural biology of CXCR4 enriches the
understanding of the CXCR4 structure and the interaction with ligands, including SDF-1 and other
small molecules significantly. Wu et al. reported the crystal structure of CXCR4 in complex with
IT1t, a small, drug-like, isothiourea derivative, and CVX15, a cyclic peptide characterized as
CXCR4 inhibitor (Figure 1.6) (119).
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Figure 1.6 The chemical structure representation of CXCR4 antagonist IT1t and CVX15.

Massive attempts have been made on the development and optimization of the CXCR4
antagonists as anti-cancer and/or anti-HIV drugs. Overall, CXCR4 antagonists can be classified
into peptide derivatives and small molecules. Cyclic peptide CVX15 and T140 can bind with
CXCR4 and serve as a CXCR4 antagonist. Downsize of T140 to cyclopentapeptides and
derivatives has successfully generated potent CXCR4 antagonists in cyclopentapeptide structures
such as FC131 and FC122. FC131[cyclo(-D-Tyr-Arg-Arg-Nal-Gly-)] has the EC50 of 0.4 µM
(120) and based on which a much more potent CXCR4 antagonist FC122 is synthesized with an
EC50 of 88 nM (121).
Base on the cyclopentapeptides results, the SAR (structure-activity relationship) studies
on cyclopentapeptide CXCR4 antagonists located the tripeptide motif L-/D-Arg1-Arg2-2-Nal3 as
the minimal sequence for the antagonistic activity. A series of tripeptidomimetics of motif L-/DArg1-Arg2-2-Nal3 was synthesized and analyzed. Although no potent tripeptidomimetics were
identified, the core structure still potentially be the bone structure for bulky CXCR4 antagonist
development (122).
Another different approach of CXCR4 antagonist development based on the small
molecules. Vitale et al. identified the phidianidine A (PHIA) as a new CXCR4 ligand through the
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screening in a small marine natural product library available at ICB-CNR Institute (123). Truax et
al. designed a series of tetrahydroisoquinoline analogs as CXCR4 antagonist with 3-650 nm
potencies (124). AMD3100, brand name plerixafor, is a CXCR4 antagonist approved by the FDA
in 2008 for the mobilization of hematopoietic stem cells (125). The effort has been made towards
simplifying the AMD3100 structure to single cyclam connect to the aromatic structure by pxylylenediamine linker (125). The computational approach to design the small molecule based on
the SDF-1α interaction with CXCR4 has yield the small molecule CXCR4 ligands of µM scale
potency (126).
1.5.4 CXCR4 molecular imaging
CXCR4, a chemokine receptor involves in numbers of the physio-pathological processes,
has gained tremendous attention as a therapeutic target. Other than that, how to evaluate the
CXCR4 expression non-invasively in vivo is the primary importance of monitoring and evaluate
the treatment effects. However, current imaging techniques and agents are not able to assess
CXCR4 expression. Hence, there is a critical unmet need for the development of CXCR4 specific
imaging agent for molecular imaging purpose.
The important biological function and the potential role of the CXCR4/CXCL12 axis in
the cancer development make CXCR4 targeting imaging and CXCR4 targeting therapy draw
tremendous attention in the past decade. Developing CXCR4 specific imaging agent based on the
research of CXCR4 antagonist development. By labeling the CXCR4 targeted small molecular or
peptides with imaging agents is a basic approach for CXCR4 imaging agent development. T140
derivatives, FC131 derivatives, AMD 3100 derivatives, SDF-1α analogs, and CXCR4 targeting
antibodies are all being used for CXCR4 contrast agent development (Figure 1.7). Among these,
three classes of compounds are most extensively evaluated (127).
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1. Bicyclams AMD3100 and AMD3465 with radiolabeling as PET or SPECT tracer.
2. Labeling of T140 peptide derivatives as PET, fluorescence tracer or hybrid tracer for
multimodal imaging.
3. Labeling FC131 cyclic peptide derivatives for PET imaging.
64

Cu-AMD3100 (Figure 1.8 A) imaging capacity has been evaluated in the xenograft

mouse model (128) and orthotopic and metastatic breast cancer mouse model (129). In the breast
cancer mouse model, the tumor shows

64

Cu-AMD3100 uptake and the imaging effect can be

blocked by unlabeled AMD3100 (129). The biodistribution study of

64

Cu-AMD3100

accumulation in liver, kidney, and immune-related organs and tissues such as bone marrow, spleen,
and lymph nodes (130). [(99m)Tc] pertechnetate labeled AMD3100 (Figure 1.8 B) was used as a
SPECT tracer to image the PC-3 bearing mouse model (131). It shows favorable CXCR4 binding
and specific tumor affinity by CXCR4 targeting.
64

Cu-AMD3465 was investigated with glioblastoma models, the tumor-to-muscle and

tumor-to-noise ratio are much higher than

64

Cu-AMD3100, suggesting the superior imaging

capacity of 64Cu-AMD3465 (132). However, a considerable amount of uptake in the liver and
kidney were observed as well, although the liver and kidney have an intrinsic expression of
CXCR4 that explains part of the uptake mediated by receptor. The non-specific liver and kidney
of cyclams structure imaging agents still need to be further addressed.
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Figure 1.7 The targeting moieties for CXCR4 molecular imaging agents.
Targeting moieties including natural ligand of CXCR4, CXCL12 derivatives, CXCR4 antibodies,
derivatives of CXCR4 antagonists and agonists were used for the current development of CXCR4
targeting imaging agent.

T140 peptide has a strong CXCR4 binding affinity; the T140 peptide derivatives have been
labeled a series of radiometals as PET imaging tracer for CXCR4 molecular imaging.

68

Ga is

suggested as a potential candidate for CXCR4 imaging for the favorable pharmacokinetics
property and better tumor-to-muscle ratio (133). 4-18F-T140 was proved to have low accumulation
in the metabolic organs, including the liver and kidney (134). The biodistribution of 4-18F-T140 is
an advantage as opposed to AMD3100 based imaging for differentiating tumors in the metabolic
organs with better signal-noise-ratio. Nishizawa K et al. reported the application of
fluorescent CXCR4 antagonist TY14003 in superficial bladder cancer (135).
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Figure 1.8 Structure of AMD3100 labeled CXCR4 imaging tracer.
A. 64Cu labeled AMD3100 for PET imaging. B. [(99m)Tc]pertechnetate labeled
AMD3100 for SPECT imaging.
F131 cyclic peptide derivatives show superiority as a PET tracer.

68

Ga-CPCR4-2 shows

high stability and CXCR4 tumor specificity in vivo. In addition, it has very low accumulation in
liver and kidney despite the renal clearance (136).
Tremendous effort has been made towards the development of CXCR4 specific imaging
tracer. The majority of CXCR4 imaging tracers are nuclear medicine tracers. By labeled CXCR4
antagonist AMD3100 and the analogs, T140 peptide and derivatives, F131 cyclic peptide and
derivatives, CXCR4 imaging have been achieved using PET, SPECT and fluorescence imaging.
A good CXCR4 molecular imaging tracer is expected to have high tumor-to-muscle signal, low
unspecific uptake, optimized pharmacokinetics property, and clearance. CXCR4 molecular
imaging through MRI has not yet been reported. To develop the CXCR4 specific MRI contrast
agent will fill the unmet need.
1.5.5 CXCR4 and uveal melanoma (UM)
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults.
Uveal melanoma almost exclusively metastasis to the liver (over 95%). Although it has
progressively more early diagnosed but the prognosis still unrealistic cause the early metastasis.
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The CXCR4/CXCL12 axis plays a crucial role in this process. First, the liver contains
significant quantities of CXCL12, the natural ligand of CXCR4; it can attract CXCR4 positive
cells. Moreover, cell-line based study of RT-PCT and flow cytometry (137) shows that all the
primary uveal melanoma cell lines expressed CXCR4. Joseph Kim showed the CXCR4 expression
in 89% (24 of 27) melanoma liver metastasis (138). A study by Bianca. D et al. on the Seventy
formalin‐fixed paraffin‐embedded uveal melanoma patients’ specimens shows the strong CXCR4
expression in the cytoplasm of uveal melanoma cells with an average immune reactive score (IRS)
of 8.2 (139). Blocking the CXCR4-CXCL12 interaction with anti-CXCL12 antibody resulted in a
reduction of chemotactic response, blocking CXCR4 expression by transfection of CXCR4 siRNA
inhibited the invasive property of uveal melanoma (140). Besides, cross-talking between the
CXCR4-CXCL12 axis and the VEGF (vascular endothelial growth factor) pathway were shown
to benefit the tumor progression.
The patient tissue study detected CXCR4 protein of 41.4 percent cases (141). Blocking
CXCR4 gene expression by transfection with CXCR4 siRNA inhibited invasive properties of
uveal melanoma cells exposed to soluble factors produced by human livers (140).
The CXCR4-SDF1 axis plays an essential role in the organ-specific uveal melanoma
metastasis. The CXCR4 expression level in primary melanoma is elevated, but the CXCR4
expression level in uveal melanoma is controversial, a cell line study conducted by H, Li
discovered the primary melanoma cell lines express CXCR4 whereas metastasis cell lines showed
the decreased expression level of CXCR4 (137).
1.5.6 CXCR4 and hepatocellular carcinoma (HCC)
Hepatocellular carcinoma (HCC) is the most common primary liver malignant disease with
poor prognosis. HCC is associated with liver cirrhosis which caused by chronic inflammatory liver
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diseases such as hepatitis B (HBV) and hepatitis C (HCV) infection, it also related to non-viral
liver diseases including alcoholic fatty liver disease and non-alcoholic fatty liver diseases.
The role of CXCR4/SDF-1α in cancer is well recognized, and the intrinsic role of CXCR4
in HCC development is widely studied as well. One germen group evaluated the association of
CXCR4 expression with HCC progression in both HCC cell lines and patient tissue study (142).
They suggested the association of CXCR4 in HCC dissemination and played an important role in
the tumor progression. In 2007, one immunohistochemical based patient tissue study located the
CXCR4 overexpression in HCC sinusoidal endothelial cells when compared with none-HCC
tissue, suggesting the CXCR4 expression mediated the neo-angiogenesis of HCC and can be a
potential HCC treatment target (143). The same year, one study of mouse HCC cell lines with high
and low metastases potential proved the relationship of CXCR4 and HCC metastasis again (144).
Their main finding is CXCR4 has a significantly higher expression on the mouse
hepatocarcinomatous cell lines with high potential of lymphatic metastasis (Hca-F) as opposed to
the mouse HCC cell line with low potential of lymphatic metastasis (Hca-P). In addition, CXCR4
was found to correlate well with HCC patient bone metastasis, and the bone metastasis-free
survival, which suggesting the CXCR4 expression as an independent risk factor for HCC (145).
CXCR4 antagonist AMD3100 is used in combination with a broad kinase inhibitor—Sorafenib to
prevent fibrosis in HCC (146).
Overall, CXCR4 expression in HCC consider as an independent risk factor and result in
poor prognosis. The CXCR4 expression in HCC elevated and involved in neo-angiogenesis and
metastasis. As a result, mapping and monitoring the CXCR4 level in vivo with non-invasive
imaging assay has strong translational potential and improves the disease management as well as
treatment.
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1.6

Motivation and challenges of this research
The development of non-invasive imaging techniques and probes is pivotally important in

improving the standard of care in cancer and cancer-related diseases. As the development in
molecular cell biology, understanding about tumor etiology reach to an unprecedented level.
Malignant diseases consist of various spectrum of molecular, cellular and systemic events and
forming complex networks through chemokines chemokine receptors and cell signal pathways.
Numerous cancer-related research and anti-tumor drug development have been done, and a lot
more is undergoing. Assessment of cancer can no longer stay at a macroscopic level and satisfy
the needs of researchers and clinicians.
Molecular imaging is a relatively new field; the development of molecular imaging
techniques is an interdisciplinary subject. It has the potential to fulfill the needs in diagnosis,
monitoring, and prognosis with a more detailed, microscopic, molecular level. The development
of molecular imaging tracers and probes has the potential to facilitate the disease follow up in a
personalized fashion tailored to individual patients. Molecular imaging that provides the local
microenvironment information can guide the treatment stratification. Screening and assessing
immune-related drugs more specific for individual targets of cancer required the assistant of
molecular imaging as well.
Molecular imaging tracer is necessary for the achieving of molecular imaging. Molecular
imaging is rooted in radiotracers owing to the intrinsic sensitivity of nuclear medicinal imaging
modalities. F-18-FDG is widely used in clinical practice. Magnetic resonance imaging has the
advantage of being non-radiation involved, with no depth limitation and 3D imaging in high
resolution. Research has been concentrated in apply magnetic resonance spectroscopy, diffusion
MRI, CEST MRI for molecular MRI.
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The significance of the CXCR4/SDF-1α axis in cancer-related events is well recognized.
CXCR4 plays roles in different types of cancers, different stages of cancers, and the
overexpression of CXCR4 in tumor tissue sees as an independent risk factor leads to poor
prognosis and higher metastasis potential. Therefore, the development of CXCR4 specific imaging
agents is significant for cancer-related researches and pre-clinical, clinical cancer research. We
devoted to developing new classes of protein-based MRI contrast agent platform for a series of
cancer-related biomarkers including HER2, PSMA, GRPR, EGFR, CXCR4, and collagen. For
better understanding of tumor microenvironments and identifying treatment targets. The platform
technique of protein-based contrast agent is translational to different metals and different targeting
labeling.
Challenges regarding this research are to develop specific biomarker targeted MRI contrast
agent with enough sensitivity for the molecular imaging application. Relaxivity is an important
factor to consider in the development of novel MR molecular imaging. Resolve the delivery of the
imaging reagents is another challenge. We aim at delivering the MR imaging agents efficiently to
the tumor region and optimized penetration for heterogeneity biomarkers detection. The cancerrelated biomarker usually in a µM local range, to develop contrast agent with CXCR4 specific
targeting capability and dynamic imaging capacity to enable the contrast agent specifically
accumulates at targeting tissue and lesions and minimize the off-target binding is another challenge
about this research.
Pharmacokinetics property of contrast agent is closely related to the imaging capacity and
translational potential. Small molecules contrast agents possess short half-life and clearance to
have a short time window for imaging. As blood pool agents, it would not be a big drawback. On
the contrary, the shorter half-life will relatively reduce the risk of unwanted metal retention.
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However, the in vivo targeting process is dynamic and influenced by blood flow, temperature, local
tissue permeability, endocytosis. It is a very complicated process and might not be as time
efficiency. We want to design contrast agents with suitable pharmacokinetic properties to enable
the efficient in vivo delivery, binding and imaging, at the same time with proper clearance and less
risk of metal toxicity caused by metal dissociation. To tune the pharmacokinetic property is a fine
line and requires a great balance between imaging capacity and safety.
Simultaneous detection of multiple biomarkers that related to each other and reveal the
spatial coregistration will take molecular imaging further. Owing to the platform technique of
protein-based contrast agent is readily translational for different metal labeling. Once labeling with
different paramagnetic metal ions, such as gadolinium, manganese, and dysprosium, ProCAs are
expected to have different relaxivities. Once different metal ions labeled ProCAs attach to different
targeting moieties, we expect to achieve simultaneous MR imaging of multi-biomarkers. To
achieve so, the time of imaging acquisition, imaging acquisition sequence, higher spatial resolution,
and the influence of innate tissue relaxivities. will be factors that have to take into consideration.
1.7

Overview of this dissertation
This dissertation consists of 10 chapters in total.
Chapter 1 is the introduction chapter and summarized the basic background information of

this research. Including the cancer disease-related background, molecular imaging development,
and approaches have been applied, and attempts have been made. Most of the molecular imaging
research is done with nuclear medicine imaging, including PET, SPECT, and some multi-models
imaging platform and tracers. Magnetic resonance imaging has the advantages of being nonradiation, non-invasive, and excellent spatial resolution. CXCR4 is an important chemokine
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receptor in various cancer-related incidence. Developing CXCR4 targeted MRI contrast agents is
expected to benefit cancer diagnosis, treatment monitoring, and prognosis.
Chapter 2 is the chapter of material and methods; it described the related experimental
details of the experiments conducted in this research. All the material is used, and the method
conducted is listed in detail in this chapter.
Chapter 3 is the chapter of CXCR4 targeted contrast agent design and production. Chapter
3 includes the rationale of design ProCA32.CXCR4, details of protein production and formulation
and related results are described in this chapter.
Chapter 4 is the biophysical property study of ProCA32.CXCR4. Chapter 4 introduce the
relaxivity, metal-binding capability, and selectivity, serum stability, transmetallation study of
ProCA32.CXCR4.
Chapter 5 is the chapter of CXCR4 expression and detailed results of cell lines, animal
models, patients’ tissue.
Chapter 6 is the chapter summarizes the application of ProCA32.CXCR4 in cancer
diagnosis, including uveal melanoma and ovarian cancer. Chapter 6 in detail documented the
animal models, MRI scans, and histology correlation of pathology results with MRI results of
mouse models.
Chapter 7 is the chapter regarding the application of ProCA32.CXCR4 in HCC diagnosis
and treatment effect monitoring. Chapter 7 records detailed background information and related
experimental results of ProCA32.CXCR4 in hepatocellular carcinoma.
Chapter 8 is a chapter regarding manganese-based contrast agent and multicolor MRI
acquisition development. Including the initial result of Mn-ProCA32.CXCR4 relaxivities.
Prediction of Mn-ProCA32.CXCR4 and Gd-ProCA32.CXCR4 concentration with relaxometer
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and the potential application for multicolor MRI. Chapter 8 also includes the development of
integrin v3 targeted contrast agent ProCA32. RGD. The rationale of design integrin v3 targeted
contrast agent was documented. The initial characterization of ProCA32.RGD, including metal
binding affinity, relaxivities, and integrin v3 targeting capability were performed.
ProCA32.RGD has been applied for breast cancer detection in a 4T1 mouse model.
Chapter 9 is the conclusion and significance of this dissertation research and summarized
all the important scientific findings of this work and significance.
2
2.1

MATERIAL AND METHODS

CXCR4 expression study

2.1.1 Flow cytometry analysis
Flow cytometry was performed to quantify the expression of CXCR4. Cultured human
uveal melanoma cells were dissociated with non-enzymatic cell dissociation solution (SigmaAldrich, St. Louis, MO). Cells were stained for 20 minutes at 4C with APC mouse anti-human
CD184 (clone 12G5) (BD Biosciences, San Jose, CA). Data acquisition was performed using a
Becton Dickson Aria IIu FACS sorter (BD Biosciences, San Jose, CA). FlowJo software (Tree
Star, Ashland, OR) was used for data analysis.
2.1.2 Immunohistochemical (IHC) analysis
UM patients’ liver tissue and UM mouse model tissue were stained with CXCR4 antibody
for IHC study. Briefly, tissue was fixed in 10% neutral buffered formalin and embedded in
paraffin. The tissue blocks were then sliced with 5 μM thickness for staining. Paraffin-embedded
sections were first deparaffinized and rehydrated. After rehydration, 1 part of 30% hydrogen
peroxide and 9 parts of absolute methanol mixture was used to quench endogenous peroxidase
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activity for 10 min, followed by washing with TBST for 3 times, each time for 5 min. Antigen
retrieval was achieved by boiling in target retrieval solution (Agilent) for 20 min. Slides were then
washed with TBST for 3 times, each time for 5 min, blocked in 5% bovine serum albumin (BSA,
Thermo Fisher) in TBST for 2 h, and incubated with 1:300 dilution of primary antibody antiCXCR4 antibody 12G5 (Abcam, ab189048) in TBST O/N at 4C. The IHC staining was performed
with a red chromogen kit following the corresponding protocol. Counter staining of the nucleus
was performed with hematoxylin. A CXCR4 positive control (brain specimen) was processed with
the same protocol. All cases of uveal melanoma (UM) hepatic metastases exhibited high
expression levels of CXCR4, indicated by the brilliant red color staining.
2.2
2.2.1

ProCA32.CXCR4 expression, purification, and PEGylation
Protein design
ProCA32.CXCR4 is designed by linking a 21-mer targeting moiety to the C-terminus of

ProCA32 with a flexible linker. The targeting moiety is derived from the N-terminus region of
CXCR4 binding virus chemokine vMIP-II. The sequence of targeting moiety consists of 21 amino
acid (LGASWHRPDKFCLGYQKRPLP) and including the key residues for CXCR4 interaction.
2.2.2

Expression

ProCA32.CXCR4 was expressed by BL21 (DE3) pLysS cell strain. Briefly,
ProCA32.CXCR4 plasmid was transformed to BL21 (DE3) pLysS competent cells and a single
colony was inoculated to 250 mL of 2.5% LB medium for small-scale culturing overnight at 37°C.
The small-scale culture was then transferred to 1 L of 2.5% LB medium for large-scale culturing
at 37°C and monitoring the optical density at 595 nm (OD595). 0.5 mM isopropyl β-D-1thiogalactopyranoside (IPTG) was used for induction protein expression when the OD595 reach
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between 0.6 to 0.8. Protein was expressed at 37°C for 3 h after induction, and the temperature was
adjusted to 25°C for overnight expression. Cell pellets were collected by centrifuging for 25 min
at 7000 rpm.

2.2.3 Purification

Cell pellets collected from expression were suspended by Phosphate-buffered saline (PBS),
in 1 g cell pellet to 10 mL PBS ratio and mixed thoroughly. Sonication is then used for breaking
up the cell membrane and release cell content, cells were sonicated for 10 times, each time for 2
min, with 5 min intervals between each to avoid over-heat. The cell lysate was then pelleted down
by centrifuging, and the supernatant was boiled for 10 min to remove impurities. The supernatant
was incubated with 3% streptomycin overnight at 4°C to remove further impurities (i.e., DNA).
After repeat centrifuging and boiling, the supernatant was placed in 10 mM HEPES (4-(2hydroxyethyl)-1-piperazineethanesulfonic acid) buffer, pH 8.0 overnight at 4°C for dialysis. After
dialysis, 40mM EGTA (ethylene glycol tetraacetic acid) was added into ProCA32.CXCR solution
to chelate Ca2+ and other cations, and HiTrap Q HP anion exchange chromatography column (GE
Healthcare) was used to finish purification.

2.2.4 Lysine PEGylation

Methoxy PEG Succinimidyl Carboxymethyl Ester reagent with the molecular weight of 2
kDa (JenKem Technology) was used for lysine PEGylation. ProCA32.CXCR4 was mixed with
PEG reagent with a molar ratio of 1:5 and then shake at room temperature for 2 h or at 4°C for
overnight. Excess non-reacted NHS-ester was quenched by 100 mM Tris buffer for 30 min at
ambient temperature. The purification of the PEGylated protein sample was achieved by FPLC.
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Polyacrylamide gel electrophoresis combined with coomassie-blue and iodine (I2) staining was
applied to test the PEGylation efficiency.

2.2.5 Cysteine PEGylation

Methoxy PEG maleimide (JenKem Technology) with a molecular weight of 2 kDa was
used for cysteine PEGylation. A good protein concentration for PEGylation is between 1-10
mg/mL. 100x molar excess of Tris (2-carboxyethyl) phosphine hydrochloride (TCEP, SigmaAldrich) was added and reacted at room temperature for 20 minutes to reduce disulfide bond of
ProCA32.CXCR4. Amicon concentrator was applied to remove the unreacted free TCEP.
Maleimide PEG was mixed with reduced ProCA32.CXCR4 with a molar ratio of 1:1. The mixture
was degassed with nitrogen, closed tightly, and reacted overnight at 4°C. MALDI (matrix-assisted
laser desorption/ionization) Mass-spectrometry and coomassie-blue and iodine (I2) staining were
applied to analyze the PEGylation product.

2.3

Determination of r1 and r2 relaxivity values
To determine the relaxivity of ProCA32.CXCR4, different concentrations of

ProCA32.CXCR4 from 0 μM (buffer only) to 100 μM were prepared in 50 mM HEPES, 100 mM
NaCl, PH 7.2. The samples were incubated at 37°C for one hour before measurement. The
relaxation times (T1 and T2) of different concentration of ProCA32.CXCR4 were measured by
Bruker minispec relaxometer (60MHz) and the phantom was scanned by 7.0 T Bruker MRI
scanner. Commercial GBCA such us Dotarem, Magnevist, Eovist etc. were prepared with
the same buffer and measured with same protocol. However, the concentration range was from 0
mM (buffer only) to 160 mM. Relaxivity values (r1 and r2) were calculated by the following
equation.
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1
𝑟𝑖 =

𝑇𝑖 𝑠𝑎𝑚𝑝𝑙𝑒

1
– 𝑇
𝑖 𝑏𝑢𝑓𝑓𝑒𝑟

[𝐺𝑑 3+ ] 𝑇
Equation 2.1

Whereas the 𝑇𝑖 𝑠𝑎𝑚𝑝𝑙𝑒 is the relaxation time of contrast agent samples and the 𝑇𝑖 𝑏𝑢𝑓𝑓𝑒𝑟 is
the relaxation time of buffer only, [𝐺𝑑3+ ]𝑇 is the Total concentration of Gd3+.
2.4

Metal-binding affinity and selectivity study

2.4.1 Determination of Tb3+ binding affinity of ProCA32.CXCR4
Fluorescence spectra were collected with QM1 fluorescence spectrophotometer (PTI) at
room temperature. Tb3+-tryptophan luminescence resonance energy transfer (LRET) emission
spectrum (500 nm to 600 nm) was acquired following a 280 nm excitation. 30 μM of
ProCA32.CXCR4 was added into DTPA chelator buffer (5 mM DTPA, 50 mM HEPES, 150 mM
NaCl, pH 7.2) for titration. DTPA has a strong binding affinity to Tb3+ (Kd= 10-21 M, 25 °C). The
“free” Tb3+ concentration can be calculated by:

[𝑇𝑏 3+ ]𝑓𝑟𝑒𝑒 = 𝐾𝑑 𝑇𝑏,𝐷𝑇𝑃𝐴 ×

[𝑇𝑏 − 𝐷𝑇𝑃𝐴]
[𝐷𝑇𝑃𝐴]𝑓𝑟𝑒𝑒
Equation 2.2

Whereas we assume the “free” Tb3+ is the portion triggered the LRET and cause
fluorescence signal change, the Tb3+ binding affinity of ProCA32.CXCR4 can be calculated by the
equation:
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𝑓=

[𝑇𝑏 3+ ]𝑓𝑟𝑒𝑒

𝑛

𝐾𝑑 𝑇𝑏,𝑃𝑟𝑜𝐶𝐴32.𝐶𝑋𝐶𝑅4 𝑛 + [𝑇𝑏 3+ ]𝑓𝑟𝑒𝑒

𝑛

Equation 2.3

where f is the fractional LRET signal change followed each of titration points, n is the hill
number.
2.4.2 Determination of Gd3+ binding affinity of ProCA32.CXCR4.
A competition method was applied to evaluate the Gd3+ binding affinity of
ProCA32.CXCR4. 10 µM of ProCA32.CXRC4 and 20 μM Tb3+ were prepared in 5 mM DTPA
(diethylenetriamine pentaacetate), 50 mM HEPES, 150 mM NaCl at pH 7.2, and incubated with
different concentrations of Gd3+, from 0 μM to 200 μM, at room temperature for overnight. By
fitting the fluorescence signal decrease at 545 nm as the Gd3+ concentration increase, the apparent
Kd of Gd3+ compete with terbium can be calculated by the equation:

([𝑇𝑏] 𝑇 + [𝐺𝑑] 𝑇 + 𝐾𝑑 𝑎𝑝𝑝 ) − √([𝑇𝑏] 𝑇 + [𝐺𝑑] 𝑇 + 𝐾𝑑 𝑎𝑝𝑝 )2 − 4 × [𝑇𝑏] 𝑇 × [𝐺𝑑] 𝑇
𝑓=

2 × [𝑇𝑏]𝑇
Equation 2.4

Where f is the fractional LRET signal change, [Tb]T is the total Tb3+ concentration, [Gd]T
is the total Gd3+ concentration. Kdapp is the apparent dissociation constant of Gd3+ compete with
Tb3+.
The dissociation constant of Gd3+ binds to ProCA32.CXCR4 can be calculated by equation:
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𝐾𝑑 𝐺𝑑,𝑃𝑟𝑜𝐶𝐴32.𝐶𝑋𝐶𝑅4 = 𝐾𝑑 𝑎𝑝𝑝 ×

𝐾𝑑 𝑇𝑏,𝑃𝑟𝑜𝐶𝐴32.𝐶𝑋𝐶𝑅4
𝐾𝑑 𝑇𝑏,𝑃𝑟𝑜𝐶𝐴32.𝐶𝑋𝐶𝑅4 + [𝑇𝑏 3+ ] 𝑇

Equation 2.5
Where KdTb,ProCA32.CXCR4 is the dissociation constant of Tb3+ binds to ProCA32.CXCR4,
[Tb3+]T is the total Tb3+ concentration.
2.4.3 Determination of Ca2+ binding affinity of ProCA32.CXCR4
The dissociation constant between ProCA32.CXCR4 and Ca2+ was determined by a
similar assay that was developed by Tsien (147). 10 µM of ProCA32.CXCR4 was prepared in 5
mM EGTA (ethylene glycol tetraacetic acid), 50 mM HEPES, 150 mM NaCl at pH 7.2. Different
concentration of Ca2+ was titrated into the system. Fluorescence change upon each titration was
monitored by the emission spectrum of 200 nm to 300 nm followed by excitation of 280 nm, the
concentration of free Ca2+ can be calculated by the equation:
[𝐶𝑎2+ ]𝑓𝑟𝑒𝑒 = 𝐾𝑑 𝐶𝑎,𝐸𝐺𝑇𝐴 ×

[𝐶𝑎 − 𝐸𝐺𝑇𝐴]
[𝐸𝐺𝑇𝐴]𝑓𝑟𝑒𝑒
Equation 2.6

Where the dissociation constant of Ca2+ to EGTA (KdCa,EGTA) is 1.51×10-7 M, The Kd of
Ca2+ to ProCA32.CXCR4 (KdCa,ProCA) can be determined by equation:
𝑓=

[𝐶𝑎2+ ]𝑓𝑟𝑒𝑒

𝑛

𝐾𝑑 𝐶𝑎,𝑃𝑟𝑜𝐶𝐴32.𝐶𝑋𝐶𝑅4 𝑛 + [𝐶𝑎2+ ]𝑓𝑟𝑒𝑒

𝑛

Equation 2.7
Where f is the fractional change of Tryptophan fluorescence intensity, [Ca2+]free is the free
Ca2+ concentration of each titration.
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Determination of Zn2+ binding affinity of ProCA32.CXCR4.

2.4.4

The dissociation constant between Zn2+ and ProCA32.CXCR4 was determined by a
modified fluorescence competition assay. In detail, 2 µM of Zn2+ and FluoZinTM-1 (ThermoFisher)
was prepared in 1:1 ratio, different concentrations of ProCA32.CXCR4 were titrated, fluorescence
emission spectrum of 500 nm to 600 nm was acquired by 495 nm excitation, the apparent Kd of
ProCA32.CXCR4 competes with Zn2+ can be calculated by the equation:

([𝑍𝑛]𝑇 + [𝑃𝑟𝑜𝐶𝐴32. 𝐶𝑋𝐶𝑅4]𝑇 + 𝐾𝑑 𝑎𝑝𝑝 ) − √([𝑍𝑛] 𝑇 + [𝑃𝑟𝑜𝐶𝐴32. 𝐶𝑋𝐶𝑅4]𝑇 + 𝐾𝑑 𝑎𝑝𝑝 )2 − 4 × [𝑍𝑛] 𝑇 × [𝑃𝑟𝑜𝐶𝐴32. 𝐶𝑋𝐶𝑅4]𝑇
𝑓=

2 × [𝑍𝑛]𝑇

Equation 2.8
Where [Zn]T is the total Zn2+ concentration and [ProCA32.CXCR4]T is the total
ProCA32.CXCR4 concentration, Kdapp is the apparent dissociation constant. Knowing the
dissociation constant of Zn2+ to Fluozin-1, the dissociation constant between Zn2+ and
ProCA32.CXCR4 can be calculated by equation:

𝐾𝑑 𝑍𝑛,𝑃𝑟𝑜𝐶𝐴32.𝐶𝑋𝐶𝑅4 = 𝐾𝑑 𝑎𝑝𝑝 ×

𝐾𝑑 𝑍𝑛,𝐹𝑙𝑢𝑜𝑧𝑖𝑛
𝐾𝑑 𝑍𝑛,𝐹𝑙𝑢𝑜𝑧𝑖𝑛 + [𝐹𝑙𝑢𝑜𝑧𝑖𝑛] 𝑇

Equation 2.9
Where Kdapp is the apparent dissociation constant of ProCA32.CXCR4 compete with
Fluozin-1.
2.4.5 Determination of Mn2+ binding affinity of hProCA32.collagen1
The Mn2+ binding affinity of hProCA32.collagen1 was determined with a competition
assay similar to Gd3+-ProCA32.CXCR4 binding affinity determination. 10 µM of
hProCA32.collagen1 was prepared with 20 µM of Tb3+ in 5 mM DTPA, 50 mM HEPES, 150 mM
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NaCl at pH 7.2, different concentrations of Mn2+ (from 0 µM to 1000 µM) were then added into
solution and incubate at ambient temperature for O/N. Fluorescence spectra of each sample are
collected, and apparent Kd of Mn2+-Tb3+ competition was fitted against the fractional fluorescence
signal change at 545 nm by the equation:
([𝑇𝑏] 𝑇 + [𝑀𝑛] 𝑇 + 𝐾𝑑 𝑎𝑝𝑝 ) − √([𝑇𝑏] 𝑇 + [𝑀𝑛] 𝑇 + 𝐾𝑑 𝑎𝑝𝑝 )2 − 4 × [𝑇𝑏] 𝑇 × [𝑀𝑛] 𝑇
𝑓=

2 × [𝑇𝑏] 𝑇
Equation 2.10

Whereas the f is the fractional fluorescence signal change, [Tb]T is the total Tb3+
concentration, [Mn]T is the total Mn2+ concentration and Kdapp is the apparent Kd of Mn2+-Tb3+
competition.
By knowing the apparent Kd of Mn2+-Tb3+ competition and the Tb3+ binding affinity of
protein contrast agent, the disassociation constant of Mn2+ to contrast agent can be calculated by
the equation:
𝐾𝑑 𝐺𝑑,𝑃𝑟𝑜𝐶𝐴32 = 𝐾𝑑 𝑎𝑝𝑝 ×

𝐾𝑑 𝑇𝑏,𝑃𝑟𝑜𝐶𝐴32
𝐾𝑑 𝑇𝑏,𝑃𝑟𝑜𝐶𝐴32 + [𝑇𝑏 3+ ] 𝑇
Equation 2.11

2.5

Determination of the water coordination number of ProCA32.CXCR4
The water coordination number of ProCA32.CXCR4 was measured by terbium

luminescence decay of ProCA32.CXCR4 – Tb3+ complex in H2O and D2O adapted from a reported
assay (148). ProCA32.CXCR4 – Tb3+ complex was prepared in the H2O and D2O solution in 1:1
and 1:2 ratio. Tb3+ was excited by the xenon lamp at 265 nm and the terbium luminescence decay
lifetime was collected at the emission of 545 nm. By fitting the decay curve with exponential decay,
KH2O and KD2O can be obtained, ΔKobs is the difference between luminescence decay of
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ProCA32.CXCR4 – Tb3+ complex in H2O and D2O. Standard curve of water number of different
chelators are used to calculate the water number of ProCA32.CXCR4.
2.6

Cell culture
Melanoma cell lines, including B16LS9, Mel290, Mel270, 92.1, M20-09-196 were used in

this study. The culture medium recipe is 500 mL RPMI 1640 1X with L-Glutamine with 10% fetal
bovine serum (FBS), 12.5 mL Corning™ HEPES, 1 M solution (fisher scientific), 5 mL Corning™
Sodium Pyruvate 100mM Solution (fisher scientific), 5 mL Corning™ cellgro™ MEM
Nonessential Amino Acid Solution (fisher scientific), 5 mL Corning™ MEM Vitamin Solution
(fisher scientific) and 5 mL Penicillin-Streptomycin solution. All cells were thawed at 37°C and
transferred to a 100 mm cell culture dish with 6 mL of medium. After reach over 90% of
confluence, cells were washed by HBSS and suspended by 1 to 2 mL of 1% trypsin and centrifuged
for 5 min at 1000 rpm. Then cells were passed to two 100 mm culture dish to keep culturing. Cells
were frozen with a commercial freezing medium containing 10 % DMSO (dimethyl sulfoxide) for
cryopreserving.
2.7

Cancer cell targeting study

2.7.1 Flow cytometry analysis
The flow cytometry was performed to quantify the expression of CXCR4. Cultured human
uveal melanoma cells were dissociated with non-enzymatic cell dissociation solution (SigmaAldrich, St. Louis, MO). The cells were stained for 20 minutes at 4C with APC mouse anti-human
CD184 (clone 12G5) (BD Biosciences, San Jose, CA). Data acquisition was performed using a
Becton Dickson Aria IIu FACS sorter (BD Biosciences, San Jose, CA). FlowJo software (Tree
Star, Ashland, OR) was used for data analysis.
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2.7.2 Immunofluorescence staining
2.7.2.1 NHS-fluorescein labeling protein
Fluorescein-5-EX N-hydroxysuccinimide ester (Sigma-Aldrich) was used to label
ProCA32.CXCR4 and ProCA32. Protein solution concentrated between 1-10 mg/mL was prepared
in 10 mM HEPES, pH 8.0 (Other non-amide-containing buffers at pH 7.0-9.0 may also be used).
NHS-fluorescein was equilibrium to room temperature before reaction. 15 molar excess of NHSfluorescein was mixed well with the protein solution and react at room temperature for 1 h. Nonreacted NHS-fluorescein was quenched by adding 100 mM Tris buffer. Protein was purified by
gel filtration.
2.7.2.2 Immunofluorescence staining with melanoma cells to evaluate the CXCR4
binding affinity of ProCA32.CXCR4
Melanoma cell lines including B16SL9, Mel290, M20-09-196 were used for
immunofluorescence staining. Melanoma cells were cultured until reaching 50-70% confluence
and fixed on cover slides with 3.7% formaldehyde solution at 4C. Fixed melanoma cells were
incubated with 5μM NHS-fluorescein labeled ProCA32.CXCR4 (the control group was incubated
with fluorescein-labeled ProCA32) for 1 h at 37 C. The cells were washed thoroughly with TBSTween 20 (TBST) buffer. DAPI (4’,6-diamidino-2-phenylindole, ThermoFisher) was used for
nucleus staining, and the cells were imaged with Zeiss microscope. For colocalization study, after
incubation with NHS-fluorescein labeled ProCA32.CXCR4, melanoma cells were then blocked
with 5% BSA (prepared in TBST buffer) for 20 min at room temperature and incubated with 0.1%
dilutions of primary antibody for CXCR4 (Abcam, ab189048) at 4 C for overnight. After
thoroughly washed with TBST buffer, melanoma cells were incubated with 0.1% dilutions of Goat
anti-Mouse secondary antibody (Invitrogen, Alexa Fluor 555) for 60 min at room temperature.
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DAPI (ThermoFisher) was applied to stain the nucleus, and slides were covered by coverslip and
sealed. Colocalization analyses of red fluorescence (555 nm excitation) and green fluorescence
(488 nm excitation) were done using Fiji’s plugin coloc2.
2.7.2.3 Immunofluorescence staining of mouse tissue
The liver tissue of Mel290 mice was collected after injection of ProCA32.CXCR4 and
ProCA32, and immunofluorescence staining was performed on collected liver tissues. 4 M
Cryosections of Mel290 mice livers were thawed at room temperature for 20 min and rehydrate
the tissue sections with TBST. Tissue sections were surrounded with a hydrophobic barrier using
Dako pen (Agilent) and blocked with 5% BSA for 60 min at room temperature then incubated with
home-made ProCA32.CXCR4 and ProCA32 primary antibody (1:50 dilution) for 60 min at room
temperature. After thoroughly washed with TBST, tissue slides were incubated with 0.1% dilution
of Goat Anti-Rabbit secondary antibody (Invitrogen, Alexa Fluro-555) for 60 min at room
temperature. DAPI (ThermoFisher) was then applied to stain the nucleus, and slides were covered
and sealed.
2.7.3 Enzyme-linked immunosorbent assay (ELISA)
An indirect ELISA assay (Fig. 2.1) was used to quantify the CXCR4 targeting capability.
Melanoma cells with CXCR4 expression were used to determine the ProCA32.CXCR4 targeting.
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Figure 2. 1 Determing the CXCR4 binding affinity with indirect ELISA.

2.7.3.1 Preparation of cell lysate.
The cells were cultured in T-75 flasks until reach to about 90-95% confluence, and gently
washed by HBSS before collected by plastic cell scraper. 1 ml of HBSS buffer was added into the
flask, and cells were scraped from the flask. The mixture solution was transferred to a pre-cold
tube and centrifuge at 8000 rpm for 10 min at 4C° to pellet down cells. The supernatant was gently
decanted and 1 ml of RIPA buffer was added to lyse the cells for 1 h at 4C°. The mixture was then
centrifuged at 12,000 rpm for 30 min at 4C° to remove the cell debris. The supernatant was
collected as cell lysate, and the total protein concentration of cell lysate was measured by Bio-Rad
assay.
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2.7.3.2 Indirect ELISA
Melanoma 290 cell lysate in NaHCO3 solution (pH 9.6) was incubated in 96-well plates
overnight at 4 °C. The 96-well plates were washed thoroughly by TBST buffer and blocked by 5%
BSA solution (prepared in TBST) for 60 min at room temperature. Different concentrations of
ProCA32.CXCR4 (0 nM to 5000 nM, prepared in TBST) was added in different wells and
incubated for one hour at room temperature. 0.1% ProCA32.CXCR4 antibody (self-generated
polyclonal rabbit antibody) was added for 60 min incubation at room temperature. The secondary
antibody, stabilized goat-anti-rabbit HRP-conjugated antibody (Pierce), was incubated for 45 min
at room temperature. After washed with TBST, 100 µL of 1-StepTM Ultra TMB-ELISA Substrate
Solution (ThermoFisher) was added into each well to visualize the color change. When a yellow
gradient color was observed, 100 µL of 1 M H2SO4 was added into each well to terminate the
reaction. The absorbance intensity at 450 nm wavelength was measured by FLUOstar OPTIMA
plate reader, and data were plotted using GraphPad Prism 5.

2.7.4 MRI phantom scanning of ProCA32.CXCR4 incubated melanoma cells
CXCR4 expression cell lines are cultured according to the requirement. Cells are washed
with PBS to remove serum and protein in the culture media. After that, cells were incubated with
ProCA32.CXCR4 at 37°C for one hour. Wash the cells gently for three times with PBS buffer.
Cells are collected with non-enzymatic cell dissociation solution and centrifuge with 1000 rpm for
5 minutes. Supernatant decanted gently to remove the PBS and gently resuspend the cells with
PBS again. Repeat three times. Cell pellets are collected and transferred to the small tube for the
phantom experiment to determine the relaxivities.
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2.7.5 Cell attachment assay
The cells were cultured overnight under standard conditions. Next day, different cells
(with appropriate cell numbers) were transferred to a new plate with wells that were coated with
different proteins (indicated in the figures) with fresh medium. The cells were further cultured for
35 min in the CO2 incubator at 37°C, upon incubation cells were washed three times gently. The
attached cells were directly counted. In all attachment assays, the attachment is presented as a total
number of cells attached to the plate per microscopic view field (calculated from the average of
three view fields in each well in four wells).
2.8

Stability study of ProCA32.CXCR4

2.8.1 Serum stability
150 µL of 500 µM ProCA32.CXCR4 was mixed with 150 µL mouse serum and incubated
at 37ºC for the serum stability study. 15 µL of samples were taken after 3 h, 4 h, 1 d, 2 d, 4 d, 6 d,
8 d, and 14 d of incubation. The samples were boiled for 10 min after being mixed with 2 µL of 1
M EGTA solution and SDS buffer and analyzed by western blot and Ponceau S staining flowing
a standard procedure. Briefly, the mixture of protein sample and mouse serum taken from different
time points at 37ºC incubation were prepared for the SDS-PAGE. Protein bands were transferred
from the SDS-PAGE to nitrocellulose membrane. Ponceau S solution (Sigma-Aldrich) was used
to stain the membrane from 5 min and rinse membrane 3-5 times in TBST buffer to achieve the
desired staining results.
2.8.2 Transmetallation study
In order to characterize the resistance of the Gd3+-ProCA32.CXCR4 complex to
transmetallation by endogenous ions such as Zn2+, a relaxometric transmetallation assessment was
performed using a reported assay (149). Briefly, ProCA32.CXCR4 and other GBCA were mixed
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with the same concentration of ZnCl2 (2.5 mM) in pH 7.0 phosphate buffer. The final mixture
contained 0.026 M KH2PO4, 0.041 M Na2HPO4, 2.5 mM Gd3+ complex, and 2.5 mM ZnCl2. When
transmetallation of Gd3+ by Zn2+ occurred, insoluble GdPO4 formed and a decreased proton
relaxation rate was observed. The longitudinal relaxation rate change of the mixture reflected the
transmetallation process of Gd3+ by Zn2+ and the thermodynamic index was calculated by r1 of the
mixture after incubation at the present of Zn2+ over the initial r1 of GBCA.
2.9
2.9.1

Animal study
Intrahepatic heterotopic xenotransplantation tumor model

10-wk-old female NU/NU mice (Jackson Laboratory, Bar Harbor, ME) were used to
establish the intrahepatic heterotopic xenotransplantation tumor model. Mel290 cells were
cultured and suspended in sterile PBS buffer. The mice were anesthetized with ketamine and
xylazine mixture and placed to the supine position. A small incision was made along the right flank
of the mouse. The liver was exposed with a small retractor. A 301/2-gauge needle was inserted
into the liver until its point reached just below the liver sub capsule under a surgical microscope.
Two million of Mel290 cells were inoculated in a volume of 20 ul PBS. The needle was then
carefully removed at the same time that a sterile swab held the injection site. Formation of white
cell bulla between hepatic parenchyma and the capsule was the criterion for successful injection.
The incision was sutured with a 5-0 absorbable suture. After two to three weeks of Mel290 cell
injection, melanoma tumor formed in the liver.

2.9.2 Intraocular melanoma mouse model with hepatic metastases

Human uveal melanoma M20-09-196 cells and 10-wk-old female NU/NU mice (Jackson
Laboratory, Bar Harbor, ME) were used to generate the intraocular melanoma mouse model.
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Subsequently, the mice with intraocular melanoma developed hepatic metastases. An aliquot of
106 uveal melanoma cells suspension in 2.5 l PBS buffer was inoculated into the supra choroid
space of the right eye of the nude mouse using a transcorneal technique. The mice were
anesthetized with an intraperitoneal injection (IP) of ketamine and xylazine mixture. A tunnel was
prepared from the limbus within the cornea, sclera and ciliary body to the choroid with a 301/2gauge needle under a surgical microscope. The tip of a 10 l glass syringe with a 31-gauge / 45degree point metal needle (Hamilton, Reno, NV) was used to introduce cell suspension into the
supra choroid space through the needle track. The eyes were enucleated after two weeks of
inoculation. Metastases in liver formed after 8-12 months of tumor cells inoculation.

2.9.3

SKOV3 Orthotropic Human Ovarian Cancer Xenograft Model
SKOV3 orthotopic human ovarian cancer xenograft mouse model was developed by Dr.

Lily Yang with the following procedure (150). SKOV3 ovarian cancer cells were cultured in
McCoy 5A medium with 10 % fetal bovine serum and 1 % penicillin and streptomycin. SKOV3
cells were collected when the confluence reaches 80 % and suspended in sterile PBS buffer. Mice
were anesthetized by injecting a mixture of 95 mg/kg ketamine hydrochloride and 5 mg/kg
xylazine of body weight in sterile saline intramuscularly. Right ovary of mice was exposed by
abdominal incision. At least 5 × 104 cells in 20 μL PBS were injected orthotopically into the
ovarian bursa of each mouse. Close the abdominal incision after injection and monitor the mice
until completely awake.
2.9.4 DEN induced HCC mouse model
Equal number of male and female mice with C57BL/6 genetic background were used for
developing DEN induced HCC mouse model. Diethylnitrosamine (DEN, Sigma–Aldrich N0756)
was dissolved in sterile saline. 14-day-old mice were treated with a single dose of
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Diethylnitrosamine (DEN, Sigma–Aldrich N0756) at a dose of 25 mg/kg body weight by IP
injection. Mice in one randomly pre-assigned group were euthanized 11 months after DEN
administration for histological and biochemical analyses. The livers were removed and weighted
right after euthanasia, the numbers of visible tumors on the liver surface were counted
macroscopically. The largest lobes were fixed in formalin and embedded in paraffin. Sections were
stained with hematoxylin and eosin and examined microscopically. Doxorubicin treatment:
Doxorubicin hydrochloride salt was dissolved in sterile DD water. Mice received doxorubicin (3
mg/kg) bi-weekly for 4 weeks. The mice were then analyzed for MRI screening and euthanized
for pathological analyses.
2.9.5 4T1 breast tumor mouse model
Luciferase stable transfected 4T1 breast cancer cells were cultured in RPMI-1640 medium
supplemented with 10 % FBS and 1 % penicillin and streptomycin until confluence reach 80 %.
Cells were detached by trypsin and suspended in sterile PBS. 5 × 104 cells were orthotopically
injected to the mammary pad of mice. The orthotopic breast tumors will form around 2 weeks, and
lung metastases will form around 3 - 4 weeks.
2.9.6 Subcutaneous UM murine model
Ten-week-old female NU/NU mice were used for the subcutaneous UM murine model.
Aliquots of 2*106 Mel 290 cells were suspended in 50 µL of PBS buffer mixed with 50 µL of
Matrigel Matrix (Corning Life Science) and injected subcutaneously both on the right and left
side of the back of NU/NU mice. After six weeks, subcutaneous tumors of 60-120 mm3 in
volume were formed.
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2.10 MRI scan
M20-09-196 mice and HCC mice were all scanned with a 7.0 T Agilent MRI scanner at
the University of Georgia. Mice were anesthetized by breathing in isoflurane through isoflurane
vaporizer. The respiration rates of animals were monitored throughout the MRI scanning and
controlled to be 70-80 times per minute. T1 weighted images, T2 weighted images were collected
by spin-echo and fast spin-echo sequence before and after one bolus injection of 0.025 mmol/kg
ProCA32.CXCR4 at 3 h, 24h, 48h. T1 map and T2 map were also collected at the same time points.
T1 map was collected by the fast spin-echo protocol. The parameters of acquisition: TR, 5000 ms;
ESP, 8.17 ms; 8 inversion times cover from 0.01 ms to 1.5 ms with the same interval in between;
FOV, 3.5 cm × 3.5 cm by a matrix of 512 × 512; thickness, 1 mm with no gap. The parameters of
T2 map acquisition: TR, 2000 ms; TE, 8 ms to 96 ms with 8 ms interval in between; FOV, 3.5 cm
× 3.5 cm by a matrix of 512 × 512; thickness, 1 mm with no gap. Control mice were injected with
one bolus same dosage of ProCA32 and imaged at the same time points with the same parameters.
The parameters of spin-echo sequence: TR, 500 ms; TE, 14.89 ms; FOV, 3.5 cm × 3.5 cm by a
matrix of 512 × 512; thickness, 1 mm with no gap. The parameters of fast spin-echo sequence:
TR/ESP, 4000 ms/ 10 ms; FOV, 3.5 cm × 3.5 cm by a matrix of 512 × 512; thickness, 1 mm with
no gap.
M290 mice MR images were all collected on a 4.7 T small-bore Varian MR scanner at
Emory University. Mice were anesthetized follow a similar procedure and T1 weighted images
were collected before and after one bolus injection of 0.025 mmol/kg ProCA32.CXCR4 at 12 min,
50 min, 3 h, 22 h, 46 h by gradient echo sequence. The parameters of gradient echo sequence:
TR/TE, 140 ms/11 ms; FOV, 4 cm × 4 cm by a matrix of 512 × 512. MR images are processed
and analyzed by Fiji and MRIcron.
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MRI results of blocking experiment were acquired with the 7.0 T Bruker MRI scanner at
Yerkes National Primate Research Center. Subcutaneous UM mice were anesthetized follow a
similar procedure as detailed above, and T1 weighted images were collected before and after one
bolus injection of 0.025 mmol/kg Cys-ProCA32.CXCR4 or Lys-ProCA32 at 3 h, 24 h, and 48 h.
Blocking group mice received i.v. injections of 0.025 mmol/kg CXCR4 blocking reagent 24 h and
12 h prior to the injection of Cys-ProCA32.CXCR4. The parameters of the RARE sequence were:
TR/TE, 560 ms/11 ms; FOV, 3.5 cm × 3.5 cm by a matrix of 256 × 256. MRI data were processed
and analyzed by Fiji and MRIcron.

2.11 Organ distribution, toxicity, and pharmacokinetics study of ProCA32.CXCR4
2.11.1 Organ distribution study.
ICP-OES was used to analyze the Gd3+ distribution in different mouse organs after injection
of ProCA32.CXCR4. Healthy CD-1 mice were injected with 0.025 mmol/kg bolus dosage of
ProCA32.CXCR4. Animals were euthanized 46 h and 7 days after receiving an injection of
ProCA32.CXCR4. Organs including heart, liver, spleen, kidney, brain, muscle, and skin were
subsequently collected and used for ICP-OES analysis. Tissues (0.1–0.5 g) of each organ were
dissolved overnight in 1 mL of 67-69% nitric acid, OptimaTM (Fisher Chemical). Undissolved solid
particles were removed by filtration, and the supernatant was retained for Gd3+ content analysis by
ICP-OES.
2.11.2 Toxicity study of ProCA32.CXCR4
ProCA32.CXCR4 acute toxicity was tested by a bolus injection of 100 μL, 7 mmol
ProCA32.CXCR4 to 10-week-old healthy CD-1 mice. ProCA32.CXCR4 with two different
PEGylation (Cys-ProCA32.CXCR4 and Lys-ProCA32.CXCR4) were tested, respectively. For

53

each experiment group, n = 3, the control group are mice with saline injection. Mice were observed
every eight hours post-injection, then euthanized after five days. Terminal blood was collected by
cardiac puncture, and serum was transferred immediately to micro-centrifuge tubes. Plasma was
separated from blood cells by centrifugation at 14,000 rpm, 4°C for 10 min. Serum samples were
used for blood biochemistry tests and kidney function tests to measure ALT, AST, and electrolyte
levels. Tissues including heart, muscle, liver, spleen, kidney, tail, and brain, were collected for
analysis of gadolinium distribution, using ICP-OES.

2.11.3 Pharmacokinetic study
Female CD-1 mice (8–10 weeks old) were used to determine the pharmacokinetic
parameters of ProCA32.CXCR4. ProCA32.CXCR4 (100 L, 0.025mmol/kg) was administered
through tail vein IV injection. The blood samples were collected at various time points using
saphenous vein up to seven days using a sparse sampling design (3–6 animals per time point).
Immediately following blood sample collection, samples were stored on ice, serum was obtained
through centrifugation, and Gd3+ concentration was determined using ICP-OES. Pharmacokinetic
parameters were calculated using the non-compartmental analysis tool of Phoenix WinNonlin
software. The areas under the concentration-time curve (AUClast and AUCinf) were calculated
using a linear trapezoidal rule. The clearance and volume of distribution (Vss) were estimated
following IV dose administration. The elimination rate constant value (k) was obtained by linear
regression of the log-linear terminal phase of the concentration-time profile using at least three
declining concentrations in terminal phase with a correlation coefficient of >0.8. The terminal halflife value (T1/2) was calculated using the equation 0.693/k.
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3

DESIGN, EXPRESSION, PURIFICATION, AND PEGYLATION OF
PROCA32.CXCR4

3.1

Introduction
CXCR4 is found to be expressed in over 23 different kinds of tumors and closely related

to cancer progression and development of metastases. Chemokine receptor 4 (CXCR4) plays a
crucial role in cell migration and cancer metastasis to several organs such as liver, bone marrow,
and lung that have the intrinsically high concentration of its natural ligand CXCL12 (140, 151,
152). (Figure 3.1). CXCR4 has gained tremendous attention over the past few decades for its
widely up-regulation in various types of cancers. It is now gradually becoming a novel molecule
target for anti-cancer diagnosis and treatment. A CXCR4 antagonist, Plerixafor (Mozobil®,
AMD3100), is approved by the FDA for stem cell mobilization. Another ongoing study is focused
on the effect of another CXCR4 antagonist, X4P-001, on T-cell infiltration in human metastatic
melanoma. The importance of CXCR4 in cancer-related incidence is the motivation of achieving
CXCR4 targeted imaging for cancer.
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Figure 3.1 Cancers metastasize through the CXCR4-CXCL12 gradient in an organspecific pattern.
Tumor cells that express CXCR4 metastasize through CXCR4-CXCL12 interaction to specific
organs that have intrinsically high concentration of CXCL12 such as the lung, liver and bone.

vMIP-II, a viral chemokine encoded by human herpesvirus 8, displays diverse interactions
with both CC and CXCR4 (153-155). vMIP-II interacts with CXCR4 as an antagonist and inhibits
the Th1-associated inflammation. Due to these properties of vMIP-II, it is a potential candidate for
anti-inflammatory and anti-HIV drugs. A crystal structure of CXCR4 and vMIP-II complex reveals
the interaction of vMIP-II to CXCR4 is through the N-terminus and N-loop of vMIP-II (156). The
central residues that participate in the interaction are mainly in the N-terminus. It supported by the
study of synthesis peptides with the N-terminus sequence of vMIP-II, the peptide contains the
amino acid sequence of residues 1- 21 of vMIP-II (LGASWHRPDKCCLGYQKRPLP), displays
appreciable CXCR4 binding affinity (IC50 = 190 nM) when compared with the vMIP-II (IC50 =
14.8 nM) (157).
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MRI imaging is widely used in clinical practice, and MRI contrast agent development can
efficiently improve the sensitivity of MRI. As stated in chapter 1, the current contrast agents in
clinical usage are not sensitive enough to achieve molecular imaging. Based on the platform of
ProCA32, after careful review of the CXCR4 targeting moieties, we designed the CXCR4 specific
targeting contrast agent, namely, ProCA32.CXCR4. ProCA32.CXCR4 was designed based on the
platform of protein-based contrast agent ProCA32. ProCA32 was developed by previous lab
member Dr. Xue, which contains two Gd3+ binding sites. By linking the CXCR4 targeting moiety
to the C terminus of ProCA32 with a flexible linker, we designed ProCA32.CXCR4 as the CXCR4
targeted MRI contrast agent for CXCR4 specific molecular imaging with MRI (Figure 3.2). Based
on the complex X-ray structure of CXCR4 and vMIP-II, we designed the CXCR4 targeting moiety,
included key CXCR4 interaction residues from vMIP-II, that reach into the binding pocket and
interact with key residues D262, D97, S285, and E288 of CXCR4 in both chemokine recognition
sites 1 and (Figure 3.4) (156).
ProCA32.CXCR4 was bacterially expressed and purified following a previously reported
protocol (63). One cysteine is introduced for site-specific PEGylation through thiol group with
maleimide PEG reagent. The post-expression modification was done through NHS-ester
PEGylation or maleimide PEGylation verified by coomassie blue staining, and iodine (I2) staining.

Figure 3.2 Sequence alignment of Rat_ProCA32 and Rat_ProCA32.CXCR4.
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Figure 3.3 Predicted secondary structure, solvent accessibility, and models of
ProCA32.CXCR4.
Prediction of secondary structure, solvent accessibility and final models of ProCA32.CXCR4
using I-TASSER (158). C-score is the confidence of protein model predicted by I-TASSER, which
is typically in the range of [-5,2], where the higher value of C-score corresponding higher
confidence of the prediction.
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Figure 3.4 Model structure of the ProCA32.CXCR4 interacting with CXCR4.
ProCA32.CXCR4 contains two Gd3+ binding sites, the C terminus of ProCA32.CXCR4 is the
CXCR4 targeting moiety which can interact with CXCR4 by residue-residue interaction and
electrostatic interaction.
3.2

Results

3.2.1 Expression, purification of ProCA32.CXCR4

ProCA32.CXCR4 was expressed by cell strain BL21(DE3) pLysS with 0.5 mM IPTG
induction followed by a protocol described in chapter 2. The expression of ProCA32.CXCR4
consists of small-scale culture and large-scale expression. Ampicillin resistant agar plates were
used for transformation of ProCA32.CXCR4 plasmid. A single colony was inoculated in 250 ml
LB media with 0.1% ampicillin for small scale culture overnight at 37 °C. The second day, small
scale culture LB media were transferred to 1-liter LB media with 0.1% ampicillin for large scale
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expression at 37°C. Measure the OD595 of the LB media to ensure large-scale culturing starts from
OD595 around 0.1. Observing the OD595 change along with time and add 0.5 mM IPTG when
culture solution OD595 reach between 0.6-0.8. After adding IPTG for inducing expression, keep
the culturing temperature at 37 °C for three hours, and reduce the temperature to 25°C for overnight
expression. Different conditions for expression have been tested: 28°C culturing for 4 hours after
IPTG induction generated comparable yield with 25°C overnight expression.

The expression of ProCA32.CXCR4 is confirmed by Coomassie blue staining of SDSPAGE (Figure 3.5 A). Molecular weighted of ProCA32.CXCR4 is 14.3 kDa and after induction
cell pellet clearly shows thicker band of protein around 14.3 kDa. The yield of ProCA32.CXCR4
expression is calculated to be in a range of 60 to 100 mg/L LB media, varies by the batch of
expression.

Purification of ProCA32.CXCR4 followed by a series of steps including sonication,
boiling, dialysis, and FPLC (fast protein liquid chromatography). Cell pellet from expression LB
media was collected by centrifuging at 8000 rpm. The cell pellet was resuspended in PBS buffer
in a ratio of 1:10, more specific, 1 gram of cell pellet resuspended in 10 ml PBS buffer. Sonication
was applied to break cell structure and release the expressed protein. Sonication was carried out
10 times in total, every time for 1 minute and with a 10 minutes interval in-between for cooling
down the solution. After sonication, the solution should become semitransparent and with good
consistency. Pellet down the solution with centrifuge and boiled the supernatant to further remove
the impurities. 3% streptomycin was used to sediment the DNA for overnight. Followed by which
the solution is pellet down with centrifuge and boiled again and dialysis with 10 mM HEPES
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buffer for overnight. After dialysis, the solution was centrifuged and pellet down, 40 mM EGTA
was added for incubation for 48 hours, and the sample is ready for FPLC.

Ion exchange column was utilized to purify ProCA32.CXCR4 after sonication and
boiling. Fractions eluted from different peaks of FPLC spectra were collected separately, SDSPAGE was applied to verify the components of each elution from corresponding peaks (Figure 3.5
B, Figure 3.6 B). As shown in the purification SDS-PAGE (Figure 3.6 B), protein sample eluted
from peak 2, peak 3, and peak 4 were proved to be ProCA32.CXCR4 (MW = 14.3 kDa) and in the
presence of both monomer and dimer form. As shown in Figure 3.5, a large percentage of the
ProCA32.CXCR4 present in the monomer form.

Figure 3.5 Expression and purification SDS-PAGE of ProCA32.CXCR4.
(A) Coomassie blue staining of BL21(DE3) pLysS cell pellets before and after IPTG induction.
Cell pellets after IPTG induction show significantly thicker protein band around 14.3 kDa. (B)
Coomassie blue staining of SDS-PAGE of samples collected before FPLC and after FPLC. After
FPLC purification, only the ProCA32.CXCR4 showed in the SDS-PAGE, in both monomer and
dimer form.
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Figure 3.6 Purification of ProCA32.CXCR4.
(A) FPLC absorbance spectrum of ProCA32.CXCR4 purification. Peak 1 fractions are unbounded
protein; peak 2 fractions represented the Ca2+ bound form of ProCA32.CXCR4, fractions from
peak 4 are the Ca2+ free form of ProCA32.CXCR4, fractions eluted from peak 3 are the mixture of
Ca2+ loaded and Ca2+ free form of ProCA32.CXCR4. Peak 5 fractions are the DNA impurity. (B)
SDS-PAGE coomassie blue staining of fractions eluted from FPLC. Protein bands showed on peak
2, peak 3, and peak 4 elution fractions. (C) The UV absorbance of protein sample collected from
FPLC peak 4. The red curve shows the absorbance spectrum of Ca2+ bound ProCA32.CXR4. The
black curve shows the Ca2+ free ProCA32.CXCR4. The UV spectrum of Ca2+ binding form
ProCA32.CXCR4 show a hump at 295 nm.

3.2.2 PEGylation of ProCA32.CXCR4
ProCA32.CXCR4 was PEGylated after expression for post-expression modification to
further optimize solubility, stability, and pharmacokinetic properties. Site-specific PEGylation
including cysteine specific PEGylation through thiol group with maleimide group of the
PEGylation reagent and lysine-specific PEGylation through amide group on the lysine side chain
with NHS ester from the PEG reagent (Figure 3.7).
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Figure 3.7 Illustration of PEGylation.
(A) Reaction mechanism of site-specific maleimide PEGylation (Cys-PEGylation). The
maleimide group of polyethylene glycol (PEG) specifically react with the thiol group from
cysteine. (B) Reaction mechanism of NHS ester-PEGylation (Lys-PEGylation). The NHS ester
group of PEG agent react with the amine group from lysine side chain.
PEGylation of both lysine-specific and cysteine specific were carried out in an oxygen-free
system with degassing the solution by flushing nitrogen. Cysteine specific PEGylation requires a
reduced environment to break the disulfide bond and expose the thiol group. Reducing reagent
TCEP (tris (2-carboxyethyl) phosphine hydrochloride) was used to reduce the disulfide bond
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before cysteine PEGylation. During PEGylation, the falcon tube was wrapped with aluminum foil
to avoid light and generation of radical.
Lysine PEGylation product contains ProCA32.CXCR4 with different PEGylation sites.
Coomassie blue staining and iodine staining of SDS-PAGE shows multiples bands for the Lysine
PEGylation products (Figure 3.8). Cysteine PEGylation generates the homogenous PEGylation
product with only one site been PEGylated, the Coomassie blue staining and iodine staining of
cysteine PEGylation product shows only two bands, one for the non-reacted ProCA32.CXCR4
and the upper one is ProCA32.CXCR4 with one cysteine PEGylated (Figure 3.8).

Figure 3.8 PEGylation SDS-PAGE of ProCA32.CXCR4.
(A) Coomassie blue staining of ProCA32.CXCR4 before and after PEGylation. ProCA32.CXC4R
form in monomer and dimer before PEGylation, as indicated by the two bands on SDS-PAGE.
Cys-PEGylation product of ProCA32.CXCR4 composed non-PEGylated ProCA32.CXCR4 and
Cys-ProCA32.CXCR4, indicated by two bands on SDS-PAGE. Multiple protein bands of LysProCA32.CXCR4 product represents Lys-ProCA32.CXCR4 with a various number of PEGylation
sites. (B) Iodine (I2) staining of ProCA32.CXCR4 before and after PEGylation. Iodine staining
shows PEG as brown color on an SDS-PAGE gel, indicate the positions of PEG and PEGylated
ProCA32.CXCR4.
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3.3

Conclusion and discussion
ProCA32.CXCR4 expression, purification, and PEGylation are critically important for the

generation of CXCR4 specific contrast agent. We aim at producing ProCA32.CXCR4 in an
economical and time-efficient fashion and the protocol allows for the translational usage for large
scale production meet industrial standards.
ProCA32.CXCR4 is bacterially expressed and purified in a relatively simple steps protocol.
The yield of expression is good (60-100 mg/L LB) by optimizing expression procedures. The
protein yield exhibit best if follow three hours after induction expression at 37°C and decrease the
expression temperature to 25°C for overnight expression. ProCA32.CXCR4 is heat resistant and
structurally stable at boiling temperature. This property enables the purification of
ProCA32.CXCR4 from a lot of the impurity proteins efficiently. FPLC can further separate
ProCA32.CXCR4 from remaining impurities and separate the metal (Ca2+) free form of
ProCA32.CXCR4 with metal (Ca2+) loaded for gadolinium loading formulation. EGTA incubation
is a critical step for chelating metal ions, majorly Ca2+. 48 hours incubation with EGTA of the
ProCA32.CXCR4 before FPLC efficiently remove the preloaded metal ions and yield more Ca2+
free ProCA32.CXCR4. Longer incubation time is tested as well, no significant difference of Ca2+
free ProCA32.CXCR4 and Ca2+ loaded ProCA32.CXCR4 ratio was observed from longer
incubation time samples.
PEGylation of ProCA32.CXCR4 has successfully achieved by both cysteine PEGylation
and lysine PEGylation. After PEGylation, the solubility and stability of ProCA32.CXCR4 is much
improved and allow for the storage of ProCA32.CXCR4 at higher concentration and longer shelf
life. Lysine PEGylation increases the molecular weight of ProCA32.CXCR4 by 4-5 sites
PEGylation on average, which increase the molecular weight by 10 kDa to 30 kDa varies by the
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length of PEG reagents being used. Lysine PEGylated ProCA32.CXCR4 potentially has longer in
vivo circulation half-life because of the larger molecular weight. Cysteine PEGylation is more ideal
in the sense that it generates homogenous PEGylation product. The efficiency of cysteine
PEGylation is slightly lower than lysine PEGylation, which means more reagents might be wasted
during cysteine PEGylation procedure. There are several steps worth noting in the PEGylation:
protein solution should be properly degassed to remove the oxygen; protein sample tube should be
properly wrapped by aluminum foil to avoid exposure to light.
pH is an essential factor for the PEGylation, maintaining a pH neutral environment
improves the efficiency and percentage of PEGylation. Avoid radical is another factor in
successfully PEGylation; it is recommended to thoroughly degas the solution and avoid light by
wrapping with aluminum foil. Different PEGylation approaches, including N terminal amide
PEGylation and different sizes of PEGylation reagents, can be tested for further optimization of
PEGylation protocol.
3.4

Summary
The expression, purification, and PEGylation of ProCA32.CXCR4 was achieved based on

a previously reported protocol of ProCA32 with minor modification to improve the yield, quantity
of metal free form of ProCA32.CXCR4 for later gadolinium loading. Different PEGylation was
tested to optimize the solubility, stability and pharmacokinetic property of ProCA32.CXCR4.
Lysine specific PEGylation is more efficient in terms of percentage of PEGylated
ProCA32.CXCR4 over the total amount when compare with cysteine PEGylation. Cysteine
specific PEGylation has the advantage of generating homogenous PEGylation for industrial
production standard.
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4
4.1

BIOPHYSICS STUDY OF PROCA32.CXCR4

Introduction
Since the FDA approval of gadopentetate dimeglumine (Magnevist; Bayer HealthCare

Pharmaceuticals) in 1988, Gd3+-based contrast agents (GBCAs) have been widely used for clinical
MR imaging. GBCAs was considered to safe until the first nephrogenic systemic fibrosis (NSF)
been identified in 1997 (159-161). NSF was thought to be a disease only involve skin symptoms,
and the original name was Nephrogenic Fibrosing Dermopathy (NFD) (160). More and more indepth study of NSF makes researchers realized that it is a systemic disease that involves multiple
organs and tissues and happened mostly in the patients with a history of dialysis because of chronic
renal diseases. In some cases, NSF patients progress rapidly and lead to severe physical disability
and deaths (162). P. Marckmann and colleagues proposed the causative role of gadodiamide
application in the development of NSF. Since then, NSF has been identified as the side effect of
gadolinium-based contrast agents, especially in the patients with compromised renal function.
Moreover, the standard and dosage of gadolinium-based contrast agents’ application have been
modified, and the patients’ renal function listed as a factor that taken into consideration. No
standard treatment was established for NSF, and some cases showed kidney transplantation and
extracorporeal photopheresis could help to treat the disease (163).
The confidence of GBCAs was reestablished since more stable gadolinium-based
contrast agents being used, and the usage of GBCA in patients with renal malfunction was limited.
More recent data demonstrated that, in patients with the history of GBCA administration,
gadolinium accumulate in tissues including brain, bone, and kidneys regardless of patients’ renal
function status. Repeatedly exposure to gadolinium increases the risk of gadolinium accumulation.
(164, 165). The brain deposition of gadolinium was first identified because the signal increase of
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dentate nuclei (DN) in unenhanced T1 weighted MR images of patients with normal renal function,
and this enhancement was associated with exposure to gadolinium-based contrast agents (166,
167). Since then gadolinium-based contrast agent was accepted as the primary etiology of brain
tissue deposition.
We have carefully considered these factors in the design of ProCA32.CXCR4 for clinical
translational purpose. The Gd3+ binding sites of ProCA32.CXCR4 was well designed to balance
Gd3+ binding for safety, and water accessibility for relaxivities. ProCA32.CXCR4 was shown to
have unprecedented gadolinium kinetic and thermodynamic stability. The Log (K Gd) of
ProCA32.CXCR4 is 21.89. Metal selectivities of ProCA32.CXCR4 for Gd3+ over Zn2+ and Ca2+
are 106-1012 times greater than approved contrast agents, Dotarem and ProHance. The inertness of
ProCA32.CXCR4 in the presence of Zn2+ verified its strong stability against transmetallation.
Moreover, the improved relaxivity of ProCA32.CXCR4 enabled excellent contrast enhancement
in vivo with only one-quarter of gadolinium dosage compared with other GBCAs. No trace of
gadolinium was detected in mice brain after ProCA32.CXCR4 administration and we have also
not observed any acute toxicity and tissue/organ toxicity. Collectively, strong Gd3+ binding
affinity, excellent metal selectivity, inertness against transmetalation and less injection dosage
makes ProCA32.CXCR4 has an excellent safety profile.
4.1.1 Gadolinium toxicity and deposition
All clinical approved GBCAs are considered to be safe when administrating in a lower
dosage (0.1 to 0.3 mmol/kg) in the patients without renal insufficiency (46). Gadolinium is a rare
earth element and belongs to the lanthanide family. The free Gd3+ is toxic for humans, and the
chelated form will be far less toxic since it can eliminate from kidney before dissociating from
chelator. As a result, the toxicity of gadolinium-based contrast agent is considered to positively
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related to the stability of gadolinium-chelator complex. The free gadolinium deposited in tissues
including brain, bone, and kidney as well as other lanthanide family metal ions. In the insufficient
renal function patients, the half-life of GBCAs elimination is significantly prolonged than the
patients with normal renal function, which allows more time for free Gd3+ being dissociated from
chelator. It is one of the reasons that most of the reported NSF patients was administrated with
nonionic linear GBCA gadodiamide (Omniscan) (168).
The GBCAs can be classified into two categories according to their chemical structure,
linear and macrocyclic. The linear ones have an open-chain structure that is not fully closed where
the macrocyclic ones are caged in the chelator by the ligands. The etiology of NSF is considered
primarily to be free Gd3+ release from the chelator complex, and this process is related to two
factors: kinetic stability and thermodynamic stability (Table 4.1). Kinetic stability of GBCAs
defined by the dissociation rate of Gd3+ from the gadolinium complex, thermodynamic stability of
GBCAs characterized by the energy that requires for the dissociation of Gd3+ from chelator
complex to happen. As a result, GBCAs with higher kinetic stability and thermodynamic stability
will less readily to release Gd3+. Notably, the description of kinetic stability and thermodynamic
stability are under pH 1.
According to the stability under physiological condition, Frenzel et al. described the
GBCAs into three different stability classes: macrocyclic, linear ionic, and linear nonionic (45).
The macrocyclic GBCAs are most stable under physiological conditions (incubation with human
serum at 37 °C, pH 7.4), the Gd3+ release rate after 15 days incubation is less than 0.1 %, and the
initial Gd3+ release rate is less than 0.007 %/d. On the contrary, the release of Gd3+ rate of linear
GBCAs are way faster than predicted value by the conditional stability constant, and nonionic
linear GBCAs are about 10 times faster than the ionic linear GBCAs. Also, the elevated phosphate
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level of human serum facilitates the release of Gd3+. These results suggesting evaluation of GBCAs
under physiological condition will be more clinically relevant, and the thermodynamic stability
under physiological condition (pH 7.4) is termed conditional stability constant (45).
Table 4.1 A summary of chemical structure and stability of clinic contrast agents.
Table adapted from reference (46).

4.1.2 Metal selectivity and stability of ProCA32.CXCR4
Two major goals are wanted to achieve in the design of ProCA32.CXCR4. First, optimized
stability is desired for safety consideration. Secondly, sufficient water access and the exchange
rate is crucial for maximizing relaxivities of ProCA32.CXCR4. By modifying the calcium-binding
pocket of parvalbumin, we designed binding pockets for gadolinium with ideal ligand
coordination. The similar radius of calcium and gadolinium facilitates the gadolinium fit in the
binding pockets, and the 3-positive charge of gadolinium ion results in the stronger coordination
of gadolinium in the binding pockets than calcium. The thermodynamic stability of
ProCA32.CXCR4 is accessed under physiological condition (human serum incubation at 37 °C,
pH 7.4) and the binding affinity (defined by the dissociation constant) of ProCA32.CXCR4 with
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different metallic ions including terbium, gadolinium, calcium, and zinc are evaluated under the
physiological condition as well.

4.1.3 Pharmacokinetics and toxicity study
Pharmacokinetics, abbreviated as PK, described what the body does to a drug.
Pharmacokinetic includes the studies the absorption, distribution, metabolism and elimination of
substances. Four fundamental parameters, including volume of distribution, half-life,
bioavailability, and excretion, provide the basis of understanding pharmacokinetic properties of a
drug (169). Pharmacokinetics parameters are closely related to each other. When a substance has
faster clearance, it will show shorter half-life, higher clearance, and lower exposure, otherwise, it
shows more prolonged blood circulation, lower clearance, and higher exposure. The study of
pharmacokinetics property of a drug predicts the in vivo behavior of a drug and helps to decide the
dosage to improve therapeutic effects and minimize side effects (170) .
Volume of distribution described by the amount of drug in the body over the concentration
of drug in the plasma or blood. In fact, lots of drugs exhibit volume of distribution larger than the
volume of the plasma or blood, because of the volume of distribution is an apparent volume pool
requires for the drug distributed evenly throughout the body. Drugs with good tissue penetration
can be distributed to the organs faster and only leave a small amount of drug in the plasma or
blood. The distribution of a drug depends on the patients’ factors and the chemical properties of
the drug. The binding of the drug to the blood cells, plasma protein, and tissue are deciding factors
for the distribution as well.
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Half-life measures the time requires for the concentration of a drug reduce 50%. Half-life
defined by both changes of volume of distribution and clearance. It provides a way to estimate the
distribution of drug reach a steady state.
The bioavailability defined by the amount of intact drug reaches to the sites of actions, or
the systemic circulation. By definition, a drug’s bioavailability will be 100% right after
administration if it administrated intravenously. The bioavailability of drug decreases when
administrated through other routes.
To study the pharmacokinetic properties of ProCA32.CXCR4 provide a better
understanding of dosage, imaging time window, specific organ distribution, and toxicity. As for
the translational application for human patients. We study the distribution of ProCA32.CXCR4 in
different organs, including the liver, kidney, spleen, heart, muscle by analyzing the gadolinium
content with ICP-OES and pharmacokinetics profile of ProCA32.CXCR4 was analyzed by the
change gadolinium concentration in whole blood followed the administration of ProCA32.CXCR4
along with time. Toxicity evaluated by the clinical pathology profile of mice followed by
ProCA32.CXCR4 injection and organ toxicity were evaluated by the H & E staining of mouse
tissue including
4.2

Results

4.2.1 Relaxivity study of ProCA32.CXCR4
Relaxivity is a crucial property of MRI contrast agent; the major goal of this study is to
design a novel contrast agent with improved relaxivities to enable molecular imaging using MRI.
The relaxivities of ProCA32.CXCR4 is evaluated at 1.4 T and 7.0 T respectively because higher
field application will allow higher resolution imaging and is the future direction of MRI. Also, we
have noticed that the relaxivities vary with different PEGylation. The relaxivities (both r1 and r2)
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of

non-PEGylated

ProCA32.CXCR4,

lysine

PEGylated

ProCA32.CXCR4

(Lys-

ProCA32.CXCR4) and cysteine PEGylated ProCA32.CXCR4 (Cys-ProCA32.CXCR4) were
evaluated, respectively.
ProCA32.CXCR4 has two gadolinium binding sites. It raises the question of what the best
loading ratio of ProA32.CXCR4 and gadolinium are to achieve the optimized relaxivities per
particle and relaxivities per gadolinium. One experiment was carried out for this study by setting
the concentration of gadolinium as 50 µM in buffer solution, different concentration of
ProCA32.CXCR4 (range from 0 µM to 100 µM) were titrated in, and both r1 and r2 values were
measured at different loading ratio. The result shows that the best relaxivities per gadolinium are
achieved when loading with ProCA32.CXCR4 in 2:1 ratio (Figure 4.1 A, B). When the
ProCA32.CXCR4 concentration increase form 0 µM to 25 µM, the relaxivities increase as the
ProCA32.CXCR4 concentration increase. When the ProCA32.CXCR4 concentration increase
from 25 µM to 100 µM, the relaxivities (both r1 and r2) decrease as the ProCA32.CXCR4
concentration increase (Figure 4.1 A, B). The relaxivities of per gadolinium are only half the value
when loading gadolinium with ProCA32.CXCR4 in 1:1 ratio when compared with load
gadolinium with ProCA32.CXCR4 in 2:1 ratio (Figure 4.1 C, D). The relaxivities of nonPEGylated ProCA32.CXCR4, cysteine PEGylated ProCA32.CXCR4 and lysine PEGylated
ProCA32.CXCR4 exhibited no difference with each other (Figure 4.1 C, D). Further relaxivities
studies are carried out under the loading ratio of ProCA32.CXCR4 to gadolinium at 1:2 unless
otherwise stated.
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Figure 4.1 Relaxivities comparison of different PEGylation of ProCA32.CXCR4.
(A) The r2 relaxivity of 50 µM Gd3+ loaded with different concentration of non-PEGylated
ProCA32.CXCR4, cysteine PEGylated ProCA32.CXCR4 and lysine PEGylated
ProCA32.CXCR4. (B) The r1 relaxivity of 50 µM Gd3+ loaded with different concentration of
ProCA32.CXCR4, ProCA32.CXCR4-Cys and ProCA32.CXCR4-Lys (C) Comparison of r2 of
different PEGylation of ProCA32.CXCR4 loaded with gadolinium in 1:1 and 1:2 ratio. (D) r1
Comparison of different PEGylation of ProCA32.CXCR4 loaded with gadolinium in 1:1 and 1:2
ratio. Measurements are done at 1.4 T in 50 mM HEPES, 100 mM NaCl at pH 7.2, 37°C.
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Figure 4.2 Relaxivities study of ProCA32.CXCR4 and comparison with clinic GBCAs.
Comparison of ProCA32.CXCR4 relaxivities with commercial GBCAs. Measurements are done
under 1.4 T magnetic field.
The per gadolinium r1 and r2 values of ProCA32.CXCR4 were 30.9 mM-1 s-1 and 40.2 mM1 -1

s , respectively, at 1.4 T (Figure 4.3 A). Both r1 and r2 relaxivity values were 8 to 10 times

greater than the clinically-approved Gd3+-based contrast agents (GBCA) (Figure 4.2 and Table
4.2). Also, ProCA32.CXCR4 exhibited good relaxivities at higher magnetic field 7.0 T as well
(Figure 4.3 B), the r1 and r2 relaxivity values of non-PEGylated ProCA32.CXCR4 were 17.4 mM1 -1

S and 88.7 mM-1S-1, respectively. Interestingly, the relaxivities of the non-PEGylated form of

ProCA32.CXCR4, lysine-PEGylated ProCA32.CXCR4 (Lys-ProCA32.CXCR4), and cysteinePEGylated ProCA32.CXCR4 (Cys-ProCA32.CXCR4) did not exhibit significant differences
(Figure 4.1 C, D and Table 4.2). The r1 and r2 relaxivities of ProCA32.CXCR4 are largely retained
after PEGylation. Overall, ProCA32.CXCR4 exhibited significantly improved r1 and r2
relaxivities when compared with clinical gadolinium-based contrast agents at both 1.4 T and 7.0
T. The unique dual relaxation properties are essential for achieving early detection of small size
tumor lesions in early stages using MRI.
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Figure 4.3 Determine Relaxivities of ProCA32.CXCR4 at different magnetic fields.
(A) Relaxivity assessment of ProCA32.CXCR4 with 60 MHz relaxometer. At 1.4 T, r1 of
ProCA32.CXCR4 is 28.3 mM-1 s-1, r2 of ProCA32.CXCR4 is 40.2 mM-1 s-1. (B) Relaxivity
assessment of ProCA32.CXCR4 with 7.0 T MR scanner. r1 of ProCA32.CXCR4 is 17.4 mM-1 s-1,
r2 of ProCA32.CXCR4 is 88.7 mM-1 s-1.

Table 4.2 Relaxivities of investigated contrast agents at the different magnetic fields.
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4.2.2 Metal-binding and metal selectivity study of ProCA32.CXCR4
4.2.2.1 Determine the Tb3+ binding affinity of ProCA32.CXCR4

In the process of designing new generation MRI contrast agent, improving the sensitivity
(relaxivity) is primarily essential. Water proton relaxation by gadolinium (III) occurs via a dipolar
mechanism and has a 1/r6 dependence on the distance between the ion and the nucleus. Because
of this, it is critical to have one or more exchangeable waters in the inner- coordination sphere.
Water exchange in and out of the first coordination sphere should be fast. Two major factors
contribute to increasing the relaxation rate of bulk solvent: the paramagnetic ion should efficiently
relax the water that accesses it, and the relaxed water should exchange rapidly with the bulk water.

ProCA32.CXCR4 has a wide metal binding pocket which allows more accessibility for
the water molecules and faster bulk water exchange rate. In comparison with commercial MRI
contrast agent such as Gd (DTPA), ProCA32.CXCR4 has more rigidity in molecular structure and
slower in rotational speed, which leads to a higher relaxivity. For gadolinium (III) based contrast
agents, high gadolinium (III) binding affinity is required for safety concern. To determine the
gadolinium binding affinity can address this issue.

Gadolinium (III) has no fluorescent property. Therefore, an indirect method first was
developed for gadolinium binding affinity measurement. Terbium has the similar element radius
and carries the same charge with gadolinium. In addition, terbium has fluorescence property and
can be excited with 330 nm wavelength light. One tryptophan was introduced close to the metalbinding sites to enable the luminescence resonance energy transfer (LRET). Fluorescence
spectrum of terbium bond ProCA32.CXCR4 was collected (Figure 4.5 A). The terbiumProCA32.CXCR4 complex fluorescence spectrum shows a peak at 545nm when excited with 280
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nm wavelength light. The intensity is increasing in 545 nm indicating Tb3+ bound
ProCA32.CXCR4 concentration increase. By fitting the intensity increase at 545 nm, dissociation
constant of Tb3+ bound with CXCR4 can be calculated from the fractional signal intensity change
corresponding to the “free terbium” concentration.
Calibration of Tb3+ can be achieved by either ICP-OES or complexometric titration. ICPOES determined the ion concentration by intensity- concentration correlation defined by standard
curve. Complexometric titration is the titration of the metal ion with the ligand that readily to form
a complex with the metal ion. Xylenol orange was used as a metal indicator for complexometric
titration of Tb3+ solution with DTPA buffer with known DTPA concentration. Once the titration
reaches the endpoint, xylenol orange turns from violet to yellow color; this colorimetric change
can also be detected more precisely by UV spectroscopy (Figure 4.4). Tb3+ solution concentration
can be calculated with the equation
𝐶𝑇𝑏 × 𝑉𝑇𝑏 = 𝐶𝐷𝑇𝑃𝐴 × 𝑉𝐷𝑇𝑃𝐴

Equation 4.1
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Figure 4.4 The UV spectrum of Tb3+-DTPA titration in xylenol orange buffer.
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The Tb3+ binding-affinity of ProCA32.CXCR4 is expected to be strong, and a DTPA buffer
system was applied to control the free terbium concentration. DTPA chelator buffer contains 5
mM DTPA, 50 mM HEPES, 150 mM NaCl, and in pH 7.2. The dissociation constant of DTPA
with Tb3+ is 10-21 M at 25 °C. The “free” Tb3+ concentration can be calculated by Equation 2.2.
Free Tb3+ has weaker 545nm emission peak when excited with 280 nm UV, a control group
without ProCA32.CXCR4 was paralleled measured for signal subtraction. The intensity difference
between the control sample and ProCA32.CXCR4 titration sample represents the signal intensity
triggered by Tb3+ binding to the ProCA32.CXCR4. By fitting the free Tb3+ concentration and the
corresponding fractional fluorescence intensity change with Equation 2.3, the Kd value of Tb3+
bound with ProCA32.CXCR4 is 3.38e-22 (Figure 4.5).

Figure 4.5 Determination of Kd value of Tb3+ binding affinity with ProCA32.CXCR4.
Dissociation constant of Tb3+ with ProCA32.CXCR4 determined with DTPA-Tb3+ buffer system
(5 mM DTPA, 50 mM HEPES, 150 mM NaCl, pH 7.2), Kd=3.38e-22 M. Data fitted with Hill
equation.
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4.2.2.2 Determine the Gd3+ binding affinity of ProCA32.CXCR4
The binding affinity of Gd3+ bound with ProCA32.CXCR4 determines the stability of
gadolinium association with ProCA32.CXCR4 and the safety profile of ProCA32.CXCR4 for in
vivo application. The Gd3+ binding affinity of ProCA32.CXCR4 is determined with DTPA buffer
system and competitional titration with Tb3+. Gd3+ and Tb3+ have the same charge and expected to
possess a similar binding affinity to ProCA32.CXCR4.
In order to determine the Gd3+ binding affinity of ProCA32.CXCR4. 10 µM of
ProCA32.CXRC4 and 20 μM Tb3+ were prepared in 5 mM DTPA, 50 mM HEPES, 150 mM NaCl
at pH 7.2. Different concentrations of Gd3+, from 0 μM to 200 μM, were incubated with Tb3+
loaded ProCA32.CXCR4 at room temperature for overnight. Fluorescence signal intensity of
LRET between Tb3+ and ProCA32.CXCR4 decreases along with the Gd3+ concentration increases
(Figure 4.6 A). By fitting the signal decrease with Equation 2.4, the apparent Kd of Gd3+Tb3+competition was calculated (Figure 4.6 B).
Tb3+-ProCA32.CXCR4 binding affinity and apparent Kd of Tb3+- Tb3+ competition was
obtained by fluorescence titration, Gd3+- ProCA32.CXCR4 binding affinity is 1.2e10-22, calculated
by Equation 2.5.
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Figure 4.6 Determination of Gd3+ binding affinity of ProCA32.CXCR4.
The Gd3+ binding affinity of ProCA32.CXCR4 is determined in DTPA buffer system (5 mM
DTPA, 50 mM HEPES, 150 mM NaCl, pH 7.2) by competing Tb3+ loaded ProCA32.CXCR4 with
different concentration of Gd3+ and fit the fluorescence signal decrease at 545 nm with one to one
binding. The Kd of Gd3+ -ProCA32.CXCR4 binding is 3.38e-22 M.

4.2.2.3

Determine Ca2+ binding affinity of ProCA32.CXCR4

Assessment of Ca2+ binding affinity of ProCA32.CXCR4 is important. ProCA32 is based
on the scaffold protein parvalbumin, which is a calcium-binding protein. The gadolinium binding
pockets of ProCA32.CXCR4 are modified calcium-binding sites. For in vivo application, one
challenge is to improve the metal selectivity of ProCA32.CXCR4. The physiologically present
metal ions such as Ca2+ and Zn2+ are competitors for Gd3+ and result in Gd3+ dissociation. The Ca2+
binding affinity of ProCA32.CXCR4 was determined by a fluorescence spectroscopy titration. A
chelator buffer system contains 50 mM HEPES, 150 mM NaCl, and 5 mM EGTA at pH=7.2 was
applied. 10 μM final concentration of ProCA32.CXCR4 was used for calcium titration. Different
concentrations of calcium chloride (CaCl2) were added into the buffer system, and the free calcium
that dissociated from the EGTA buffer system is assumed binds to ProCA32.CXCR4 metal
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binding pockets. The “free” calcium concentration was calculated using Equation 2.6 (Roger
Tsien):

The fluorescence emission spectra record the wavelength from 300 nm to 400 nm followed
by excitation of 280 nm. The fluorescence intensity changes at 310 nm corresponding to each
titration point were used to calculate the dissociation constant of Ca2+ bind to ProCA32.CXCR4
using Equation 2.7, Ca2+ binding affinity of ProCA32.CXCR4 is 1.3 ± 0.1 e-8 M by hill equation
fitting (Figure 4.7 B).

Figure 4.7 Determine the Ca2+ binding affinity of ProCA32.CXCR4.
The Ca2+ binding affinity of ProCA32.CXCR4 is determined in EGTA chelator buffer (50 mM
HEPES, 150 mM NaCl, and 5 mM EGTA at pH=7.2). (A) Fluorescence spectra blue shift, and the
intensity increases as the CaCl2 titrated to the solution. (B) Fitting of the fluorescence intensity
change in 520 nm along with an increase in Ca2+ concentration. The Ca2+ binding affinity of
ProCA32.CXCR4 is 1.3±0.1 e-8 M. Data fitted by Hill equation.

ProCA32.CXCR4 has two metal-binding sites and cooperative bindings between the
binding sites. Hill equation describes the cooperative binding assuming fixed cooperativity and
denoted by Hill number n. When n  1, means the whole system exhibits positive cooperativity,
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when n  1, the whole system exhibits negative cooperativity. Hill equation assumes the multiple
binding sites possess same binding affinity.
In order to address the Ca2+ binding affinity of two binding sites, Adair equation
hypothesized binding affinity depend on the ligand saturation instead of being a fixed parameter.
It describes the binding affinity of each site more individually by an apparent macroscopic
association constant Ki. By fitting the “free” Ca2+ concentration versus the fluorescence intensity
change with Adair equation, Kd of Ca2+ binding affinity of two binding sites is 1.0 × e108 M and
6.7e × 107 M respectively (Figure 4.8).

Figure 4.8 The Ca2+ binding affinity of ProCA32.CXCR4 Fitted with Adair equation.
The Ca2+ binding affinity of ProCA32.CXCR4 is determined in EGTA chelator buffer (50 mM
HEPES, 150 mM NaCl, and 5 mM EGTA at pH=7.2) and fitted with Adair equation to
determine the Ca2+ binding affinity of each metal-binding sites. The Kd of Ca2+ProCA32.CXCR4 bindings are 1.0 e108 M and 6.7 e107 M, respectively.
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4.2.2.4 Determine the Zn2+ binding affinity of ProCA32.CXCR4
The Zn2+ binding affinity of ProCA32.CXCR4 was determined by a competitional binding
assay.1 μM of ZnCl2 and 4 μM of Fluozin-1 were added in 50 mM HEPES, 150 mM NaCl, at pH
7.2 for titration. Different concentrations of ProCA32.CXCR4 from 0 μM to 80 μM were added to
compete with Fluozin-1 for Zn2+ binding. Fluorescence spectra cover wavelength 500 nm to 600
nm were recorded following each titration. Fluorescence signal intensity changes at 510 nm were
fitted with one to one binding and apparent Kd of ProCA32.CXCR4 competition with Fluozin-1 is
acquired (Figure 4.9).
Dissociation constant of Fluozin-1 bound to Zn2+ is known to be 8 µM. The Kd between
ProCA32.CXCR4 and Zn2+ were calculated with Equation 2.9 to be 1.6 ± 0.3 e-8.

Figure 4.9 Determine the Zn2+ binding affinity of ProCA32.CXCR4.
The Zn2+ binding affinity of ProCA32.CXCR4 is determined by competition assay. (A) By
competing binding of Fluozin-1 to Zn2+ with ProCA32.CXCR4, fluorescence intensity decreases.
(B) Fitting the fluorescence intensity decrease at 510 nm along with ProCA32.CXCR4
concentration increase, apparent Kd of ProCA32.CXCR4-Fluozin-1 competition is 2.01 M.
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4.2.3 Determine water number (q) of ProCA32.CXCR4

Water number q of ProCA32.CXCR4 is a key factor affecting the relaxivities of contrast
agents. The water number of ProCA32.CXCR4 is measured by a lifetime of terbium luminescence
decay with ProCA32.CXCR4: Tb3+ loading ratio of 1:1 and 1:2 respectively (Figure 4.12). There
are two components of terbium luminescence decay: radiative decay (Г) and non-radiative decay
(K). Many factors contribute to non-radiative decay, such as quenching, energy transfer, and
molecular collation. Water number is an important factor influent non-radiative decay. By
replacement of H2O molecule with D2O, the water number contribution to the terbium
luminescence decay is eliminated because D2O does not cause luminescence decay. By this way,
the difference between terbium lifetime (Δkobs) of ProCA32.CXCR4 prepared in H2O and D2O
respectively reflect the water number of ProCA32.CXCR4.
The correlation of water number and Δkobs is established by the water number of other
chelators and their Δkobs, respectively (Figure 4.11). Water number standard curve was determined
by fluorescence lifetime of other chelators: DTPA, EDTA, and NTA. The water number of DTPA,
EDTA, NTA, and aqua is determined by X-ray powder diffraction by reported literature (171).
The water number of ProCA32.CXCR4 are 0.5 and 0.64 respectively with 1:2 and 1:1
ProCA32.CXCR4 and Tb3+ loading ratio. The water number of ProCA32.CXCR4 is consistent
with ProCA32-P40.
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Figure 4.10 Fluorescence lifetime of different chelators and the corresponding Δkobs.
The fluorescence lifetime of different chelators including EDTA, NTA, DTPA and aqua. The
corresponding lifetime difference of EDTA, NTA, DTPA, and aqua are 0.67 ms-1, 1.07 ms-1,
0.23 ms-1 and 1.97 ms-1.
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Figure 4.11 Standard curve of water number of different chelators versus Δkobs.

Figure 4.12 Determine water number of ProCA32.CXCR4 with different loading ratio with
Tb3+.
Δkobs of ProCA32.CXCR4 is determined by ProCA32.CXCR4 load with Tb3+ in 1:1 and 1:2 ratio.
(A) Δkobs of ProCA32.CXCR4 when loaded with Tb3+ in 1:1 ratio is 0.11 ms-1. (B) Δkobs of
ProCA32.CXCR4 when loaded with Tb3+ in 1:2 ratio is 0.14 ms-1
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4.2.4 Serum stability study of ProCA32.CXCR4

Serum stability of ProCA32.CXCR4 describes the capability of ProCA32.CXCR4 to stay
structurally intact under physiological conditions. Serum stability study of ProCA32.CXCR4
carried out by incubating 150 µL of 500 µM ProCA32.CXCR4 with 150 µL of mouse serum at
37C for up to 14 days. 15 µL of the mixed sample was taken at 0 hours, 3 hours, 4 hours, 1 day,
2 days, 4 days, 6 days, 8 days, and 14 days after incubation. 300 µL of mouse serum without adding
ProCA32.CXCR4 was served as control. Samples collected from different time points were
analyzed by gel electrophoresis and ponceau red staining of the nitrocellulose membrane.
ProCA32.CXCR4 is stable up to 14 days when incubated with mouse serum under 37C (Figure
4.13), whereas the mouse serum protein started to degrade at 4 hours after incubation at 37C
(Figure 4.14). ProCA32.CXCR4 can stay structurally stable under physiological conditions, and
the serum stability guaranteed the in vivo application of ProCA32.CXCR4.
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Figure 4.13 Serum stability study of ProCA32.CXCR4
ProCA32.CXCR4 is stable in mouse serum at 37°C for up to 14 days. Ponceau red staining of
nitrocellulose membrane with gel transfer shows the ProCA32.CXCR protein bands (highlighted
by red frame) is intact up to 14 days when incubated with mouse serum at 37°C.
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Figure 4.14 Ponceau red staining of mouse serum incubates at 37°C for up to 14 days.

4.2.5 Transmetallation study of ProCA32.CXCR4
The kinetic inertness of gadolinium complex regarding the transmetallation process from
physiological ions is an important factor to evaluate the suitability of such gadolinium complex as
an MRI contrast agent. A relaxometric transmetallation assessment was performed to characterize
the kinetic inertness of the Gd3+-ProCA32.CXCR4 complex to transmetallation process in the
presence of Zn2+. ProCA32.CXCR4 is mixed with the same concentration of ZnCl2 (2.5 mM) in
pH 7.0 phosphate buffer. The final mixture contained 0.026 M KH2PO4, 0.041 M Na2HPO4, 2.5
mM Gd3+ complex, and 2.5 mM ZnCl2. When transmetallation of Gd3+ by Zn2+ occurred, insoluble
GdPO4 formed, and a decrease in longitudinal relaxation rate was observed. The longitudinal
relaxation rate change of the mixture along with time reflected the transmetallation process of Gd3+
by Zn2+. The thermodynamic index was calculated by r1 of the mixture after incubation at the
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present of Zn2+ over the initial r1. Transmetallation of other GBCAs is measured following the
same protocol as a comparison.
The transmetallation study (Figure 4.15) indicated that ProCA32.CXCR4 complex with
Gd3+ has the highest stability in the presence of Zn2+, with a higher thermodynamic index (R1(t) =
4320 min/ R0(t)= 0 min) of 0.958, over Gadovist (0.952), ProHance (0.926), and Dotarem (0.932)
(Table 4.3). Other linear reagents such as Magnevist® (gadopentetate) and Eovist® (gadoxetate)
cannot protect Gd3+ well against transmetallation by Zn2+, and relaxivity measurements of those
contrast agents were significantly reduced when incubated in the presence of Zn2+ (Table 4.3).

Figure 4.15 Transmetallation study of ProCA32.CXCR4 and other GBCAs.
Transmetallation study of ProCA32.CXCR4 and other GBCAs are carried out with a relaxometric
assay. Thermodynamic index (R1(t) = 4320 min/ R0(t)= 0 min) represents the preserve of
longitudinal relaxivity at the presence of Zn2+. ProCA32.CXCR4, ProHance, and Dotarem show
higher kinetic inertness than other GBCAs such as MultiHance, Magnevist, and Omniscan.
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Table 4.3 Thermodynamic index of ProCA32.CXCR4 and other GBCAs at 72 hours
incubation with a Zn2+-containing phosphate buffer.

4.2.6 Biodistribution study of ProCA32.CXCR4
Biodistribution study of ProCA32.CXCR4 aims to assess the amount of ProCA32.CXCR4
distributed to different organs after a specific time of ProCA32.CXCR4 injection. ICP-OES was
used to analyze the gadolinium content of different organs, and tissues follow different dosages of
ProCA32.CXCR4.
The distribution of Cys-ProCA32.CXCR4 to organs including liver, spleen, heart, and
kidney were analyzed following the injection of imaging dosage (100 µL of 5 mM CysProCA32.CXCR4). Gadolinium concentration (µM/g), percentage injection dosage per gram
tissue (%ID/g), and percentage injection dosage per organ (%ID/organ is calculated). Mice
injected with Cys-ProCA32.CXRC4 were euthanized 50 minutes, 3 hours, 25 hours, and 30 hours
after above described dosage of Cys-ProCA32.CXCR4.
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A standard curve is made of ICP-OES measurement of different known concentration of
gadolinium solution versus intensity (Figure 4.16). Different tissues, including liver, spleen, heart,
and kidney, were weighted and dissolved in concentrated nitric acid and filtered before ICP-OES
analysis. The concentration of gadolinium in tissue solutions was calculated by the standard curve
and intensity.

Figure 4.16 Standard curve of gadolinium intensity.

The analysis of gadolinium concentration in different organs at different time points ( 50
minutes, 3 hours, 25 hours, and 30 hours) followed Cys-ProCA32.CXCR4 are listed below (

Table 4.4 to

Table 4.7, Figure 4.17 to Figure 4.20). Results show that Cys-ProCA32.CXCR4 has high
liver affinity, the percentage injection dosage in liver account for 17.65 % of total injection after
50 minutes of injection. The gadolinium concentration in the liver keeps increase up to 25 hours
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after injection. At 25 hours after injection, the amount of gadolinium in the liver account for 66.64
% of total injection dosage.

Table 4.4 The concentration of gadolinium in the liver at different time points follow the
injection of Cys-ProCA32.CXCR4.

Figure 4.17 Percentage injection dosage of gadolinium in the liver.
Biodistribution of gadolinium (characterized by percentage injection dosage in the liver) after 50
minutes, 3 hours, 25 hours, and 30 hours injection of ProCA32.CXCR4.
The gadolinium has the second-highest gadolinium distribution is spleen. However, it is
significantly lower than the liver. At the peak time point (25 hours), 8.32 % of the total injection
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dosage of Cys-ProCA32.CXCR4 goes to the spleen. Cys-ProCA32.CXCR4 barely distributed to
the kidney and heart.

Table 4.5 Gadolinium concentration in the kidney at different time points followed the
injection of Cys-ProCA32.CXCR4.

Figure 4.18 Gadolinium distribution in the kidney.
Biodistribution of gadolinium (characterized by percentage injection dosage) in kidney after 50
minutes, 3 hours, 25 hours, and 30 hours injection of ProCA32.CXCR4.

Table 4.6 Gadolinium concentration in the spleen at different time points followed the
injection of Cys-ProCA32.CXCR4.
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Figure 4.19 Gadolinium distribution in the spleen.
Gadolinium concentration (characterized by percentage injection dosage) in spleen after 50
minutes, 3 hours, 25 hours, and 30 hours injection of ProCA32.CXCR4.

Table 4.7 Gadolinium concentration in the heart at different time points followed by the
injection of Cys-ProCA32.CXCR4.
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Figure 4.20 Gadolinium concentration in the heart.
Gadolinium concentration (characterized by percentage injection dosage) in the heart after 50
minutes, 3 hours, 25 hours, and 30 hours injection of ProCA32.CXCR4.
Biodistribution of gadolinium in different organs after 5 days injection of different
PEGylation of ProCA32.CXCR4 was analyzed to compare the influence of PEGylation on
biodistribution and the gadolinium retention after a more extended time. The gadolinium
concentration in the liver of the mouse with Cys-ProCA32.CXCR4 injection at 5 days further
decreases than 30 hours, the other organs including heart, spleen, and kidney as well. Interestingly,
compared with Cys-ProCA32.CXCR4, Lys-ProCA32.CXCR4 exhibited higher gadolinium
retention; it might be a result of Lys-ProCA32.CXCR4 has multiple PEGylation sites and a longer
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half-life. The result suggests Lys-ProCA32.CXCR4 has longer time window for imaging than CysProCA32.CXCR4 and could require less dosage when compared with Cys-ProCA32.CXCR4.

Figure 4.21 Gadolinium bio-distribution after 5 days injection of ProCA32.CXCR4 with
different PEGylation.
The liver and spleen are the organs most retain gadolinium, followed by lung, kidney, muscle,
and brain has almost no distribution.
4.2.7 Pharmacokinetics study of ProCA32.CXCR4.
Detailed pharmacokinetics study showed ProCA32.CXCR4 has good exposure and
bioavailability, AUC0-72h of ProCA32.CXCR4 was 113.20 µg·h/mL (Table 4.8), larger than
ProCA32-P40 (33.77 µg·h/mL). Because of ProCA32.CXCR4 is CXCR4 targeted contrast agent
and expected to have higher tissue affinity caused by CXCR4 targeting. The clearance of
ProCA32.CXCR4 was 0.31 mL/min/kg, slightly less than Eovist (0.4 mL/min/kg).
ProCA32.CXCR4 had a half-time of 9.19 h, with a mean residence time (MRT) of 19.58 h.
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Figure 4.22 Pharmacokinetics curve of ProCA32.CXCR4.

Table 4.8 Pharmacokinetics parameters of ProCA32.CXCR4 and comparison with Eovist
and ProCA32-P40.
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4.2.8 Toxicity study of ProCA32.CXCR4

In the toxicity study, ProCA32.CXCR4 with cysteine PEGylation and lysine PEGylation
were tested respectively. The acute toxicity was tested by a bolus injection of 100 μL, 5 mM
ProCA32.CXCR4 to 10-week-old healthy CD1 strain mice. Each group contains 3 animals, control
group with saline injection. Mouse blood collected through a terminal collection by cardiac
puncture. Serum was collected as previously described in the material and methods section.
Alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP),
albumin, and bilirubin levels in blood serum were tested to evaluate ProCA32.CXCR4 acute
toxicity. Alanine transaminase (ALT) is used to metabolize protein in the body. If the liver is
damaged or not functioning properly, ALT is released into the blood. This causes the ALT level
to increase. An elevated level of ALT indicates liver damage. Aspartate aminotransferase (AST)
is an enzyme found in several different tissues and organs, including the heart, liver, and muscles.
Since AST are not exclusively located in the liver, it usually assists the diagnosis of liver damage
together with ALT. An elevated AST level indicates liver or muscle damage. Alkaline phosphatase
(ALP) is an enzyme found in bones, bile ducts, and liver. High level of ALP is an indication for
liver damage, blockage of the bile ducts, or bone diseases. Children and adolescents may have
elevated levels of ALP because of bone development. Albumin is the main protein generated by
the liver. It has many important biological functions. Albumin test measures the ability of the liver
to produce albumin. A decrease in albumin level is an indication of abnormal liver function.
Bilirubin is generated in the breakdown process of red blood cells. Bilirubin passes through the
liver before excreted through bile ducts. Damaged livers cannot efficiently process bilirubin, which
leads to the abnormally elevated level of bilirubin in the blood.
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Pathology profile of mice with the injection of ProCA32.CXCR4 is listed in Table 4.9.
ALP, ALT levels of mice with the injection of the cysteine PEGylated ProCA32.CXCR4 and
lysine PEGylated ProCA32.CXCR4 are comparable with the results from control mice. AST levels
show slightly increase when compared with control mice. It could be caused by the in vitro
hemolysis during the serum sample preparation, which needs to be further verified by repeat the
toxicity result: Albumin, total bilirubin, bilirubin-conjugated, and bilirubin-unconjugated levels in
ProCA32.CXCR4 injected mice has no significant difference when compared with control mice.

Mice tissues, including brain, muscle, kidney, lung, heart, liver, and spleen, were collected
and fixed by formalin and embedded by paraffin. Tissues are sliced to 5 µM thickness sections
and stained with H&E staining (Figure 4.23). H&E staining of tissues from mice after seven days
and fourteen days after injection of ProCA32.CXCR4 shows no difference with healthy tissues.
Pathology profile analysis of ProCA32.CXCR4 combined with H&E staining of mice tissues
suggesting the ProCA32.CXCR4 exhibit no acute toxicity in the mouse study.
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Table 4.9 Clinical pathology profile of mice with the injection of ProCA32.CXCR4.
Mouse serum samples collected 2 days after injection of saline (control, n = 3) or 0.025 mmol/kg
of Lys-ProCA32.CXCR4/Cys-ProCA32.CXCR4 (n = 3) were used for pathology profiling. Data
are expressed as mean  SD.
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Figure 4.23 H&E staining of mice tissues collected 7 and 14 days after injection of
ProCA32.CXCR4.
Mice (n=3) organs, including brain, kidney, heart, spleen, muscle, lung, and liver, were collected
7 and 14 days after injection of 0.025 mmol/kg ProCA32.CXCR4. No obvious tissue damage
occurred in the mouse organs.
4.3

Conclusion and discussion
The biophysics properties including relaxivities, metal binding affinities, water number,

inertness to transmetallation process were well defined and characterized. ProCA32.CXCR4
shows both high longitudinal and transverse relaxivities, at the lower and higher magnetic field.
The r1 and r2 values per gadolinium for ProCA32.CXCR4 are 30.9 mM-1 s-1 and 40.2 mM-1 s-1,
respectively, at 1.4 T. At 7.0 T magnetic field, the r1 and r2 of ProCA32.CXCR are 17.4 mM-1 s-1,
88.7 mM-1 s-1, respectively. The relaxivities will be doubled if calculated as per ProCA32.CXCR4
particle relaxivities since ProCA32.CXCR4 has two gadolinium binding sites. PEGylation has no
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significant influence on relaxivities. ProCA32.CXCR4 with different PEGylation and nonPEGylation exhibit no significant difference in relaxivities. The relaxivities of ProCA32.CXCR4
are significantly improved in comparison with other GBCAs and enable more sensitive MR
imaging.
The best loading ratio of ProCA32.CXCR4 with gadolinium to achieve the optimized
relaxivities is 1:2 when setting the concentration of gadolinium and increase the concertation of
ProCA32.CXCR4, the relaxivities of ProCA32.CXCR4 – Gd3+ complex first increase and then
decrease. Relaxivity values reach to the highest when the concentration of ProCA32.CXCR4 :
Gd3+ equals to 1:2. It can be explained by the two Gd3+ binding sites of ProCA32.CXCR4 have
different gadolinium binding affinity which caused by a difference in metal coordination. Fitting
Ca2+ binding curve of ProCA32.CXCR4 with Adair equation also validated that two metal-binding
sites of ProCA32.CXCR4 possess different metal binding affinities. Water number measurement
of ProCA32.CXCR4 by terbium fluorescence lifetime shows that ProCA32.CXCR4-Tb3+ complex
(ProCA32.CXCR4: Tb3+ =1:2) has water number of 0.5. The water number measurement validated
the inequivalence of two metal-binding sites in coordination. The two binding sites of
ProCA32.CXCR4 only possess one water, one metal-binding site coordinates metal through water
molecule while the other binding site does not. When the concentration of gadolinium is fixed,
ProCA32.CXCR4 concentration increases, the Gd3+ initially saturated two binding sites, so an
increase in relaxivities are observed. When the concentration of ProCA32.CXCR4 reaches the half
concentration of gadolinium, highest relaxivities are observed because theoretically, all Gd3+ can
bind to ProCA32.CXCR4. When keep increasing the ProCA32.CXCR4 concentration after that
point, more Gd3+ starts to go to the binding site with higher affinity. As a result, a decrease in
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relaxivities is observed because the binding site with higher affinity does not coordinate Gd3+
through a water molecule.
The relaxivities of Mn2+ based ProCA32.CXCR4 have been assessed under both lower and
higher magnetic field. Mn-ProCA32.CXCR4 has superb relaxivities at both 1.4 T and 7.0 T.
ProCA32.CXCR4 has a comparable binding affinity with Gd3+ when compared with small
chelator based GBCAs. However, ProCA32.CXCR4 metal selectivity over physiologically present
metal ions such as Zn2+ and Ca2+ are much better than other GBCAs. ProCA32.CXCR4 inert to
metal transmetallation at the presence of Zn2+ and possess high kinetic stability. Serum stability
shows ProCA32.CXCR4 is stable in serum at 37 °C incubation up to 14 days. No degradation was
observed.
Pharmacokinetics study shows ProCA32.CXCR4 has good exposure and relatively fast
clearance. The volume of distribution of ProCA32.CXCR4 is three times higher than non-targeted
ProCA32, which is the evidence that ProCA32.CXCR4 has better tissue distribution result from
CXCR4 targeting.
ProCA32.CXCR4 majorly distributed to the liver after intravenous administration. The
percentage injection dosage of each organ shows that liver retains the majority amount of
ProCA32.CXCR4, followed by the spleen. Kidney and heart have a very small amount of
ProCA32.CXCR4 distributed.
The toxicity of ProCA32.CXCR4 is described by pathology profile analysis of mouse
serum and H&E staining of mouse tissues, including brain, muscle, kidney, lung, heart, liver, and
spleen. No abnormality of mouse serum pathology profile was identified and H&E staining of
tissues of the mouse with ProCA32.CXCR4 injection have no significant difference in comparison
with normal mouse tissues. ProCA32.CXCR4 exhibited no acute toxicity according to the results.
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4.4

Summary
CXCR4 targeted contrast agent ProCA32.CXCR4 is expressed and purified with high yield

as described in chapter 3. In chapter 4, biophysics properties and pharmacokinetic properties and
toxicity of ProCA32.CXCR4 are well characterized.
ProCA32.CXCR4 has both high longitudinal relaxivity and transverse relaxivity in the
lower and higher magnetic field. r1 value of ProCA32.CXCR4 is lower at 7.0 T as opposed to the
value in 1.4 T. r2 value of ProCA32.CXCR4 is higher at 7.0 T as opposed to the value in 1.4 T.
Both cysteine PEGylation and lysine PEGylation largely retains the relaxivities of
ProCA32.CXCR4. ProCA32.CXCR4 has much-improved relaxivities than other GBCAs and
enable the application in molecular imaging. ProCA32.CXCR4 has comparable Gd3+ binding
affinity with small chelator based GBCAs but better metal selectivity over physiologically present
metal ions like Ca2+ and Zn2+. The binding affinity to different metal ions is summarized in Table
4.10. Mn-ProCA32.CXCR4 has better relaxivities than Gd-ProCA32.CXCR4; especially the r2
value of Mn-ProCA32.CXCR4 (Table 4.11).
Table 4.10 Summary of the metal-binding affinity of ProCA32.CXCR4.

Table 4.11 Summary of relaxivities of Gd-ProCA32.CXCR4 and Mn-ProCA32.CXCR4.
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ProCA32.CXCR4 has superior metal selectivity for Gd3+ over Zn2+ (log(KGd/KZn) =16.1)
(Table 4.12) that is 1011 to 1012 order of magnitude higher than small chelator contrast agents. For
other physiological metal ions such as Ca2+, ProCA32.CXCR4 also exhibited better metal
selectivity than small chelator GBCA, such as Dotarem® (gadoterate meglumine) and ProHance®
(Gadoteridol) (Table 4.12).
Table 4.12 Metal (Zn2+, Ca2+, Gd3+, and Tb3+) binding affinity and metal selectivity of
ProCA32.CXCR4 and comparison with clinical contrast agents.

ProCA32.CXCR4 has good serum stability and stay intact in serum up to 14 days.
ProCA32.CXCR4 inert to the transmetallation process and exhibit good kinetic stability.
Pharmacokinetics profile shows ProCA32.CXCR4 has good exposure when compared with nontargeted contrast agent ProCA32. ProCA32.CXCR4 demonstrates no acute toxicity.

Since the FDA approval of gadopentetate dimeglumine (Magnevist; Bayer HealthCare
Pharmaceuticals) in 1988, Gd3+-based contrast agents (GBCAs) have been widely used for clinical
MR imaging. However, nephrogenic systemic fibrosis (NSF) and gadolinium brain deposition in
patients and animals associated with GBCAs administration raised the concern of gadolinium
toxicity (164, 165, 172). We have carefully considered these factors in the design of
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ProCA32.CXCR4 for clinical translational purpose. The Gd3+ binding sites of ProCA32.CXCR4
were well designed to balance Gd3+ binding for safety, and water accessibility for relaxivities.
ProCA32.CXCR4 was shown to have unprecedented gadolinium kinetic and thermodynamic
stability. The Log (KGd) of ProCA32.CXCR4 is 21.89. Metal selectivities of ProCA32.CXCR4 for
Gd3+ over Zn2+ and Ca2+ are 106-1012 times greater than approved contrast agents, Dotarem and
ProHance. The inertness of ProCA32.CXCR4 in the presence of Zn2+ verified its strong stability
against transmetallation. Moreover, the improved relaxivity of ProCA32.CXCR4 enabled
excellent contrast enhancement in vivo with only one-quarter of gadolinium dosage compared with
other GBCAs. No trace of gadolinium was detected in mice brain after ProCA32.CXCR4
administration and we have also not observed any acute toxicity and tissue/organ toxicity.
Collectively, strong Gd3+ binding affinity, excellent metal selectivity, inertness against
transmetalation and less injection dosage makes ProCA32.CXCR4 has an excellent safety profile.

In summary, ProCA32.CXCR4 has high relaxivity, good stability, good pharmacokinetic
profile, and low toxicity and makes an ideal candidate for CXCR4 specific MR imaging with
translational potential for clinical applications.
5

VALIDATION OF CXCR4 AS A BIOMARKER FOR LIVER METASTASIS AND
TARGETING ANALYSIS OF PROCA32.CXCR4

5.1

Introduction
Chemokine receptor 4 is by far the most widely expressed chemokine receptor in various

cancers, over 23 different types of cancer cells showed elevated CXCR4 expression levels (93).
CXCR4/SDF-1α axis mediates the organ-specific metastasis (173). CXCR4 ligand SDF-1α has
high expression in the organs, including lung, liver, and bone marrow that represented common
metastasis destinations in breast cancer and pancreatic cancer (103, 174).
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Uveal melanoma (UM) has the specific liver metastases tendency; approximately 50 % of
uveal melanoma patients will eventually develop liver metastases (175). In the patients that
develop metastases, 93 % metastasizing to the liver (176). The involvement of liver metastases is
a sign of poor prognosis and leading to deaths because of the lack of effective treatment. The liverspecific metastases of uveal melanoma raise the interest of studying the CXCR4 expression level
in uveal melanoma cells. CXCR4 expression levels on primary eye uveal melanoma, and uveal
melanoma metastases were reported. H, Li et al. reported the differentiation CXCR4 expression
level on primary uveal melanoma cell lines and metastatic uveal melanoma cell lines (137), the
primary uveal melanoma cell lines express CXCR4 whereas the metastatic uveal melanoma cell
lines express little or no CXCR4. An immunohistochemistry study on UM patient tissues shows
the positive IHC staining of CXCR4 in both primary UM tissues and metastatic UM tissues (177).
Another study based on UM patient tissues reported the CCR7 expression in uveal melanoma is a
risk factor for poor prognosis, whereas the CXCR4 expression has no clinical relevance (178). H.
Grossniklaus et al. reported CXCR4 generally expressed by uveal melanoma cell lines and CXCR4
antagonist downregulated the formation of hepatic micrometastases in mouse model study (179).
The CXCR4 expression in UM is controversial and not conclusive. However, the uveal
melanoma liver metastasis pattern indicating the relevancy of CXCR4 expression and liver
metastases formation in uveal melanoma patients. Blocking CXCR4 expression by siRNA
transfection in UM cells resulted in inhibition of chemotactic responses as well as invasiveness of
UM cells (180). Therefore, the CXCR4 can be a potential biomarker and predicting factor for uveal
melanoma. We aim to evaluate the CXCR4 expression level with uveal melanoma cell lines, UM
patient tissues, and UM mouse models and establish the understanding of CXCR4 expression in
UM development.
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Ovarian carcinoma is a common gynecologic malignancy and one of the leading causes of
cancer deaths in women, in which epithelial ovarian cancer is the most common pathology subtype.
Region-based studies showed that ovarian cancer has the trend of decreasing age of diagnosis and
increasing in incidence rate (181, 182). Survival of ovarian cancers has improved owing to surgery
management and chemotherapy, but the overall prognosis remains dismal. Therefore, new
therapeutic targets and approaches require ovarian cancers.
CXCR4 and CXCL12 are found to be highly expressed in ovarian cancers whereas there is
no or minimum expression of CXCR4 in healthy ovarian tissue (98, 183), and anti CXCR4 therapy
has proved to be effective in ovarian cancer (184). It makes CXCR4 a promising therapeutic and
diagnostic target for ovarian cancer. The overexpression of CXCR4 is recommended as an
independent risk factor of bad prognosis and resistance for chemotherapy (183, 185). Imaging of
ovarian cancer and metastases is critically important for cancer management. CXCR4 targeted
imaging agent will be beneficial for the detection of ovarian cancer and metastases and
differentiate the chemo sensitive type to stratify therapy.
5.2

Results

5.2.1 Cell lines selection
Human uveal melanoma Mel290, Mel270, 02-1486, OMM1, OMM2.3, OMM2.5, 92.1,
OCM1 cells, and mouse uveal melanoma Queens, B10BR11.1 cell is selected for CXCR4
expression analysis using flow cytometry.
5.2.2 Evaluate the CXCR4 expression level of melanoma cells
Flow cytometry was used for screening and evaluating the CXCR4 expression level across
different melanoma cell lines. In the melanoma cell lines been studied, all of them has CXCR4
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expression. In Mel290 and M20-09-196), over 90% of cell populations from exhibited CXCR4
over-expression (Figure 5.1, Figure 5.2).
CXCR4 expression in uveal melanoma also evaluated with immunofluorescence staining
of CXCR4. Human uveal melanoma cell OMM2.3 and mouse melanoma cell B16LS9 showed
CXCR4 expression, indicated by green fluorescence in Figure 5.3. CXCR4 expression was
observed in the cytoplasm and cell membrane.

Figure 5.1 CXCR4 is expressed by uveal melanoma cell lines.
Metastatic UM cell lines have elevated CXCR4 expression. FACS result shows generally elevated
CXCR4 expression across the different UM cell lines.

Figure 5.2 CXCR4 expression in uveal melanoma cell lines.
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CXCR4 expression in human a
melanoma cells

Metastatic UM cell lines have elevated CXCR4 expression. FACS results show generally elevated
CXCR4 expression across the different UM cell lines, especially in Mel 290, Mel 270, and M2009-196, in which over 80% of cell counts were CXCR4 positive, measurements of each cell line
are triplicate.
CXCR4

PI

Merge

RT-PCR

RT-PCR
OMM2.3

B16LS9

Figure 5.3 CXCR4 expression in human and mice melanoma cell.
Data from Dr. Hua Yang.
5.2.3 In vivo CXCR4 expression study
Flow cytometry analysis and immunofluorescence staining of CXCR4 with uveal
melanoma show CXCR4 overly expressed across different uveal melanoma cell lines. Owing to
the possibility of discrepancy in cell lines and the in vivo expression of CXCR4, metastatic uveal
melanoma

mouse

models

and

uveal

melanoma

patient

tissues

are

analyzed

by

immunohistochemical staining of CXCR4 to further investigated the CXCR4 expression in vivo.
UM patients’ liver tissue with metastases were stained with CXCR4 antibody for IHC
study. A CXCR4 positive control (brain specimen) was processed with the same protocol. 73% of
uveal melanoma (UM) hepatic metastases (8 out of 11 cases) exhibited high expression levels of
CXCR4, indicated by the brilliant red color staining (Figure 5.4). Patient information see table
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Table 5.1 Patient information of melanoma liver metastasis cases.

Patient #
1
2
3
4
5
6
7
8
9
10
11

Age
58
32
66
59
49
61
37
66
59
47
64

Primary Melanoma
Leg, left
Chest
Scalp
"Side" (Neck), left
Back
Ocular, left-sided
Back
Ocular (Choroidal), left
Back
Shoulder, Right
Uveal, left
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Figure 5.4 CXCR4 immunohistochemical staining of uveal melanoma liver metastases and
brain tissue as the positive control.
(A), (B) CXCR4 immunohistochemical staining of brain tissue. (C), (D) metastatic UM patient
liver tissue. The metastatic UM in the liver shows strong red staining that indicates CXCR4
expression throughout melanoma cells.

CXCR4 expression in metastatic uveal melanoma mouse models was validated by
immunohistochemical staining as well. Metastatic uveal melanoma mouse models derived from
M20-09-196, M20-07-070, and 92.1 cells were established by protocol introduced in chapter 2.9.2.
FACS results show that the CXCR4 expression level in M20-09-196, M20-07-070, and 92.1 are
high, medium, and low. Metastatic mouse models establish with these three UM cell lines. Both
the primary tumor tissue and the metastases in the liver were stained with CXCR4 antibody, and
immune reactive score (IRS) was analyzed.
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CXCR4 IHC staining of mouse tissue shows that, in the primary uveal melanoma tumor,
the CXCR4 expression level is consistent with the seeding cell lines. M20-09-196, M20-07-070,
and 92.1 mouse primary uveal melanoma tissue staining exhibited high, medium, and low CXCR4
expression level, respectively. However, the CXCR4 IHC staining of liver metastases exclusively
shows high CXCR4 expression level (Figure 5.5 and Figure 5.6).

Figure 5.5 Immunohistochemical staining of CXCR4 in metastatic mouse models.
Immunohistochemical staining of CXCR4 in metastatic mouse models M20-09-196, M20-07-070
and 92.1. Primary ocular uveal melanoma tissue and uveal melanoma metastases in the liver were
stained with CXCR4. CXCR4 expression level is low, medium, and high for 92.1, M20-07-070
and M20-09-196 respectively in the primary tumor. CXCR4 expression level in metastases in the
liver is high in three mouse models. (Data from Dr. Hua Yang).
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Figure 5.6 The immune reactive score (IRS) of CXCR4 in mouse models.
Immune reactive score of CXCR4 in mouse models M20-09-196, M20-07-070, and 92.1 were
analyzed. In primary ocular UM, the IRS for M20-09-196, M20-07-070 and 92.1 are 5.4, 2.2 and
1.4 respectively. When UM metastasis to liver, the liver metastases exhibited elevated IRS
regardless of the IRS of primary UM. (Data from Dr. Hua Yang)

Figure 5.7 CXCR4 IHC staining of M20-09-196 mouse liver.
Metastatic uveal melanoma mouse model M20-09-196 has high CXCR4 expression level in the
UM liver metastases regions, indicated by the red color staining, CXCR4 antibody is ab124824.
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Figure 5.8 CXCR4 IHC staining of metastatic uveal melanoma mouse model 92.1.
Uveal melanoma mouse model developed by 92.1 melanoma cells has liver uveal melanoma
metastases and high CXCR4 expression of liver metastases, indicated by red color and arrow.

5.2.4 ProCA32.CXCR4 targeting study
5.2.4.1 Immunofluorescence staining to study the CXCR4 targeting of
ProCA32.CXCR4
CXCR4 expression cell line M290 was selected to study CXCR4 targeting capability of
ProCA32.CXCR4 by immunofluorescence staining (Figure 5.9). 5 µM of fluorescein labeled
ProCA32.CXCR4 was used to incubate the fixed Mel290 UM cells for one hour at 37 °C. Then
washed gently by TBST buffer for three times. DAPI was used to stain the cell nucleus. The same
concentration of fluorescein labeled ProCA32 was incubated with Mel290 with the same protocol
as a control. After wash, ProCA32.CXCR4 incubated Mel290 cells shows green fluorescence,
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whereas the control cells do not. The targeting capability of ProCA32.CXCR4 is proved by the
immunofluorescent staining of Mel290.

Figure 5.9 Immunofluorescence staining of Mel 290 cells.
CXCR4 targeting property of ProCA32.CXCR4 was studied with immunofluorescence staining of
Mel290. (A) Mel 290 cells incubated with fluorescein-labeled non-targeted ProCA32 only shows
blue color nucleus staining (DAPI). (B) Mel 290 cells incubated with fluorescein labeled
ProCA32.CXCR4 shows green color staining on the cell surface.
Double staining of ProCA32.CXCR4 and chemokine receptor 4 are expected to reveal the
spatial colocalization of ProCA32.CXCR4-CXCR4 interaction. Mel290 cells are fixed and
incubated with 5 µM of fluorescein labeled ProCA32.CXCR4 at 37°C for one hour, then
chemokine receptor 4 was stained by primary antibody and secondary fluorescence antibody
following a standard protocol described in chapter 2. Double staining of ProCA32.CXCR4 and
CXCR4 confirmed that ProCA32.CXCR4 bound to CXCR4 with a high spatial correlation
(Pearson’s r value = 0.82) (Figure 5.10)
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Figure 5.10 Immunofluorescence staining of Mel 290 cells and spatial colocalization with
CXCR4 receptors.
Fluorescence staining with Mel290 to study the CXCR4 binding effect of ProCA32.CXCR4. (A)
Blue fluorescence is nucleus staining with DAPI. (B) Green fluorescence shows fluorescein
labeled ProCA32.CXCR4. (C) Red fluorescence staining indicates CXCR4 receptors on the cell
membrane. (D) Overlay of blue, red, and green fluorescence of nucleus, CXCR4, and
ProCA32.CXCR4. ProCA32.CXCR4 has good spatial colocalization with CXCR4; Pearson’s r is
0.82.
5.2.4.2 Quantification of CXCR4 binding affinity with indirect ELISA

A modified enzyme-linked immunosorbent assay (ELISA) was carried out to quantify the
CXCR4 binding affinity of ProCA32.CXCR4. It followed the steps shown in Figure 5.11.
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Different concentration of ProCA32.CXCR4 (from 0 nM to 10000 Nm, 16 points in total) was
added to the wells in 96-well plates that coated with Mel290 cell lysate for incubation. The
absorbance of each well increases as ProCA32.CXCR4 concentration increase. By plotting the
data with Prism with one to one binding model, the Kd value of ProCA32.CXCR4 bind to CXCR4
receptor is calculated.

The enzyme-linked immunosorbent assay relies on the interaction between epitope and
antibody to measure the concentration of an analyte in solution. The absorbance of each well
reflects the quantity of ProCA32.CXCR4. The ELISA distinguishes the specific binding and nonspecific binding of all elements in the solution through a serial of binding processes to a solid
surface, normally a 96-well microplate material in polystyrene. There are many variants of ELISA
designed for different application, but all of them depend on the basic components of coating,
blocking, probing, and signal measurement.

Figure 5.11 Illustration of ELISA protocols.
Indirect ELISA follows the steps of coating of CXCR4, incubate ProCA32.CXCR4 with coated
plates, wash, primary antibody incubation, and secondary antibody incubation.
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The coating of ELISA usually depends on the passive absorption of analytes, including
proteins, peptides, hormones, and antigens to a polystyrene microplate surface. Most proteins can
be attached to the polystyrene in carbonate/bicarbonate buffer (pH 9.6), and the transparent
polystyrene facilitates the following colorimetric signal measurement. In typical procedure
designed to detect an antigen in a protein mixture solution, the antigen immobilization is achieved
either by direct coating the protein mixture to the 96-well microplate or through antibody absorbed
to a microplate that can capture the specific antigen. The antibody coated on the microplate to
capture the antigen called “capture antibody,” it helps more specific capture antigen and
immobilizes on the plate instead of coating all protein elements form mixture solution by direct
coating.

Plate blocking is another important step in the ELISA experiment. Blocking buffer, such
as BSA, nonfat dry milk, is usually rich in protein and occupy the unsaturated surface of the plate
with irrelevant protein. The blocking step of ELISA helps prevent non-specific binding, reduce
ELISA background signal and stable proteins absorbed to the microplates with better interaction.

ProCA32.CXCR4 shows µM range binding affinity to the CXCR4 receptor. PEGylation
slightly affected the binding affinity. The CXCR4 binding affinity for ProCA32.CXCR4 is 0.39 ±
0.02 μM and 1.69 ± 0.28 μM for cysteine PEGylated ProCA32.CXCR4. The binding curve
indicated a 1:1 binding stoichiometry, and the CXCR4 receptor number per Mel290 cell is 1.2 
0.1  106.
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Figure 5.12 CXCR4 targeting study of ProCA32.CXCR4.
CXCR4 targeting capability of ProCA32.CXCR4 is determined by indirect ELISA. The
dissociation constant of ProCA32.CXCR4 binds to CXCR4 is 0.39  0.02 µM.

Figure 5.13 CXCR4 targeting study of Cys-ProCA32.CXCR4.
CXCR4 targeting capability of Cys-ProCA32.CXCR4 is determined by indirect ELISA. The
dissociation constant of ProCA32.CXCR4 binds to CXCR4 is 1.69  0.28 µM.
5.3

Conclusion and summary
CXCR4 is widely expressed in cancer cells and plays an important role in mediating

organ-specific metastasis. Cancers metastasis to lung, liver, and bone marrow, express an
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elevated level of CXCR4, such as breast cancer and pancreatic cancer. Uveal melanoma exhibits
the liver-specific metastasis pattern and the intrinsic SDF-1α expression in liver is thought to be
the reason for liver-specific metastasis of uveal melanoma.
The expression of CXCR4 in uveal melanoma is controversial. Scientists reported different
results regarding the CXCR4 expression in uveal melanoma, both primary tumor and metastases.
Most of the researchers conclude CXCR4 is expressed in both primary and metastases of uveal
melanoma and is a risk factor for poor prognosis. CXCR4 blockage treatment inhibits tumor
growth and metastasis.
We studied the CXCR4 expression using uveal melanoma cell lines, patient tissues and
metastatic mouse models, and evaluated the CXCR4 expression level in vitro and in vivo. The cell
lines study with FACS assay demonstrated that CXCR4 expressed across different uveal
melanoma cell lines, the expression level varies. CXCR4 immunohistochemical staining with
uveal melanoma patient tissues displays high positive staining rate in uveal melanoma tissues.
Metastatic mouse models tissue analysis exhibits that CXCR4 expression elevated in the uveal
melanoma metastases in the liver.
The targeting study of ProCA32.CXCR4 is carried out by immunofluorescent staining and
ELISA. ProCA32.CXCR4 is verified to bind to CXCR4 with an excellent spatial colocalization
(Pearson’s r is 0.82), and the binding affinity is quantified to be 0.39 ± 0.02 μM and 1.69 ± 0.28
μM for non-PEGylated ProCA32.CXCR4 and ProCA32.CXCR4 with cysteine PEGylation. The
PEGylation affects the binding affinity but not to a significant extent.
In summary, CXCR4 overexpressed in uveal melanoma, especially uveal melanoma
metastases in the liver and is a useful imaging biomarker candidate for detecting liver metastases.
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ProCA32.CXCR4

is

validated

to

have

CXCR4

targeting

capability

with

both

immunofluorescences staining assay and enzyme-linked immune absorbent assay.
6

APPLICATION OF PROCA32.CXCR4 FOR EARLY DETECTION AND

CHARACTERIZATION OF UVEAL MELANOMA AND OVARIAN CANCER
6.1

Introduction

6.1.1 CXCR4 in uveal melanoma
Uveal melanoma (UM) is the most common primary intraocular malignancy.
Approximately 50% of UM patients will develop metastases (175). Uveal melanoma metastasizes
to the liver in ~93% of patients who have metastases and results in death in almost all cases due to
lack of effective treatments (176). Through histological analysis of postmortem patient samples,
UM liver metastases can be classified into three stages based on size (i.e., diameter): stage 1 (≤50
µm in diameter), stage 2 (51–500 µm in diameter), or stage 3 (>500 µm in diameter) (186).
Pathologically, UM hepatic metastases primarily have two growth patterns: infiltrative or nodular.
The infiltrative pattern occurs when circulating metastatic UM cells lodge in the sinusoidal space
and eventually replace the hepatic lobule. The nodular pattern metastases, however, originate in
the periportal area. UM cells co-opt the portal vein, and when the tumor grows, it exhibits
angiogenesis and effaces the adjacent hepatocytes (187).
There are major barriers facing clinicians in UM management, such as the lack of noninvasive and sensitive imaging methods for metastases, and the resistance of UM to traditional
systemic chemotherapies (188, 189). Contrast-enhanced CT is a widely used modality for
screening for hepatic metastases (190); however, it has limited capacity regarding liver lesion
characterization

(191).

2-18F-fluoro-2-deoxy-D-glucose

(18FDG)

positron

emission
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tomography/computed tomography (PET/CT) can locate the “hot-spot” for characterization of
liver metastases, but the radiation-dosimetry and the comparatively low specificity are things for
concern (192).
MRI is a preferred clinical imaging modality for the assessment and characterization of
liver malignancy since it does not use ionizing radiation, and has high soft tissue penetration
providing morphological, anatomical, and functional information. Dynamic-enhanced MRI, with
liver-specific contrast agents, is widely used for liver lesion characterization. However, the
sensitivity and specificity of clinical MRI are low for lesions less than 1 cm (193). Also, MRI with
the administration of clinically-approved contrast agents cannot differentiate the different growth
patterns of UM metastases in the liver (194). Previous studies have demonstrated that molecular
imaging of corresponding biomarker expression, such as HER2, improves detection sensitivity for
cancers (195). However, diagnostic biomarkers for imaging UM liver metastases have not yet been
established until today. Therefore, there is a pressing unmet medical need to develop MRI contrast
agents for early detection and follow-up of liver metastases, especially for high-risk patients.
CXCR4 plays a crucial role in cell migration and cancer metastasis to several organs such
as liver, bone marrow, and lung that have the intrinsically high concentration of its natural ligand
CXCL12 (140, 151, 152). A CXCR4 antagonist, Plerixafor (Mozobil®, AMD3100), is approved
by the FDA for stem cell mobilization. Another ongoing study is focused on the effect of another
CXCR4 antagonist, X4P-001, on T-cell infiltration in human metastatic melanoma (196). CXCR4
expression has been proposed as a prognostic factor and a potential therapeutic target. Elevated
expression of CXCR4 has been reported in several uveal melanoma cell line studies (197, 198). In
addition, blocking CXCR4 gene expression by transfection with CXCR4 siRNA has been found
to inhibit invasive properties of uveal melanoma cells exposed to soluble factors produced by
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human livers (140). Taken together, we hypothesize that CXCR4 will be a potential biomarker
with treatment implications for imaging UM metastases in the liver.
6.2

Results

6.2.1 Detection of uveal melanoma using molecular dynamic contrast imaging
6.2.1.1 Molecular dynamic contrast imaging of ProCA32.CXCR4

A liver implanted uveal melanoma mouse model, generated with CXCR4 expression
melanoma cell line, Mel290, was used to evaluate and validate the in vivo molecular imaging
capability of ProCA32.CXCR4 at 4.7 T. Molecular dynamic contrast imaging (MDCI) was
performed to display implanted uveal melanoma in mouse liver by the administration of CysProCA32.CXCR4 via intravenous tail injection, followed by the acquisition of T1-weighted
gradient echo MRI as a function of time. The non-targeted contrast agent, ProCA32, was used as
a control. The melanoma tumor regions exhibited different enhancement patterns between mice
with ProCA32 and Cys-ProCA32.CXCR4 injection. In Mel290 mice with ProCA32 injection, the
tumor MRI signal intensity increased at 12 min and 50 min post-injection and decreased after 3
hours of injection (Figure 6.1, Figure 6.2). However, the tumor MRI signal intensity in the Mel290
mice with Cys-ProCA32.CXCR4 injection gradually increased to a maximum at 22 h postinjection, and then began to decrease due to excretion (Figure 6.1, Figure 6.2). The time plot of
melanoma tumor signal-noise-ratio (SNR) change followed by Cys-ProCA32.CXCR4 injection
showed that melanoma tumors SNR increased over 40% at 22 hours post-injection when compared
with pre-injection, whereas SNR of tumor region in the Mel290 mice with ProCA32 injection
showed a mild increase (10%) right after injection (12 min) then washed out at 3 hours postinjection (Figure 6.2 B). On the other hand, MR images of Mel290 mice with Cys-
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ProCA32.CXCR4 and ProCA32 injection exhibited similar patterns of SNR changes in the liver
regions over time (Figure 6.2 C). The liver SNR of both mice with Cys-ProCA32.CXCR4 and
ProCA32 injection increased drastically right after injection and up to 3 hours, the percentage
increase of SNR is around 45% at 3 hours post-injection when compared with pre-injection. Such
enhancement at the liver region gradually decreased due to elimination. Cys-ProCA32.CXCR4
can target and well distribute to the Mel290 mice tumor tissue. The MR images of the tumor region
in Mel290 mice with ProCA32.CXCR4 injection showed that the tumor rim enhanced at early time
points after injection and penetrated the center along with the time (Figure 6.2 A, D).

The MRI images follow the ProCA32.CXCR4 dynamically change along with time depend
on the expression level of CXCR4. Tumor tissues with high expression of CXCR4 exhibited
delayed enhancement than the normal liver tissue since the kinetic targeting to CXCR4 and showed
the peak of intensity enhancement around 24 hours after injection. The normal liver tissue,
however, shows the peak of signal noise ratio enhancement at 3 hours after injection for the
biodistribution of ProCA32.CXCR4 to the liver along with time. This dynamic enhancement of
ProCA32.CXCR4 is a combined result of blood circulation and CXCR4 targeting and allowing
the differentiation of CXCR4 high expression tissue from the CXCR4 low expression tissue.
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Figure 6.1 T1 weighted MR images of Mel290 with ProCA32 and ProCA32.CXCR4
injection and the signal-noise ratio of liver and tumor regions.
(A) T1 weighted MR images of Mel 290 uveal melanoma mice with ProCA32.CXCR4 injection
(upper row) and ProCA32 injection (lower row) at different time points. Yellow circle regions are
tumor region in the liver. (B) Quantification analysis of liver SNR change before and after
ProCA32.CXCR4 and ProCA32 injection at different time points. (C) Quantification analysis of
the SNR changes of Mel 290 mice tumor region before and after injection of ProCA32.CXCR4
and ProCA32 at different time points. For the Mel 290 mice with ProCA32.CXCR4 and ProCA32
injection, liver intensity change has the similar pattern after administration of ProCA32 and
ProCA32.CXCR4. With both contrast agent intravenous bolus administration, liver SNR increases
right after (10 min) and keep increasing up to 3 hours, after 3 hours, the SNR decrease. The tumor
SNR of mice with ProCA32.CXCR4 administration keeps increase after injection up to 22 hours
and the tumor SNR of ProCA32 mice and ProCA32.CXCR4 mice have significant differences
which showing the CXCR4 targeting effect of ProCA32.CXCR4.
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Figure 6.2 Progressive MR imaging of liver implanted melanoma mice M290 with an
injection of ProCA32.CXCR4.
(A) T1 weighted gradient echo MR images of control mice (with the injection of non-targeted
agent ProCA32) and mice with ProCA32.CXCR4 injection. MRI was scanned before, and after
injection at different time points until 48 hours, the tumor is represented by the color region in MR
images. (B) The percentage increase of SNR of melanoma tumor at different time points shows
the dynamic binding process of ProCA32.CXCR4. Mice with ProCA32.CXCR4 injection showed
gradual increase intensity in melanoma tumor region up to 24 hours, showing the CXCR4 targeting
effect and intensity washed out at 48 hours (further time points not acquired). (C) Time plot of
Liver SNR percentage increase following ProCA32 and ProCA32.CXCR4 injection. The liver
SNR of both ProCA32 injected mice and ProAC32.CXCR4 injected mice shows a similar pattern
of the SNR time plot, liver intensity drastically increases up to 3 hours after injection of both
contrast agents and going down after 3 hours. (D) Time plot of tumor rim and tumor center SNR
change of mice with ProCA32.CXCR4 injection. ProCA32.CXCR4 exhibits good tumor
penetration, at early time points (12 min) following injection of ProCA32.CXCR4, tumor rim SNR
increased, the intensity in the center of the tumor going up until 24 hours after injection, from (A)
can see the tumor region with ProCA32.CXCR4 injection shows well distributed and heterogeneity
enhancement.
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6.2.1.2 Histology analysis and in vivo targeting of ProCA32.CXCR4

The immunofluorescence staining of Cys-ProCA32.CXCR4 administrated, Mel290 mouse
tumor tissue showed strong and broadly distributed red immunofluorescence (Figure 6.3). In
contrast, red fluorescence staining was not observed at the tumor tissues of the Mel290 mice with
ProCA32 injection. Gd3+ content analysis using ICP-OES indicated that the tumor tissue of Mel290
mice with ProCA32.CXCR4 injection exhibited significantly higher Gd3+ content than tumor
tissue of Mel290 mice with the ProCA32 injection (Figure 6.4). These results further validated the
CXCR4 targeting capability of ProCA32.CXCR4 in vivo with excellent tumor permeability.

Figure 6.3 Immunofluorescence staining of ProCAs on Mel 290 mouse tissues.
Mouse liver and tumor tissue stained with immunofluorescence for ProCA32 antibody. Mel290
mouse livers with ProCA32.CXCR4 and ProCA32 injection are stained with primary rabbit
antibody against ProCA32 and fluorescence secondary antibody. The nucleus is stained with
DAPI. Melanoma in the liver shows melanin (black color) in the bright field and red fluorescence
staining recognize the presence of ProCA32/ProCA32.CXCR4. For the Mel290 mouse with
ProCA32.CXCR4 injection (upper row), the tumor region shows well spread red fluorescence
color, which indicates the presence of ProCA32.CXCR4 at the tumor tissue. For the Mel290 mouse
with ProCA32 injection (lower row), tumor regions exhibit no red fluorescence signal, only the
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DAPI staining shows. Heart tissue is negative control; heart from both mice showed no presence
of red fluorescence.

Figure 6.4 Biodistribution study of Mel290 mice with contrast agents injection.
Mel290 mouse tissues were collected and analyzed by ICP-OES after 2 days injection of contrast
agent ProCA32.CXCR4 and ProCA32. Mel290 mouse tissues, including heart, kidney, tumor,
liver, spleen, and muscle, were analyzed. The gadolinium content in heart, kidney, liver, spleen,
and muscle showed no significant difference between mouse with ProCA32.CXCR4 injection and
mouse with ProCA32 injection. The tumor of Mel290 mouse with ProCA32.CXCR4 injection has
a significantly high amount of gadolinium when compared with the tumor of Mel290 mouse with
ProCA32 injection, which demonstrated the in vivo affinity of ProCA32.CXCR4 to the CXCR4
high expression of tumor tissue.

6.2.2 Detection of uveal melanoma metastases in the liver with ProCA32.CXCR4

We demonstrated the unique imaging capability of ProCA32.CXCR4 for detection of liver
metastases, improving the current detection limit, and enabling nodular pattern detection in
metastatic M20-09-196 mice at 7.0 T. The early detection of UM metastases in the liver of M2009-196 mice can be achieved using either Cys-ProCA32.CXCR4 or Lys-ProCA32.CXCR4. Liver
micrometastases ranging from 0.01 mm2 to 0.08 mm2, which are “invisible” using Eovist or nontargeted ProCA32 (Figure 6.6, Figure 6.7), were detected with spin echo acquisition and fast spin
echo acquisition following tail vein injection of 0.025mmol/kg Cys-ProCA32.CXCR4 (Figure
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6.5). Following the same imaging protocol, a mouse model with Lys-ProCA32.CXCR4 injection,
in place of Cys-ProCA32.CXCR4, exhibited metastases enhancement on post-injection as well
(Figure 6.9). Both the Cys-ProCA32.CXCR4 and Lys-ProCA32.CXCR4 can enhance the small
metastatic lesions in the liver. Targeting effect shows at 48 hours after administration.

Figure 6.5 T1 weighted, and T2 weighted MRI scanning imaging at different time points
after Cys-ProCA32.CXCR4 injection.
The first row shows the T1 weighted MR images after Cys-ProCA32.CXCR4 injection. The red
arrows pointed to the metastases brighten up after injection of contrast agent. The second row
shows the T2 weighted images; the green arrows pointed to the enhanced metastases after contrast
agent injection.

Figure 6.6 MRI imaging of Lysine-PEGylated ProCA32 injected mouse.
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T1 weighted MR images and T2 weighted MR images were collected before and after the injection
of lysine PEGylated ProCA32. T1 weighted MR images and T2 weighted MR images are collected
by spin echo pulse sequence and fast spin echo pulse sequence, respectively. No metastasis lesion
was observed after the administration of ProCA32 on both T1 and T2 weighted images.

Figure 6.7 MR images of metastatic UM mice M20-09-196 before and after injection of
ProCA32 and Eovist.
T1 weighted spin echo and T2 weighted fast spin echo MR images of M20-09-196 mice before
and after injection of ProCA32 (left) and Eovist (right). After 48 hours of ProCA32 injection, no
lesion enhanced on MR images. 30 min after injection of Eovist, no lesion enhanced on MR images
as well.

133

Figure 6.8 MR images of metastatic UM mice M20-09-196 and histological correlation.
(A) T1 weighted spin echo and T2 weighted fast spin echo MR images of M20-09-196 before and
48 hours after Cys-ProCA32.CXCR4 injection. At 48 hours after injection, both T1 weighted and
T2 weighted MR images showed four lesions light up when compared with before injection, the
colormap is the zoom-in view of the yellow rectangular region. (B) H&E and IHC staining of
M20-09-196 liver with UM metastases. H&E staining shows four metastasis lesions, highlighted
by different color circles, that exhibit a similar location as the metastases in MR images. Higher
magnification images show the growth pattern of metastases to be the nodular pattern. S100
immunohistochemical staining confirms the lesions are metastatic UM. CXCR4
immunohistological staining confirms the CXCR4 expression on UM metastases.
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Figure 6.9 T1 weighted and T2 weighted MR images at different time points after LysProCA32.CXCR4 injection.
The first row shows the T1 weighted MRI images after Lys-ProCA32.CXCR4 injection. The red
arrows pointed to the metastases brighten up after injection of contrast agent. The second row
shows the T2 weighted images; the green arrows pointed to the enhanced metastases after contrast
agent injection.

Figure 6.10 MR images of metastatic UM mice M20-09-196 before and after injection of
Lys-ProCA32.CXCR4.
T1 weighted spin echo and T2 weighted fast spin echo MR images of M20-09-196 mice before
and after injection of Lys-ProCA32.CXCR4. 48 hours post-injection of Lys-ProCA32.CXCR4,
there are three lesions lighten up on both T1 and T2 weighted MR images. Color map shows the
zoom-in view of the metastases.
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These small liver lesions, detected by MRI with Cys-ProCA32.CXCR4, were further
verified by detailed H&E staining analysis, and were found to be exclusively nodular growth
pattern (labeled by the yellow, blue, red, and green circle) (Figure 6.8 B). The inter-lesion distances
and diameters of lesions on MR images correlated well with the corresponding measurements in
H&E staining of tissue sections (y=1.09x + 0.08) (Figure 6.12). The statistical analysis showed
that MR images could readily differentiate the tumor from the healthy liver, with an AUC of 0.84
(Figure 6.12). IHC staining of S100 further confirmed the lesions to be metastatic melanoma, and
IHC staining of CXCR4 verified the CXCR4 expression on metastatic melanoma (Figure 6.8).

Figure 6.11 Immunohistological study of M20 mouse liver tissue using Mouse anti-human
CXCR4 (ab189048).
The brown color staining region on liver indicates the CXCR4 expression. CXCR4 has a high
expression on metastatic melanoma cells, scale bar, 200 µM.
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Figure 6.12 Statistics analysis of M20-09-196 mouse with Cys-ProCA32.CXCR4 injection.
(A) The measurement of distances between the metastases and diameters of the metastases in the
MR images correlates well with the H&E histological staining ( y=1.09x + 0.08). (B) The
stastistical analysis shows ProCA32.CXCR4 provides diagnosis validation for melanoma
metastases in liver, AUC = 0.8429, P-value  0.0001. Analysis based on 11 metastases found on
MR images.

6.2.3 Validation of the in vivo CXCR4 targeting capability of ProCA32.CXCR4 by receptor
blocking experiment
We validated the in vivo CXCR4 targeting capability of Cys-ProCA32.CXCR4 by receptor
blocking experiment. A subcutaneous uveal melanoma (UM) murine model was developed to
demonstrate that UM tumor signal intensity enhancement following Cys-ProCA32.CXCR4
administration could be blocked by first administering the CXCR4 blocking reagent. (Figure 6.14.
A). The blocking reagent was administrated to subcutaneous uveal melanoma model prior to
imaging, following the protocol illustrated in Figure 6.13.
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Figure 6.13 The protocol of blocking reagent administration.

We specifically constructed a CXCR4 blocking reagent by fusing the CXCR4-targeting
moiety (LGASWHRPDKFCLGYQKRPLP) of ProCA32.CXCR4 to the C-terminal of the GST
tag to ensure proper blocking. Injection of the non-targeted Lys-ProCA32 only resulted in initial
SNR enhancement at 3 h post-administration due to blood pool distribution. This enhancement
returned to baseline at 24 h. In contrast, injection of Cys-ProCA32.CXCR4 resulted in maximum
SNR enhancement at 24 h post-injection and returned to the baseline at 48 h. Prior injection of
CXCR4 receptor blocking reagent specifically eliminated the enhancement at 24 h by CysProCA32.CXCR4 but retained the 3 h initial enhancement due to blood pool effect. (Figure 6.14
B, C, Figure 6.15) These results indicated that ProCA32.CXCR4 can specifically bind to the
CXCR4 receptor over-expressed on the tumors and enables molecular targeting MR imaging.
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Figure 6.14 Validating CXCR4 binding specificity by receptor blocking study.
(A) Comparison of subcutaneous UM tumor intensity change on T1-weighted MR images
following administration of Cys-ProCA32.CXCR4 with and without prior administration of
blocking reagent; subcutaneous UM tumors are represented by color region. Tumor from UM mice
that received Cys-ProCA32.CXCR4 injection showed a significant increase in MRI signal
intensity after Cys-ProCA32.CXCR4 administration. This enhancement could be blocked by first
administrating the CXCR4 receptor blocking reagent. (B) Comparison of UM tumor SNR change
following administration of Cys-ProCA32.CXCR4 and blocking reagent + Cys-ProCA32.CXCR4.
For the mice that received Cys-ProCA32.CXCR4 injection, the SNR of UM tumor significantly
increased at 24 h after Cys-ProCA32.CXCR4 administration. This enhancement was blocked by
first administrating a blocking reagent. As seen with the mice that received the blocking reagent
and then the Cys-ProCA32.CXCR4 injection, the SNR of UM tumor was significantly lower in
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comparison with the UM tumor SNR of the mice with Cys-ProCA32.CXCR4 administration. (C).
UM tumor SNR change following administration of Cys-ProCA32.CXCR4, blocking reagent +
Cys-ProCA32.CXCR4 and Lys-ProCA32. At 3 h after administration, mice from all three groups
showed SNR increase. At 24 h, mice with blocking reagent + Cys-ProCA32.CXCR4
administration and mice with Lys-ProCA32 administration showed an SNR wash out; while mice
that received Cys-ProCA32.CXCR4 exhibited further SNR increases compared with 3 h. At 48
hours, mice that received blocking reagent + Lys-ProCA32.CXCR4 and mice that received LysProCA32 administration exhibited further SNR further decrease. Mice that received CysProCA32.CXCR4 administration showed SNR wash out in comparison with 24 h.

Figure 6.15 MR images of subcutaneous UM mice before and after administration of CysProCA32.CXCR4, blocking reagent + Lys-ProCA32.CXCR4 and Lys-ProCA32.
T1-weighted MR images of xenografted mice with subcutaneous UM tumors before and after
administration of Cys-ProCA32.CXCR4, blocking reagent + Cys-ProCA32.CXCR4 and LysProCA32; imaging time points include pre-injection, 3 h, 24 h, and 48 h post-injection. Tumors
are identified by red arrows. Three groups of mice exhibited tumor signal intensity increases at 3
h after injection of contrast agents. Mice that received the injection of Cys-ProCA32.CXCR4
presented further tumor signal enhancement at 24 h after injection, and signal intensity then
washed out at 48 h. CXCR4 blocking reagent pre-treated mice and Lys-ProCA32 administration
showed signal washout at 24 h and further decreases at 48 h.
6.2.4 Detection of liver metastases in SKOV3 orthotopic ovarian cancer mouse model
Orthotropic human ovarian cancer xenograft model was established by Dr. Lily Yang in a
protocol detailed described in chapter 2.9.3. SKOV3 cells are stably transfected with firefly
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luciferase. Followed the injection of luciferase substrate (D-luciferase, free acid), bioluminescence
images showed the tumor enhancement around the ovary region. Tissues collected 20 minutes after
injection of luciferase substrate showed metastases in spleen, liver, lung, and kidney (Figure 6.16)

Figure 6.16 Bioluminescence images of orthotopic ovarian tumors and metastases.
Bioluminescence images of SKOV3 ovarian cancer mice show the subcutaneous and orthotopic
tumors. Organs, including spleen, liver, lung, and kidney, have metastasis lesion. (Data from Dr.
Jingjuan Qiao)
T1 and T2 weighted MR images of SKOV3 ovarian cancer mice were collected with
gradient echo acquisition and fast spin echo acquisition respectively at 4.7 T. T1 weighted MR
images of SKOV3 mice show the liver enhancement followed by the administration of
ProCA32.CXCR4 up to three hours, and the liver intensity started to wash out after three hours of
injection. The tumor metastases have SNR enhancement, which exhibited the same pattern
observed in Mel290 mice (Figure 6.18). The signal-noise ratio of metastases in the liver increased
after administration of ProCA32.CXCR4 gradually and reach to the highest SNR at 24 hours after
injection. Moreover, the SNR started to wash out after 24 hours after injection. However, owing
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to the higher liver enhancement in 4.7 T than in 7.0 T, metastases, in contrast, exhibited darker
lesions when compared with the rest of liver tissues.

Figure 6.17 T1 weighted MR images (gradient echo) of SKOV3 orthotopic mice model with
ProCA32.CXCR4 injection.
T1 weighted MR images of SKOV3 mice collected before and after the injection of
ProCA32.CXCR4. Metastatic tumor lesions (pointed by red arrows) shows strong contrast with
liver tissue and can be distinguished after the administration of ProCA32.CXCR4.
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Figure 6.18 The intensity percentage increase of tumor region in SKOV3 mice model after
ProCA32.CXCR4 injection.

6.3

Conclusion and discussion
The liver is a common site for cancer metastasis. UM almost exclusively metastasizes to

the liver. The mechanism of the liver-specific metastases is not well known yet. Based on the
findings that liver cells produce some chemoattractants (i.e., CXCL12) (199) and elevated
expression of CXCR4 in several UM cell line studies (197, 200), one hypothesis is tumor cells that
are overly express CXCR4 hijack the CXCR4/CXCL12 axis during the metastatic process and
spread to the liver (140, 151, 152). CXCR4 is proposed to be a prognostic marker in acute
myelogenous leukemia, breast cancers, colorectal cancers, and melanoma (99, 197, 201, 202).
Thus, the development of imaging agents for CXCR4 may be highly informative regarding cancer
diagnosis and prognosis.
By demonstrating elevated CXCR4 expression levels in UM patient liver metastases, UM
cell lines, as well as metastatic UM mouse models, we validated the diagnostic value of CXCR4
as an imaging biomarker in UM. Multiple attempts have been made towards to develop CXCR4
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molecular imaging agents over the years using different imaging technologies including SPECT,
PET, and near-infrared imaging (203-205). MRI has the advantage of being able to provide high
spatial resolution imaging without ionizing radiation and depth limitation. However, limited by
the sensitivity of current MRI contrast agents and the low local concentration of receptors on the
tumor cell surfaces (50), the application of MRI in molecular imaging is very challenging. We
developed a CXCR4 targeted MRI contrast agent ProCA32.CXCR4 that exhibited 8 to 10 times
increase in both r1 and r2 relaxivities over clinical GBCAs and enabled sensitive MRI detection of
CXCR4. We have applied a metastatic UM mouse model M20-09-196, with small metastases in
the liver, to demonstrate the imaging capacity of ProCA32.CXCR4. MR imaging following
ProCA32.CXCR4 administration is able to detect UM micro-metastases in mouse livers as small
as 0.1mm2, which is a significant improvement in the detection limit of MRI for liver lesions (193).
Several factors contributed to the robust detection of micro-metastases at the early stages. First,
CXCR4 targeting enabled ProCA32.CXCR4 accumulation at metastases sites. Secondly, high
relaxivities of ProCA32.CXCR4 significantly improved the sensitivity of MR imaging. Compared
with small molecule chelator, ProCA32.CXCR4 has secondary coordination shell and optimized
rotational correlation time, which contributes to the relaxivities improvement (206).
Furthermore, both high r1 and r2 of ProCA32.CXCR4 doubled the confidence and avoided
artifacts of detection by applying both T1 and T2 weighted acquisition. Another challenge in
imaging UM metastases in the liver is to identify pathological growth patterns of metastases with
MR imaging (194). MR images of M20-09-196 mice following administration of
ProCA32.CXCR4 exclusively enhanced nodular growth pattern metastases. This enhancement
might be caused by the CXCR4 expression difference of metastases with different growth patterns.
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Administration of ProCA32.CXCR4 achieved detection of liver metastases using MDCI
by MRI. In UM mouse model Mel290, the intensity changes over time exhibited different patterns
in liver metastases than in the adjacent liver. Tumor region intensity steadily increased up to 24
hours after ProCA32.CXCR4 injection due to in vivo dynamic binding to CXCR4, followed by a
slow wash out after 24 hours to 48 hours. However, tumor region intensity showed a small transient
increase (at 12 min) right after ProCA32 injection due to in vivo distribution and wash out after 3
hours.
On the other hand, the liver region in both mice injected with ProCA32.CXCR4 and
ProCA32 showed similar enhancement patterns over time. This unique property of
ProCA32.CXCR4 provides a possibility of acquiring MDCI using MRI. MDCI provides an
additional avenue to non-invasively differentiating tumors from healthy livers taking advantage of
biomarker binding capability. Besides, ProCA32.CXCR4 has excellent tumor permeability, which
is different from some nanoparticles or chelator-based targeting contrast agent that mostly enhance
the tumor boundary (207). This allows for mapping heterogeneous CXCR4 expression inside the
tumor. This property may facilitate monitoring of CXCR4 expression changes through the tumor
tissue during progression and treatment.
The relatively long half-life of ProCA32.CXCR4 makes the best imaging time for
optimized tumor enhancement around 24 to 48 hours after injection, which might be one limitation
for clinical usage. We are in the process of optimizing PEG modification of ProCA32.CXCR4 to
tune the PK/PD properties. Another concern would be ProCA32.CXCR4 nonspecific interactions
with CXCR4 expressed on normal cells (i.e., immune-related cells). Further studies should be done
to evaluate ProCA32.CXCR4 carefully before it can be taken to clinical application.
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6.4

Summary
In this study, we verified that CXCR4 is a diagnostic imaging biomarker by its elevated

expression level in liver metastases in UM patients, UM cell lines, and mouse models.
Additionally, we have successfully designed a CXCR4-targeted, protein-based contrast agent,
ProCA32.CXCR4, which can detect UM hepatic metastases as small as 0.1mm2. The detected
liver micrometastases were further validated by histological analysis, which is well-correlated with
MR images. Our results indicate that ProCA32.CXCR4 enables precision MRI capable of defining
molecular signatures for identifying metastases.
In summary, we report results validating our hypothesis that CXCR4 is a diagnostic
imaging biomarker for liver metastases using UM patient samples, UM cell lines, and animal
models. Additionally, we successfully designed a CXCR4-targeting, protein-based contrast agent,
ProCA32.CXCR4, for early detection of UM hepatic metastases. The detected liver
micrometastases were validated by histological analysis and correlated well with MR images. Our
results indicate that this contrast agent can enable precision MRI (pMRI) capable of defining
molecular signatures for identifying metastases, and possibly for treatment stratification.
7

PRECLINICAL APPLICATIONS OF PROCA32.CXCR4 FOR DETECTION OF
FIBROSIS AND HCC AND MONITORING TREATMENT EFFECT

7.1

Introduction

7.1.1 Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy with
increasing new cases (208, 209). Statistics show that: from 2011 to 2015, the liver cancer death
rate rose 2.7% every year in female patients and 1.6% for male patients (1). Chronic liver diseases,
including hepatitis B (210, 211), hepatitis C (211), alcoholic and non-alcoholic fatty liver (212)
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and cirrhosis are the major risk factors for the HCC. Inflammation and fibrosis are two major
phytological processes in HCC development. Chronic hepatitis caused by HBV and HCB
combination infection significantly increases the risk of HCC development. HBC can lead to HCC
even without the involvement of fibrosis (213). However, HCC progressed from HCV infection
almost exclusively established on the cirrhotic liver (214).
7.1.2 Current state-of-art for HCC detection and surveillance monitoring
Since 2001, imaging-based diagnosis of HCC has been established to replace the biopsybased diagnosis, and HCC diagnosis can be established based on imaging combined with
laboratory tests (215). The HCC diagnosis at a late stage has a poor prognosis for the limit options
of treatments. The early detection of HCC is of significant importance because of surgical resection
yields similar or even better outcome than orthotopic liver transplantation, which solved the
problem of the long waiting list, the high expense of transplantation and give patients better
prognosis (216).
Different scientific associations and societies have developed slightly inconsistence
imaging-based diagnostic systems and algorithm (Figure 7.2) for hepatocellular carcinoma. The
imaging-based diagnostic systems have evolved because of the advance of understanding about
HCC imaging features. The systems are developed for patients with a high risk of developing HCC
for screening and surveillance. The first line for screening patients with high risk usually combines
ultrasound with serum test screening of biomarkers (including alpha-fetoprotein (AFP), protein
induced by vitamin K absence) according to the Japan Society of Hepatology (217). With people
shows positive results on the screening test, dynamic CT/ MRI are recommended for imaging
diagnosis and staging. The imaging features of HCC including arterial phase hyperenhancement,
wash out appearance, corona enhancement, capsule appearance, etc. (215, 217) The typical
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vascular pattern of HCC lesions are well agreed on including the hyper-enhancement in the arterial
phase and hypo-enhancement (washout) appearance in the venous phase. The wash in and wash
out features are caused by the blood supply difference of HCC lesions and healthy liver, which
lead to the wash-in of contrast agents differently. The HCC lesions primarily have blood supply
from the artery, so it has hyper-enhancement on arterial phase.
A comprehensive review of guidelines including the Asian Pacific Association for the
Study of the Liver (APASL), Japanese Society of Hepatology (JSH), American Association for
the Study of Liver Diseases (AASLD), and the European Association for the Study of the Liver
(EASL) summarized the difference and similarity across the guidelines from those major scientific
societies (218-221). Tumor size is the primary concern to assess HCC according to the AASLD
and EASL. The JSH and APASL emphasize more on the vascular imaging pattern of HCC lesion.
There is a slight difference between the societies regarding the choice of imaging contrast media
as well, JSN advocates the liver-specific contrast agent, whereas the AASLD and EASL accept
exclusively extracellular MRI contrast agents. The contrast agents for HCC detection can be
majorly divided into extracellular agents and post-vascular phase agents (Figure 7.1). Most used
extracellular vascular contrast agents for CT, MRI and contrast-enhanced US (CEUS) are iodine
contrast agent, gadolinium-based small chelators and Sonovue respectively. The post vascular
phase agents can be classified into two groups: Kupffer-specific contrast agents and hepatocytespecific contrast agents. Sonazoid has very stable Kupffer-specific enhance around 20 min after
injection. Gadolinium contrast agents for MRI, Primovist, and Multihance have the benefit of
showing the regular vascular pattern on imaging right after injection and later hepatocyte-specific
enhancement after being uptake by hepatocytes starts from 4 to 5 min after injection. A systematic
review carried out to compare the sensitivity of MRI and multidetector CT shows that MR imaging
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has higher per-lesion sensitivity (80%) than CT (68%) and recommended for diagnosis of HCC in
the chronic liver disease patients (222).

Figure 7.1 Summary of contrast agents currently used for HCC diagnosis across different
imaging modalities.
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Figure 7.2 The algorism of establishing HCC diagnoses according to the European
Association for the Study of the Liver (EASL). Figure adapted from (223).

The differentiation of HCC from other liver nodules including high-grade dysplasia, benign
hypervascular liver lesions, and malignant hypervascular liver lesions are of significant importance
because the lesions listed above have hypervascular structure and similar vascular phase
enhancement with HCC. Especially for the early stage of HCC lesions which has not formed
enough artery blood supply, which might not show typical vascular enhancement patterns (218).
7.1.3 Treatment options for HCC
Orthotopic liver transplantation yield the best outcome for HCC patients who are eligible.
HCC patients met Milan criteria had a significantly better prognosis, and longer survival time, the
five-year survival rate for patients treated with local tumor destruction, resection, and orthotopic
liver transplantation is 37.6%, 55.5% and 77.2% respectively (224).
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The poor prognosis of HCC and lack of effective treatments make seeking for new
diagnostic and therapeutic approaches an unmet and urgent medical need. Sorafenib is an oral
multi-kinase inhibitor that targets the Raf kinases, vascular endothelial growth factor receptor
(VEGFR), and platelet-derived growth factor receptor (PDGFR) tyrosine kinases for anti-tumor
and anti-angiogenesis effects. It demonstrated beneficial for overall survival (225). Most HCC
patients have gone through cirrhosis, followed by inflammation, this process is mediated by
chemokines (225). As a result, the role of chemokines in HCC development and the potential in
targeted therapies has raised the interest of research in the related field. CCL20-CCR6 mediate the
MAPK phosphorylation and affect the HCC progression (226).
CXCR4-CXCL12 axis is involving in cell migration and immune-cell recruitment. CXCR4
was found to have elevated expression in cirrhotic liver inflammatory foci (227). CXCR4 has
multiple functions in the liver inflammation prior to liver cirrhosis and HCC, hepatocytes overexpress CXCL12 following liver injury (228). We hypothesis there will be CXCR4 overexpression
in HCC and it can be a potential biomarker for treatment stratification, and drug treatment effect
monitoring.
7.2

Results

7.2.1 Pathology analysis of DEN-induced HCC
Mice with a C57BL/6 genetic background were used to develop DEN induced the HCC
mouse model. All animal experiments performed in this study complied with an animal protocol
reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at Georgia
State University.

151

Detailed material and method see chapter 2.9.4. Three DEN-induced HCC mice with
different treatment and one normal mouse as control were used for monitoring and comparing the
CXCR4 expression level change using MRI scanning with one bolus tail vein injection of
ProCA32.CXCR4 (0.025mmol/kg).
DEN induced HCC mice were treated with four different combination treatments. One
group of animals treated with saline buffer, one group of animals treated with Doxorubicin, one
treated with Doxorubicin and ProAgio (229). Mice from different groups were selected for MRI
imaging to monitoring and comparing the treatment effects of different combination. All mice for
MRI imaging were injected with one bolus dosage of ProCA32.CXCR4 through the tail vein. MRI
scanning of the liver region of mice was collected before, 3 hours, 24 hours and 48 hours after
contrast agent injection (Doxorubicin treated mouse and HCC mouse treated with a combination
of Doxorubicin and ProAgio deceased after 24 hours and 48 hours scanning not collected). Right
after imaging, mice were euthanized. Organs and tissues, including liver, heart, spleen, kidney,
brain, tail, and muscle, were collected. The mice livers were measured and weighted, one small
piece of liver from each mouse was reserved for ICP-OES analysis, the rest was fixed with 10%
neutral buffered formalin for 3-7 days and embedded with paraffin for further histology analysis.
DEN-induced HCC mice liver is cirrhotic and enlarged, as seen in Figure 7.3, HCC weight
is heavier and texture harder than the normal liver. Unifocal, multifocal tumor formed in the liver,
color paler than normal liver tissue. There is no observable difference after Doxorubicin treatment
and Doxorubicin and ProAgio combination treatment.
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Figure 7.3 Comparison of normal mouse liver and HCC mouse liver with different treatment.

7.2.2 MRI images of HCC mice
7.2.2.1 Normal control mouse
DEN-induced HCC mice with buffer, Doxorubicin, and Doxorubicin combined with
ProAgio treatment were selected for MRI imaging. Normal mouse with ProCA32.CXCR4
injection is imaged with the same protocol as control. Dosage of ProCA32.CXCR4 injection is
0.025mmol/kg, MRI images collected before the injection of ProCA32.CXCR4 and 3 hours, 24
hours, 48 hours after injection. T1 weighted images, T2 weighted images, T1 mapping, and T2
mapping were collected at each time points. 12 to 16 slides of MRI images were collected for each
mouse with 1mm thickness, no gap. Detailed parameter for imaging collection sees chapter 2.10.
Normal mouse with ProCA32.CXCR4 injection shows a similar pattern as observed before
for liver imaging. On both T1 weighted and T2 weighted imaging, the signal-noise ratio
enhancement after injection showed a consistent pattern (Figure 7.4). T1 weighted MRI imaging
shows an SNR increase after 3 hours injection of ProCA32.CXCR4 and SNR washed out at 24
hours and 48 hours after contrast agent administration. T2 weighted MRI imaging shows SNR
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decreased after 3 hours of ProCA32.CXCR4 administration and SNR recover at 24 hours and 48
hours after contrast agent administration.
T1 mapping of the mouse liver shows the liver t1 time change before and after
ProCA32.CXCR4 injection (Figure 7.5). Before ProCA32.CXCR4 injection, the liver t1 time is
618.0 ms, at 3 hours after ProCA32.CXCR4 administration, the liver t1 decrease to 484.3 ms.
Along with the washout of contrast agent, t1 time of liver increased at 24 hours and 48 hours, to
523.7 ms and 558.3 ms respectively.
T2 mapping MRI scanning shows the quantitative representation of the t2 time of the liver
(Figure 7.6), the mean t2 time of liver before ProCA32.CXCR4 administration is 39.0 ms, it
decreased to 35.0 at 3 hours after contrast agent administration, after 24 hours and 48 hours
administration of ProCA32.CXCR4, the mean value of t2 time of liver goes back to 33.0 ms and
37.0 ms respectively along with the concentration of ProCA32.CXCR4 in liver washed out.
The signal enhancement of the whole liver is homogenous. In normal mouse,
ProCA32.CXCR4 distributed to the liver through blood flow and caused signal intensity change,
and the enhancement reached a peak at 3 hours and washed out along with ProCA32.CXCR4 wash
out. The enhancement pattern of the normal mouse with ProCA32.CXCR4 injection is consistent
on T1 weighted, T2 weighted, T1 mapping, and T2 mapping acquisition, which shows the
distribution of ProCA32.CXCR4 in the liver after injection. ProCA32.CXCR4 distributed to the
liver after tail vein injection, and the concentration reaches to the peak and 3 hours after and wash
out ever since. As a result, the normal mouse with ProCA32.CXCR4 injection shows T1 signal
enhancement, T2 signal decrease at 3 hours after injection, t1 and t2 time shortening at 3 hours
after injection when compared with pre-scan and the change goes back at 24 hours and 48 hours
after injection along with the washout of ProCA32.CXCR4.
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The H&E staining of the normal liver shows the regular structure of mouse liver, liver
lobule well- structured and hepatocytes lays in line with each other and form sinusoidal lining cells
form sinusoidal space.

Figure 7.4 T1, T2 weighted MRI images and SNR of the normal mouse at different time
points following ProCA32.CXCR4 injection.
Normal mouse with ProCA32.CXCR4 injection shows hyper signal intensity enhancement on T1
weighted MRI images, and hypo signal intensity enhancement on T2 weighted MRI images after
administration of ProCA32.CXCR4. The quantitative analysis of SNR shows consistent
enhancement pattern followed ProCA32.CXCR4 injection. On T1 weighted acquisition, SNR
increases at 3 hours after injection of contrast agent and wash out at 24 hours and 48 hours after
injection. On T2 weighted acquisition, SNR decreases at 3 hours after contrast agent injection and
come back at 24 hours and 48 hours after injection.
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Figure 7.5 T1 mapping MRI images and t1 time of normal mouse at different time points
follow ProCA32.CXCR4 injection.
T1 mapping of normal mouse follows the injection of ProCA32.CXCR4 shows the t1 time of liver
decrease at 3 hours after injection of ProCA32.CXCR4 and goes back after 24 hours and 48 hours
after injection.

Figure 7.6 T2 mapping MRI images and t2 time of normal mouse at different time points
follow ProCA32.CXCR4 injection.
T2 mapping of normal mouse follows the injection of ProCA32.CXCR4 shows the t2 time of
liver decrease at 3 hours and 24 hours after injection of ProCA32.CXCR4 and goes back at 48
hours after injection.
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Figure 7.7 H&E staining of normal mouse liver.

Buffer treated HCC mouse has enlarged and cirrhotic liver with tumor forming in the liver
(Figure 7.3), the MRI images of buffer treated HCC mouse shows the tumor nodule forming in the
left part of liver on both T1 weighted and T2 weighted images (Figure 7.8, Figure 7.9 red circle
regions). The pre-scanning of T1 and T2 weighted MRI images shows the left part of the liver has
10 – 20 HCC tumor nodules with a diameter of 0.5 to 3 mm. The HCC tumor nodules show
hyperintensity in T2 weighted imaging because of the intrinsic higher t2 time of tumors. The
quantitative analysis of SNR of HCC tumor nodules is based on the data of the tumors in the red
circle. The SNR analysis of tumors on T1 weighted imaging clearly shows HCC tumor has slightly
higher SNR than normal liver (Figure 7.4), the HCC tumor SNR on T1 weighted images is 34.7
whereas the normal mouse SNR is 31.3. The SNR of HCC tumors on T2 weighted images is
significantly higher than normal liver SNR; the normal liver SNR is 7.1. However, the HCC tumor
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T2 SNR is 46.8. The dramatic difference in SNR enables the HCC tumor distinguishing on T2
weighted images.
Interestingly, after the injection of ProCA32.CXCR4, the HCC tumors intensity
significantly enhanced when compared with pre-scanning on T1 weighted images. The tumor SNR
keep increasing up to 24 hours. Quantitative analysis of SNR on pre and after contrast agent
administration T1 weighted images (Figure 7.8) shows that at 3 hours after administration of
ProCA32.CXCR4, the SNR of HCC tumors increase from 34.7 to 63.8, and SNR continuing
increasing at 24 hours to 81.1 and wash out since then. At 48 hours after ProCA32.CXCR4
administration, the SNR goes back to 48.1.
The T1 weighted imaging SNR change pattern at different time points after
ProCA32.CXCR4 administration in buffer treated HCC mouse is different from the normal mouse
and consistent with the SNR change pattern of uveal melanoma mouse with ProCA32.CXCR4
injection. For the mice carry CXCR4 high expression tumors (both uveal melanoma and HCC),
the T1 weighted SNR increase after the administration of CXCR4 targeted contrast agent
ProCA32.CXCR4 up to 24 hours, and SNR wash out after that. For buffer treated HCC mouse, the
SNR at 24 hours after injection is one time higher when compared with before injection (Figure
7.8), however, the uveal melanoma SNR is around 50% more than pre-scan (Figure 6.1). It
indicates that the interaction of ProCA32.CXCR4 with CXCR4 in vivo are similar in uveal
melanoma mouse models and HCC mouse model. HCC tumors might have higher CXCR4
expression levels than uveal melanoma, so it has higher SNR enhance than uveal melanoma. The
T1 mapping result is consistent with the T1 weighted images and further proved the CXCR4
molecular imaging is achieved by administration of ProCA32.CXCR4. T1 mapping of buffer
treated HCC mouse (Figure 7.10) shows that the t1 time of HCC tumor is intrinsically longer than
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liver, the t1 time for HCC tumor is 1590 ms, after the administration of ProCA32.CXCR4, the t1
time is shortening to 1401 ms at 3 hours and 1355 ms at 24 hours and goes back to 1588 at 48
hours. The T2 mapping of the same animal (Figure 7.12) shows the similar change pattern as T1
mapping, the t2 time of HCC tumors is 93.7 ms, which is higher than the t2 time (39 ms) of the
normal liver. After administration of ProCA32.CXCR4, the t2 time is shortening up to 24 hours, t2
time of HCC tumor is 74.3 ms at 3 hours and 66.0 ms at 24 hours and goes back to 84.3 ms at 48
hours.

Figure 7.8 T1 weighted MRI images and SNR comparison of buffer treated HCC mouse at
different time points following ProCA32.CXCR4 injection.
T1 weighted MR images of buffer treated HCC mouse shows increase SNR on T1 weighted images
on pre-scan. Red circle regions represent tumor nodules with high CXCR4 expression, after the
injection of ProCA32.CXCR4, HCC tumor nodules with high CXCR4 expression exhibit
enhancement up to 24 hours, at 24 hours, the SNR of tumor nodules is two times higher than the
pre-scan SNR. At 48 hours, the SNR decreases. Green circle regions represent tumor nodules with
low CXCR4 expression. For tumor nodules with low CXCR4 expression, the SNR enhancement
is lower than tumor nodules with high CXCR4 expression.
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Figure 7.9 T2 weighted MRI images and SNR comparison of buffer treated HCC mouse at
different time points follow ProCA32.CXCR4 injection.
T2 weighted MR images of buffer treated HCC mouse shows the tumor nodules circled by red
circle exhibit higher SNR. Tumor nodules circled by the red circle shows about double of the value
of SNR when compare with the rest part of the liver (represented by the green circled regions).
After the injection of ProCA32.CXCR4, the SNR of tumors decreases at 3 hours after injection
and goes back afterward. The green circled liver region has slightly decreased after the injection
of ProCA32.CXCR4.
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Figure 7.10 T1 mapping MRI images and t1 time of tumor nodules of buffer treated HCC
mouse at different time points following ProCA32.CXCR4 injection.
T1 mapping of buffer treated HCC mouse to analysis the t1 time of tumor nodules (represented by
red circled regions). The t1 time of tumor nodules on pre-scan is 1590 ms, after the administration
of ProCA32.CXCR4, the t1 time is shortening to 1401 ms at 3 hours and 1355 ms at 24 hours and
goes back to 1588 at 48 hours. T1 mapping results of buffer treated HCC mouse is consistent with
T1 weighted images.

Figure 7.11 T1 mapping MRI images and t1 time of other regions of buffer treated HCC
mouse at different time points follow ProCA32.CXCR4 injection.
T1 mapping of buffer treated HCC mouse to analysis the t1 time of regions other than tumor nodules
(represented by red circled regions). The t1 time of 809.3 ms, after the injection of
ProCA32.CXCR4, t1 time of the same region decreases to 703.0 at 3 hours after injection and goes
back to 797.5 ms at 48 hours after ProCA32.CXCR4 injection.
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Figure 7.12 T2 mapping MRI images and t2 time of buffer treated HCC mouse tumor
nodules at different time points following ProCA32.CXCR4 injection.
T2 mapping of buffer treated HCC mouse to analysis the t2 time of tumor nodules (represented by
red circled regions). T2 mapping of the buffer treated HCC mouse shows the similar change pattern
of CXCR4 high expression nodules as T1 mapping, the t2 time of HCC tumors on before injection
scan is 93.7 ms, which is higher than the t2 time (39.0 ms) of the normal liver. After administration
of ProCA32.CXCR4, the t2 time is shortening up to 24 hours, t2 time of HCC tumor is 74.3 ms at
3 hours and 66.0 ms at 24 hours and goes back to 84.3 ms at 48 hours.

Figure 7.13 T2 mapping MRI images and t2 time of buffer treated HCC mouse other
regions than tumor nodules at different time points following ProCA32.CXCR4
injection.
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T2 mapping of buffer treated HCC mouse to analyze the t2 time of other regions than CXCR4 high
expression nodules. The t2 time of the other region than tumor region of buffer treated HCC mouse
(represented by the red circle region) shows the t2 time of red circle region slightly decreases at 3
hours after injection of ProCA32.CXCR4 and goes back afterwards.

Figure 7.14 Correlation of MR images and histological results of buffer treated HCC
mouse.
Histological correlation of buffer treated HCC mouse liver with both T1 and T2 weighted MR
images.

Doxorubicin treated HCC mouse has distinctly different MRI imaging results than the
buffer treated HCC mouse, the T1 weighted images (Figure 7.15) of Doxorubicin treated mouse
shows the signal decrease in both liver and tumor region when compare with pre-scan. The T1
SNR slightly decrease at 3 hours after administration of ProCA32.CXCR4 and goes back at 24
hours. The T2 SNR decrease at 3 hours after administration of ProCA32.CXCR4 and further
decrease at 24 hours. The t1 and t2 time of the HCC tumor treated with Doxorubicin decreased at
3 hours after administration and went back at 24 hours (Figure 7.17, Figure 7.18). The t1 time of
HCC mouse treated with Doxorubicin is 1474 ms on the pre-scan and decrease to 1293 ms at 3
hours after ProCA32.CXCR4 injection. At 24 hours after administration of ProCA32.CXCR4, the
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t1 time of HCC tumor goes back to 1429 ms. The t2 time of Doxorubicin treated HCC mouse tumor
is 92.3 ms before the administration of ProCA32.CXCR4 and decrease to 75.7 ms at 3 hours after
injection, at 24 hours, the t2 goes back to 93.7 ms. The t1 and t2 time of Doxorubicin treated HCC
tumor is similar with buffer treated HCC tumor, but the dynamic change of the t1 and t2 time is
different which is caused by the CXCR4 expression change with Doxorubicin treatment.
The results proved that, for the HCC tumor treated with buffer and Doxorubicin, it is
difficult to conclude the treatment effect, since the SNR on T1 weighted, T2 weighted images are
similar with two different treatments. The T1 mapping and T2 mapping gave the results of t1 and
t2 time of HCC tumor, which is similar as well for the buffer treated mice, and Doxorubicin treated
mice. The MRI imaging without administration cannot provide enough information for treatment
effect evaluation. With the administration of CXRC4 targeted contrast agent ProCA32.CXCR4,
however, we can have further information regarding the molecular signature of HCC tumor change
followed by different treatments. For the HCC mouse treated with buffer, tumor intensity and t 1
time significantly enhanced after ProCA32.CXCR4 was introduced, which enabled by the CXCR4
binding of ProCA32.CXCR4 and achieving of CXCR4 molecular imaging using MRI.
On the contrary, HCC mouse with Doxorubicin treatment did not show this change. For
the reason that, after chemotherapy, CXCR4 level decreased before visible tumor size shrinking
and tumor number decreased can be observed. It is enabling early assessment of treatment effect
before any anatomical structure change can be detected. Treatment effect assessment and
monitoring is another important application of molecular imaging using MRI. With the advantage
of non-radiation exposure to MRI scanning, patients can be repeatedly assessed for treatment
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follow-up. Molecular imaging provides information on a molecular level; such incidences happen
ahead of macroscopic changes can be observed.

Figure 7.15 T1 weighted images of Doxorubicin treated HCC mouse.
Six continuous T1 weighted MRI images of Doxorubicin treated HCC mouse at before, 3 hours
and 24 hours after the injection of ProCA32.CXCR4. Red circle regions represent the HCC region
from which the SNR was analyzed. The SNR of tumor nodules of Doxorubicin treated HCC mouse
shows a decrease after 3 hours injection of ProCA32.CXCR4 and goes back at 24 hours after
injection of ProCA32.CXCR4.
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Figure 7.16 T2 weighted MRI images of Doxorubicin treated HCC mouse.
Six continuous T2 weighted MRI imaged of Doxorubicin treated HCC mouse at pre-injection, 3
hours and 24 hours after injection of ProCA32.CXCR4. The red circle regions represent the tumor
regions selected for SNR analysis. T2 weighted images of Doxorubicin treated HCC mouse shows
SNR decrease at 3 hours after the injection of ProCA32.CXCR4 and SNR go back at 24 hours
after injection of ProCA32.CXCR4.
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Figure 7.17 T1 mapping MRI images of Doxorubicin treated HCC mouse.
Six continuous slides of T1 mapping of Doxorubicin treated HCC mouse at different time points
following ProCA32.CXCR4 injection. T1 time analysis based on the regions circle by red circles.
T1 time of the tumor nodules of Doxorubicin treated HCC mouse shows the t1 time decrease
followed the administration of ProCA32.CXCR4. The t1 time of tumor nodules before
ProCA32.CXCR4 injection is 1474.0 ms, at 3 hours after injection, the t1 time decreases to 1293.0
ms and at 24 hours goes back to 1429.0 ms. The t1 time results are not consistent with the T1
weighted images of the same animal. T1 mapping is a more precise way to represent the tissue
relaxation rate change followed the administration of contrast agents.
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Figure 7.18 T2 mapping MRI images and t2 time of Doxorubicin treated HCC mouse at
different time points following ProCA32.CXCR4 injection.
Six continuous slides of T2 mapping of Doxorubicin treated HCC mouse at different time points
following ProCA32.CXCR4 injection. T2 time analysis based on the regions circle by red circles.
T2 time of tumor nodules of Doxorubicin treated HCC mouse decrease to 75.7 ms at 3 hours after
the administration of ProCA32.CXCR4. T2 time of tumor nodules on pre-scan is 92.3 ms at 24
hours after ProCA32.CXCR4 administration, the t2 time goes back to 93.7 ms. The t2 time change
pattern of Doxorubicin treated HCC mouse is consistent with the T2 weighted images and T1
mapping results of the same animal.
The HCC mouse receiving combination treatment of Doxorubicin and ProAgio is different
from HCC mouse with buffer treatment and HCC mouse with Doxorubicin treatment. The HCC
mouse with a combination treatment of Doxorubicin and ProAgio shows no tumor nodules when
compare with other treatment groups. The middle region of the liver (Figure 7.19, red circle region)
has slightly higher intensity when compare with the rest, which is the fibrotic/ cirrhotic liver tissue.
The SNR analysis of this region shows no significant difference after injection of
ProCA32.CXCR4. On the T1 mapping and T2 mapping (Figure 7.20, Figure 7.21), the cirrhotic
region remained unchanged after the administration of ProCA32.CXCR4. This is a very interesting
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finding because the cirrhotic region from buffer treated HCC behaves differently on MRI images
followed by the same contrast agent administration. The buffered treated HCC mouse has signal
enhancement after injection of ProCA32.CXCR4 but the combination treatment HCC mouse
cirrhotic liver seems has ProCA32.CXCR4 delivery difference because no significant
enhancement observed followed the contrast agent injection. This phenomenon might be related
to the neovascular forming, followed by the ProAgio treatment. The newly formed vascular is not
connecting to the existing vascular structure so ProCA32.CXCR4 is not able to deliver to the
ProAgio treated mouse liver. This is causing hypo enhancement after the ProCA32.CXCR4
administration. On top of ProAgio, the Doxorubicin treatment reduced the CXCR4 expression
level, which leads to the reduce of enhancement based on CXCR4 molecular imaging. Overall,
due to the new vascular forming effect of ProAgio and CXCR4 expression reduction followed by
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Doxorubicin treatment, the combination treatment mouse shows dim enhancement followed the
administration of ProCA32.CXCR4.

Figure 7.19 T1, T2 weighted MRI images and SNR of Doxorubicin and ProAgio treated
HCC mouse at different time points following ProCA32.CXCR4 injection.
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Figure 7.20 T1 mapping MRI images and t1 time of Doxorubicin and ProAgio treated HCC
mouse at different time points follow ProCA32.CXCR4 injection.

Figure 7.21 T2 mapping MRI images and t2 time of Doxorubicin and ProAgio treated HCC
mouse at different time points following ProCA32.CXCR4 injection.
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Figure 7.22 T1 weighted images before and after injection of ProCA32.CXCR4 of HCC
mice with different treatment.
Comparison of T1 weighted images of HCC mouse with different treatment, before and after
different time points of ProCA32.CXCR4 administration. Buffer treated HCC mouse shows a
significant enhancement of whole liver regions, CXCR4 high expression nodules enhanced more
than the rest region of liver, indicating the CXCR4 targeting effect at 24 hours after the injection
of ProA32.CXCR4, which is consistent with the MR imaging results from other animal models,
including uveal melanoma mouse model. Normal mouse and HCC mouse with other treatment do
not show the CXCR4 targeted enhancement. ICP-OES to analysis the gadolinium content of tumor
tissues confirmed the CXCR4 targeting effect of ProA32.CXCR4 and consistent with the MR
images enhancement.
7.3

Discussion and conclusion
HCC is a primary liver malignancy with poor prognosis and a prevalent healthcare concern

for society. Advance in imaging diagnosis already make HCC diagnosis establish based on
imaging the reality. Improvement in diagnosis algorithm successfully improved the percentage of
HCC patient surveillance and early detection. The introduce of Milan criteria for screening liver
transplantation candidates significantly improve the success rate for HCC patients qualified for
orthotopic liver transplantation. With all the advances in HCC surveillance and management, new
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approaches for early detection and treatment effect evaluation using clinical imaging remains an
unmet medical need.
Chemokines are considered to play an important role in HCC development for their roles
in cell migration, inflammation, and immune cell recruitment. These incidences usually happen
before cirrhosis forming, and chronic viral infection is a major etiology for HCC. Researchers have
found that the CXCR4-CXCL12 axis involved in chronic viral hepatitis transition to liver cirrhosis
and HCC. As a result, imaging targeting CXCR4 can be a new approach for HCC detection and
related treatment effect monitoring.
With DEN induced HCC mouse model, we observed the elevated CXCR4 expression level,
which proved by the hyperintensity T1 weighted imaging followed by CXCR4 targeting MRI
contrast agent PrOCA32.CXCR4. Owing to the high relaxivities of ProCA32.CXCR4, CXCR4
molecular imaging has been achieved in HCC tumor mice and showed elevated CXCR4 expression
level in HCC mouse tumor. T1 mapping and T2 mapping of the same mouse has consistent result
demonstrating the targeting effect at a longer time after injection of ProCA32.CXCR4 (24 hours).
Within difference HCC tumor nodules, there is inconsistency regarding tumor tissue t1 and t2 time.
However, the longitude analysis of tissue relaxation time along time points shows consistent
tendency change based on CXCR4 expression level difference. For HCC mouse with buffer
treatment, it has higher CXCR4 expression levels, which lead to a delayed time point after injection
enhancement owing to the dynamic CXCR4 binding process. For HCC mouse with Doxorubicin
treatment, it does not exhibit the same pattern of contrast enhancement at different time points,
which is a result of CXCR4 level difference and molecular dynamic contrast enhancement property
alteration.
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Doxorubicin has limited treatment effect on HCC patients, the liver appearance of
Doxorubicin treated HCC mouse has no significant improvement when compared with buffer
treated HCC mouse. Interestingly, the CXCR4 molecular imaging shows the molecular dynamic
enhancement property difference between the treated HCC mice and untreated ones. ICP-OES
analysis of gadolinium content in HCC tumor gives the consistent result that after doxorubicin
treatment, HCC tumor has lower gadolinium content when compared with the control. It is the
evidence that Doxorubicin might affect the CXCR4-CXCL12 axis but no significant improvement
in tumor size shrinking, etc.
CXCR4 is potentially a target for HCC treatment drug development, and CXCR4 imaging
can be used for monitoring the treatment effect. ProCA32.CXCR4 achieved first CXCR4
molecular imaging to assess biomarker expression in HCC in our knowledge and is a potential tool
for related treatment effect monitoring and assessment.
8

MULTICOLOR MRI BY DUAL CONTRAST ENHANCEMENT IMAGING AND
INTEGRIN V3 TARGETED CONTRAST AGENT

8.1

Introduction

8.1.1 Mn2+ based MRI contrast agents
The report of NSF and gadolinium-associated brain deposition bring about the
development of safer alternative of gadolinium-based contrast agents. One approach is to replace
Gd3+ with other paramagnetic metal ions that relax the water proton efficiently. Non-lanthanide
metals have been investigated for their potential to be MRI contrast agent as alternative of
gadolinium. Manganese is undoubtedly an attractive candidate for low toxicity. Unlike
gadolinium, manganese is a physiologically present metal that serves as co-factor of a series of
enzyme and essential to maintaining human health. Study regarding the toxicity assessment of
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manganese demonstrated it as a low toxic substance (230). Although Mn2+ possess fewer unpaired
electrons (five) when compared with gadolinium (seven), it still provides decent positive
enhancement on MR imaging.
The only Mn2+ based contrast agent that had been proved for clinical usage was
mangafodipir trisodium (Mn-DPDP), marketed under the tradename of Teslascan® in 1990. MnDPDP has similar T1 relaxivity (2.8 mM-1· s-1) with gadolinium diethylenetriaminepentaacetic
acid (4.5 mM-1· s-1) in aqueous solution. However, in liver relaxivity of Mn-DPDP is 21.7 mM-1·
s-1, which is significantly higher than gadolinium-based contrast agents (231). Mn-DPDP does not
have inner sphere water molecule and shows slow transmetallation with endogenous metal ions
such as Ca2+, Zn2+, etc. The released manganese is uptake by hepatocytes and shows high relaxivity
in liver tissue. However, due to the low sales, and concern about toxicity, Mn-DPDP withdrawn
from the United States in 2003 and Europe in 2010.
Thermostability and inertness to transmetallation have to be taken into consideration when
design manganese-based MRI contrast agents. Cu2+ and Zn2+ usually have a higher affinity to
given ligand than Mn2+ in general. Ca2+ and Mg2+ have lower affinity but are present in higher
concentration physiologically. Thus, although Mn2+ is less toxic than Gd3+, the high amount of
manganese exposure can still cause adverse neurological effects and Parkinson-like symptoms
(232).
8.1.2 Multicolor MR imaging with dual contrast agents
Flask et al. recently reported that in the presence of two MRI contrast agents A and B, the
T1 and T2 relaxation could be described by the following equations:
1
1
=
+ 𝑟1𝐴 × [𝐴] + 𝑟1𝐵 × [𝐵]
𝑇1 𝑇1 𝑝𝑟𝑒
Equation 8.1
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1
1
=
+ 𝑟2𝐴 × [𝐴] + 𝑟2𝐵 × [𝐵]
𝑇2 𝑇2 𝑝𝑟𝑒
Equation 8.2

where [A] is the concentration of imaging agent A; T1pre and T2pre are the pre-contrast T1
and T2 relaxation times; T1 and T2 are the post-contrast T1 and T2 relaxation times; r1A and r2A are
the relaxivities of contrast agent A; [B] is the concentration of contrast agent B, and r1B and r2B are
the relaxivities of contrast agent B.
Based on these equations, we hypothesis that if T1pre, T2pre, T1, and T2 are measured
before and after simultaneous injection of two different contrast agents with known relaxivities,
[A] and [B] can be calculated by equation 5.1 and 5.2. Assuming these two different contrast agents
have preferred sensitivity to longitudinal and transverse relaxation parameter, respectively. (e.g.,
a Gd3+-based T1 agent and an Mn2+-based T2 agent). The recently developed Magnetic Resonance
Fingerprinting (MRF) methodology simultaneously generate inherently co-registered T1 and T2
relaxation time maps using a unique acquisition and quantification strategy that combines a prior
acquisition parameter variation with a dictionary-based pattern matching algorithm.
Optimized MRF acquisition obtains quantitative T1 and T2 maps in 10–50 seconds per
imaging slice, providing the possibility to dynamically generate quantitative maps of these two
important MRI parameters simultaneously.
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Figure 8.1 The workflow of multicolor MRI with dual contrast agent.

Based on our platform of developing protein-based contrast agents with different
paramagnetic metals, and our achievement in targeted ProCAs, we reasoned that Multi-color
protein MRI contrast agents targeted to biomarkers could be developed by designing several types
of paramagnetic metal-binding sites into our developed ProCAs. We can further develop multicolor pMRI using multi-contrast Magnetic Resonance Fingerprinting (MRF) methodology (MCMRF) to investigating the tumor microenvironment.
8.1.3 Integrin v3
Integrins are one of the best-understood cell adhesion receptors. Integrins mediate cell
adhesion, transmit a signal between the extracellular ligand with cytoplasmic domain and
triggering intracellular signal pathways (233). The initial understanding of integrins’ function is a
cellular linkage between cells to extracellular matrix (ECM) proteins. A common integrin
recognition motif shared by various extracellular matrix protein is the RGD peptide sequence
(234). Integrins also mediate cell-cell adhesion with a more restricted recognition. The DXSXS
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motif from the metal ion-dependent adhesion site (MIDAS) is proved to be critically important for
RGD sequence binding (235), and the mutation in that site can affect ligand binding (236).
Integrin family consists of more than 24 integrins and each of them formed by a noncovalent association of two different subunits  and . Integrins always form a heterodimer. 18 
and 8  subunits assort with each other and form 24 distinct integrins (233) (Figure 8.2Error!
Reference source not found.). Integrins involved in cell attachment, migration, angiogenesis and
cancer formation, etc.

Figure 8.2 Integrin receptors.
Figure adapted from reference (233).
Angiogenesis is crucial in tumor progression. Tumor growth will be mostly limited if no
neovascular formed (237). The angiogenesis can turn on the dormant tumor cell switch, promote
tumor invasion, and metastasis. ECM structure degradation facilitates tumor cell invasion. As an
essential cell adhesion molecule and adhesion mediator of the cell to ECM, integrins play an
extremely important role in cancer development. Among a wide range of integrins, v3 is the
most important one in angiogenesis (238). Even more notably, v3 presents on activated
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endothelial cells and newly form vascular but absent on normal vasculature and resting endothelial
cells. A study of wound healing revealed that v3 is highly expressed on blood vessels in
granulation tissue but not normal skin (238). Taken together, v3 is a suitable biomarker for
assessing the angiogenesis in tumors.
Breast cancer is the second most diagnosed cancer in women in the United States.
Biomarker HER2 (human epidermal growth factor receptor) is a well-recognized biomarker for
breast cancer staging and diagnosis and a successful example of the biomarker in cancer diagnosis
and therapy. Integrin v3 is related to angiogenesis and proposed as a prognostic factor for breast
cancer. One study demonstrated the functional role of integrin v3 in breast cancer and the
association with the invasiveness of breast cancer (239); administration of monoclonal antibodies
LM609 blocks the breast cancer growth and angiogenesis. As a result, v3 targeted imaging can
potential evaluate the angiogenesis of breast tumor and predict the invasively of breast tumor.
Attempts have been made towards v3 targeted molecular imaging. An 18F labeled RDG
dimer peptide with PEG4 linker has successfully achieved v3 specific enhancement using PET
imaging (240). A radiolabeled RGD peptide

99m

Tc-NC100692, which can target v3 was

demonstrated to enable enhancement of breast cancer malignant lesions (241). We propose a
protein-based contrast agent contain the repetition of RGD sequence for v3 can serve as an MRI
contrast agent and imaging integrin v3 non-invasively with no involvement of radiation.
8.2

Results

8.2.1 Relaxivities measurement of Mn2+ based ProCA32.CXCR4
The relaxivity of manganese ProCA32.CXCR4 was measured in a similar protocol as
gadolinium ProCA32.CXCR4. Bivalent manganese ions and ProCA32.CXCR4 was loaded in a
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2:1 ratio and both longitudinal and transverse relaxivity were measured with 1.4 T relaxometer
and 7.0 T Bruker scanner. Mn-ProCA32.CXCR4 exhibits both high r1 and r2 relaxivities. In 1.4 T,
the r1 equals to 60.0 mM-1s-1 and r2 equals to 133.2 mM-1s-1 (Figure 8.3). In 7.0 T, the r1 equals to
11.9 mM-1s-1 and r2 equals to 142.8 mM-1s-1.

Figure 8.3 Relaxivities measurement of Mn-ProCA32.CXCR4 in 1.4 T.
The longitudinal and transverse relaxivity of Mn-ProCA32.CXCR4 was assessed with 1.4 T
relaxometer. Mn2+ and ProCA32.CXCR4 loaded in 2:1 ratio. The r1 equals to 60.0 mM-1s-1 and r2
equals to 133.0 mM-1s-1. Measurements are done in buffer consists of 50 mM HEPES, 100 mM
NaCl at pH 7.2, 37°C.
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Figure 8.4 Relaxivities measurement of Mn-ProCA32.CXCR4 with 7.0 T Bruker scanner.
The longitudinal and transverse relaxivity of Mn-ProCA32.CXCR4 was assessed with a 7.0 T
Bruker scanner. The r1 equals to 11.94 mM-1s-1 and r2 equals to 142.79 mM-1s-1Measurements are
done in buffer consists 50 mM HEPES, 100 mM NaCl at pH 7.2, 37°C.

The relaxation time of contrast agents’ solution has a linear relationship with their
relaxivities in the according magnetic field and the intrinsic relaxation time of buffer.
1
1
=
+ 𝑟1 × [𝐶]
𝑇1 𝑇1 𝑏𝑢𝑓𝑓𝑒𝑟
Equation 8.3
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1
1
=
+ 𝑟2 × [𝐶]
𝑇2 𝑇2 𝑏𝑢𝑓𝑓𝑒𝑟
Equation 8.4
T1, T2 is the relaxation time of contrast agent solution, T1 buffer and T2 buffer are the relaxation
time of buffer only. [C] is the concentration of contrast agent, r1 and r2 are the relaxivities of
contrast agent.
Based on the linear relationship of relaxation time and contrast agent concentration,
Christian E. Anderson et al. proposed a linear model for systems contains two contrast agents
(242), the solution contains two contrast agents A and B, the relaxation time of solution is
contributed by both contrast agents’ relaxivities. (Equation 8.1, 8.2)
The concentration of two contrast agents can be estimated based on the longitudinal
relaxation time and transverse relaxation time of solution system that contains two contrast agents
if the relaxivities of contrast agents are known. (Figure 8.5) C, D shows that the estimated
concentration of contrast agents and the known concentration of contrast agents has functional
linear correlations.
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Figure 8.5 Determine the concentration contrast agents from relaxivities measurement, 1.4
T.
(A), (B). Relaxivities measurement of both Gd-ProCA32.CXCR4 and Mn-ProCA32.CXCR4
under 1.4 T. (C), (D). Correlation of known concentration and estimated concentration of GdProCA32.CXCR4 and Mn-ProCA32.CXCR4 respectively.
8.2.2 Mn2+ binding affinity measurement of hProCA32.collagen1

Figure 8.6 Determine the manganese binding affinity of hProCA32.collagen1.
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The Manganese binding affinity of protein contrast agent is pivotally significant. By an
Mn2+-Tb3+ competition assay described in chapter 2.4.5, the Kd of Mn2+ binds to
hProCA32.collagen1 was calculated to be 1.13 × 10-20 M (Figure 8.6).
8.2.3 Expression, purification, and characterization of ProCA32.RGD for integrin

V3 imaging
ProCA32.RGD was designed base on ProCA32, with the four repetitions of RDG sequence
at the C terminus for Integrin v3 binding. ProCA32.RGD sequence and structure are showed in
Figure 8.7. ProCA32.RGD is bacterially expressed, purified follow the similar protocol of
ProCA32.CXCR4 expression and purification. ProCA32.RGD expressed with competent cell
BL21 (DE3) pLysS strain. After the 0.5 mM isopropyl β-D-1-thiogalactopyranoside induce
expression, the ProCA32.RGD was successfully expressed (Figure 8.8. A).
After the expression by competent cell, the cell pellet was collected and ProCA32.RGD
purification was carried out, followed the established protocol of purification described in chapter
2.2.3. Briefly, followed the overnight expression after IPTG induction, cell pellet is collected by
centrifuge and resuspended in PBS buffer. Cells were broken with sonication; the supernatant was
collected after centrifuge. Supernatant then boiled, incubated with streptomycin and dialyzed in
10 mM HEPES buffer for overnight. Ion exchange column was used to separate ProCA32.RGD
with impurities and finish the purification of ProCA32.RGD (Figure 8.8.C).
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Figure 8.7 Predicted secondary structure, solvent accessibility, and models of
ProCA32.RGD.
Prediction of secondary structure, solvent accessibility, and final models using I-TASSER (158).
C-score is the confidence of protein model predicted by I-TASSER, which is typically in the
range of [-5,2], where the higher value of C-score corresponding higher confidence of the
prediction.

Figure 8.8 Expression and purification of ProCA32.RGD.
(A), (B) ProCA32.RGD expression and purification SDS-PAGE with Coomassie blue staining.
(A) Cell pellet samples after different time of ProCA32.RGD expression is collected and analyzed
with Coomassie blue staining, after the induction with IPTG, ProCA32.RGD was expressed,
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orange box highlighted the ProCA32.RGD bands. (C) The FPLC spectrum of ProCA32.RGD,
samples eluted from different peaks were analyzed by SDS-PAGE (B).
8.2.4 Relaxivities and metal-binding affinity measurement of ProCA32.RGD
Longitudinal relaxivity and transverse relaxivity of ProCA32.RGD was measured with 1.4
T relaxometer followed the standard protocol described in chapter 2.3. Different concentration of
ProCA32.RGD (from 0 µM to 40 µM) were prepared in 50 mM HEPES, 100 mM NaCl, PH 7.2;
in a loading ratio with gadolinium of 1:2. The longitudinal relaxivity of ProCA32.RGD is 29.2
mM-1s-1 and the transverse relaxivity of ProCA32.RGD is 40.7 mM-1s-1 under 1.4 T magnetic field
(Figure 8.9). The relaxivities of ProCA32.RGD is consistent with the values of ProCA32 and
ProCA32.CXCR4. All protein-based contrast agents mentioned above exhibited both high r1 and
r2 relaxivity and enable the robust contrast enhancement in MR imaging.

Figure 8.9 Relaxivity measurement of ProCA32.RGD.
Relaxivity assessment of ProCA32.RGD with 60 MHz relaxometer. At 1.4 T, r1 of
ProCA32.CXCR4 is 29.2 mM-1 s-1, r2 of ProCA32.CXCR4 is 40.7 mM-1 s-1.
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The metal-binding affinity of ProCA32.RGD was measured following the protocol
described in chapter 2.4. The metal binding affinity of ProCA32.RGD to Ca2+, Zn2+, Tb3+ and Gd3+
were summarized in Table 8.1 Summary of the metal-binding affinity of ProCA32.RGD..
ProCA32.RGD presents high affinity to Tb3+, Gd3+ and excellent selectivity of Gd3+ over Ca2+ and
Zn2+. The high metal binding affinity and good selectivity of Gd3+ over physiologically present
metals such as Zn2+ and Ca2+ of ProCA32.RGD provided the foundation to be a contrast agent
with robust imaging capacity.

Table 8.1 Summary of the metal-binding affinity of ProCA32.RGD.

Data from Dr. Yueshuang Leng.

8.2.5 Integrin v3 targeting study of ProCA32.RGD
ProCA32.RGD was designed as Integrin v3 targeting contrast agent for integrin v3
targeted molecular MR imaging application. The integrin v3 targeting capability of
ProCA32.RGD was assessed by immunofluorescence staining and cell attachment assay.
Immunofluorescence staining of ProCA32.RGD was carried out with human umbilical vein
endothelial cells (HUVECs). HUVECs have high expression level of v3. With same
concentration incubation (5 µM) of ProCA32 and ProCA32.RGD, HUVECs with non-targeted
contrast agent ProCA32 incubation shows no fluorescence on the cell surface and HUVECs with
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integrin v3 targeted contrast agent ProCA32.RGD incubation show strong red fluorescence on
the cell surface. Which proved that ProCA32.RGD interacts and targets integrin v3.
Cell attachment experiment was carried out to test the specific binding of ProCA32.RGD
to integrin v3. There are over 28 different kinds of integrins in the big integrin family. The
specific binding of ProCA32.RGD to integrin v3 will facilitate integrin v3 specific imaging.
Chinese hamster ovary (CHO) cells transfected with different kinds of integrins, including v3,
IIb3, v5, and v6 were used for cell attachment study. Results of cell attachment study (Figure
8.10) show that CHO cells with integrin v3 expression has a significantly higher attachment to
ProCA32.RGD than CHO cells expresses no integrin and other integrins including v3, IIb3,
v5, and v6. Cell attachment study demonstrated the specific targeting of ProCA32.RGD to
integrin v3.

Figure 8.10 Integrin v3 targeting study of ProCA32.RGD.
HUVEC cell with integrin v3 expression was used for immunofluorescence staining to test the
integrin v3 targeting capability of ProCA32.RGD. HUVEC cells with ProCA32 incubation
(control) shows rare red color fluorescence on the cell surface. HUVEC cells with ProCA32.RGD
incubation exhibit strong fluorescence staining on the cell surface that indicates the presence of

188

ProCA32.RGD. CHO cells with different transfection of integrins (v3, IIb3, v5, v6) were
incubated with ProCA32.RGD to test the specific binding of ProCA32.RGD. CHO cell with v3
expression shows significantly higher cell attachment than CHO cell with other integrins
expression and control.

8.2.6 Application of ProCA32.RGD for breast cancer and metastases detection
Orthotopic breast cancer mouse model derived from the 4T1luc cell was used for testing
the imaging capability of ProCA32.CXCR4. The 4T1 cell was stably transfected with firefly
luciferases and an aliquot of 5 × 104 cells injected orthotopically in the mouse breasts. Orthotopic
breast tumors formed after 10 to 14 days of the injection of 4T1luc cells.
Before MR imaging, 4T1luc mice were injected with luciferase substrate (D-luciferin, Free
Acid, ThermoFisher) and imaged by a bioluminescence system to visualize the location of tumor
and potential metastases formed. After 10 min of D-luciferin injection, 4T1luc mice start to show
the bioluminescence enhancement around the breast, mouse located in the right side shows
enhancement gradually around kidneys, indicating there are potentially kidney metastases forming
in that mouse. Bioluminescence imaging was taken every five minutes after 10 min; the highest
luminescence enhancement showed around 25 to 30 min after injection of luciferase substrate
(Figure 8.11).
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Figure 8.11 Bioluminescence imaging of 4T1luc mouse model.
Bioluminescence imaging of 4T1luc breast cancer mice after different time of injection of
luciferase substrate (D-luciferin, Free Acid, ThermoFisher).
T1 weighted, T2 weighted, and T2 mapping images of 4T1luc mice were collected by 7.0 T
Bruker scanner (Figure 8.12, Figure 8.13). The signal-noise ratio analysis of tumor on T1 weighted
images shows that: before injection of ProCA32.RGD, the SNR of the tumor is 14.3, similar to the
liver SNR; after the injection of ProCA32.RGD, the SNR of the tumor keep increasing up to 50
min after injection. At 24 hours after injection of ProCA32.RGD, the SNR decreases to a similar
level to the pre-scanning.
ProCA32.RGD has both high r1 and high r2 values; the T2 weighted images shows a similar
enhancement pattern as T1 weighted images. After the injection of ProCA32.RGD, the SNR on T2
weighted image decrease when compared with pre-scan. SNR of the tumor on T2 weighted images
keep decreasing up to 40 min after injection and after 24 hours, the contrast effect washed out, and
the tumor SNR recovered back to the pre-scan level.
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Figure 8.12 T1 weighted MR images of 4T1luc breast cancer mouse.
T1 weighted MR images of 4T1luc breast cancer mice were collected before and 20, 30, 40, 50
min and 24 hours after injection of ProCA32.RGD. SNR of breast tumors (represented by red
circled regions) increase after the administration of ProCA32.RGD, the enhancement keeps
accumulating up to 50 min. The SNR decreased after 24 hours of administration.

Figure 8.13 T2 weighted MR images of 4T1luc breast cancer mouse.
T2 weighted MR images of 4T1luc breast cancer mouse were collected before and after 20, 30, 40,
50 min and 24 hours after the administration of ProCA32.RGD. SNR of T2 weighted MR images
(represented by red circled regions) was keep decrease up to 50 min after ProCA32.RGD
administration and washed out after 24 hours after administration.

191

8.3

Conclusion and discussion
In this chapter, we discussed the potential application of protein-based contrast agents

platform technique using other magnetic metals than gadolinium. We investigated the manganesebased contrast agent specifically using CXCR4 targeted protein contrast agent ProCA32.CXCR4.
The relaxivities (both r1 and r2) of ProCA32.CXCR4 under 1.4 T and 7.0 T magnetic field
are investigated, respectively. The r1 of Mn-ProCA32.CXCR4 equals to 60.0 mM-1s-1 and r2 equals
to 133.2 mM-1s-1 at 1.4 T. The r1 and r2 of Mn-ProCA32.CXCR4 are 11.9 mM-1s-1 and 142.8 mM1 -1

s , respectively. Manganese based protein contrast agent shows both high r1 and r2 relaxivities

under 1.4 T. At 7.0 T, the r1 decreased when compared with 1.4 T, but r2 is highly reserved. As
oppose to Gd-ProCA32.CXCR4, Mn-ProCA32.CXCR4 has a dominant effect on transverse
relaxivity than longitudinal relaxivity. The r1 / r2 of Gd-ProCA32.CXCR4 and MnProCA32.CXCR4 are different and suitable for application of multicolor MR imaging in vivo.
Besides the relaxivity advantage of Mn2+ based protein contrast agents, we proved that the binding
affinity of Mn2+ to hProCA32.collagen1 is strong enough to prevent potential Mn2+ associated
toxicity.
The correlation of estimated contrast agents’ concentration calculated using equation 5.1
and 5.2 and relaxation time measurement of Gd-ProCA32.CXCR4 and Mn-ProCA32.CXCR4
mixture with the known concentration of Gd-ProCA32.CXCR4 and Mn-ProCA32.CXCR4 has a
linear relationship. It is the in vitro validation of MRF and dual contrast agent application. Further,
in vivo experiment, including initial liver perfusion and live animal study are needed to be
performed to establish the MRF approach with protein contrast agent platform technique.
Integrin v3 targeted contrast agent ProCA32.RGD was developed and characterized.
ProCA32.RGD has high relaxivities (r1 = 29.2 mM-1 s-1, r2 = 40.7 mM-1 s-1, 1.4 T), high metal
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binding affinity and good metal selectivity over physiologically present metal ions such as Zn 2+
and Ca2+.
The imaging capacity of ProCA32.RGD was tested in 4T1luc breast cancer mice. NonPEGylated ProCA32.RGD was used for animal experiment. Since the molecular weight of the
non-PEGylated contrast agent is smaller than the PEGylated one. The corresponding
pharmacokinetics and pharmacodynamics properties are expected to be different from the
PEGylated agents. MR images acquired before and 20 min, 30 min, 40 min, 50 min, and 24 hours
after injection. SNR of breast tumor significantly increased after administration of ProCA32.RGD,
at 50 min after injection, the enhancement of intensity reaches the peak and washout effect
observed at 24 hours after injection. Similar patterns observed on T2 weighted MR images, SNR
decrease after administration of ProCA32.RGD up to 50 min after injection and the wash out effect
and SNR increase observed after.
Application of ProCA32.RGD in breast cancer detection is an initiative of studying in vivo
application of integrin v3 targeted contrast agent. Non-PEGylated ProCA32.RGD was used in
the animal experiment and successfully enhance tumor for the first time. Non-PEGylated
ProCA32.RGD enhance the tumor at earlier points. However, the enhancement pattern of
PEGylated and non-PEGylated ProCA32.RGD need to be compared, and pharmacokinetics
difference of these two agents need to be studied before a solid conclusion can be reached.

9

SIGNIFICANCE AND FUTURE DIRECTION

Molecular imaging is aiming at revealing the molecular and cellular level information
regarding diseases in a non-invasive way. The development of technology enables achieving
molecular imaging through a variety of imaging platforms. PET and SPECT are the imaging
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modalities that researchers focused on most to achieve molecular imaging for their high sensitivity.
Most of the achievement of molecular imaging has been done with nuclear medicine approaches
involving radiation.
The standard care of cancers has been evolved and improved over the past decades and
primarily improved the life quality of cancer patients as well as extended the survival life span of
cancer patients. A considerable effort has been made toward the development of novel therapeutic
approaches for cancers. This brings the medical needs of advanced imaging techniques for
characterization of diseased region repeatedly and safely for cancer early diagnosis and during the
follow up of disease progression. Therefore, MRI becomes an attractive alternative approach for
the non-radiation involvement and no-depth limitation.
The biggest challenge to achieve molecular MRI is the relatively low sensitivity of current
contrast agents for clinical usage. The average r1 value of gadolinium-based contrast agents is
between 3-5 mM-1s-1. As a result, in order to achieve molecular imaging of biomarkers using
contrast agents with such relaxivity requires the local concentration of contrast agents to be mM
range. However, the concern of the toxicity of gadolinium-based contrast agents restrained the
high dosage applications. How to balance the dosage of gadolinium contrast agents to maximize
imaging capacity and minimize toxicity remains a difficulty in gadolinium contrast agents’
development. Another challenge of achieving molecular imaging is lacking contrast agents with
biomarker targeting capability. The development of biomarker targeting contrast agent with
improved relaxivities is expected to resolve the problem.
Taken safety, enhance capacity together, the good strategy of designing MRI contrast
agents for molecular imaging of specific biomarkers should consider improving the relaxivity,
gadolinium binding affinity, and metal selectivity over physiologically existing metals. Besides,
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constructing a structure that targeting keys biomarkers plays an essential role in disease
development is a necessity of achieving biomarker molecular MRI.
The criteria for screening a good biomarker for molecular imaging should include location,
disease relevance, therapeutic value. More specifically, biomarkers located at extracellular
compartment are easier to access; the biomarkers can predict the cancer progression with their
expression level and help the staging of cancer are of better disease relevance; the biomarkers are
therapeutic targets and responsive to treatment have better therapeutic value. In this dissertation,
we first verified CXCR4 as a good biomarker for uveal melanoma detection. Our rationale of study
CXCR4 based on following facts: CXCR4 is by far the most common chemokine receptor
expressed by cancers and over 23 different kinds of cancers express CXCR4; CXCR4-CXCL12
axis directs the cancer metastasis; CXCR4 considered as an adverse prognostic factor and
therapeutic targets for cancer-related therapies. Based on the fact that uveal melanoma almost
exclusively metastases to the liver, we studied the CXCR4 expression with cell line, tissue, and
mice models. The role of CXCR4 in uveal melanoma development and the value of CXCR4 in
uveal melanoma is controversial according to the previous researches from different groups. We
evaluated the CXCR4 expression levels of different metastatic uveal melanoma cells and
metastases UM in patients’ livers. CXCR4 is generally over-expressed throughout the cell lines
and UM metastases in livers. Metastatic mouse model study shows the CXCR4 expression levels
of UM metastases in liver elevated even the primary UM in the eye are of low to medium CXCR4
expression. These results validated the high expression level of CXCR4 in UM metastases in the
liver, and CXCR4 is a potential biomarker for UM metastases imaging. The overexpression of
CXCR4 is observed in UM metastases. We are the first to systematically studied and established
a biomarker to trace and image the UM metastases in the liver. In the future, the pathological role
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of CXCR4 in UM metastases will be further studied and investigated. Multiple cancer
immunotherapies target CXCR4 are under investigation and proved to be beneficial for UM
metastases management. The CXCR4 molecular imaging will be beneficial for treatment planning
and effect monitoring of UM patients with liver metastases involvement.
CXCR4 imaging agents that able to detect cancers are previously reported by researchers.
Most of them are PET or SPECT agents. We are devoting in develop CXCR4 targeted MRI
contrast agent to achieve CXCR4 molecular imaging without radiation and better safety profile.
We successfully developed the CXCR4 targeted contrast agent ProCA32.CXCR4 for molecular
imaging with MRI. ProCA32.CXCR4 is expressed and purified with high yield. The metal binding
affinities, relaxivities, thermokinetic stability, transmetallation, and toxicity of ProCA32.CXCR4
are extensively studied and evaluated. ProCA32.CXCR4 has high gadolinium binding affinity,
good metal selectivity over physiologically present metal ions such as calcium and zinc. The good
gadolinium binding affinity and metal selectivity make ProCA32.CXCR4 a safe contrast agent for
translational usage. ProCA32.CXCR4 possess bulkier structure than the small chelator contrast
agents and inner-sphere water and outer sphere water that boost the relaxivities. Taken together,
ProCA32.CXCR4 is a safe MRI contrast agent with significantly improved relaxivity. CXCR4
targeting capability of ProCA32.CXCR4 is proved by immunofluorescence cell lines study and
indirect ELISA. ProCA32.CXCR4 possess significantly improved relaxivities and CXCR4
targeting capability, which enables imaging the small uveal melanoma metastases in mice livers
and showing heterogeneity enhancement of UM tumor lesions owing to the good permeability.
CXCR4 molecular imaging with ProCA32.CXCR4 significantly improved the current detection
limit for liver lesions (1-2 cm). With ProCA32.CXCR4 administration, metastatic UM lesions
range from 0.01 mm2 to 0.08 mm2 were enhanced and detected.
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Administration of ProCA32.CXCR4 achieved detection of liver metastases using
molecular dynamic contrast imaging by MRI. In the Mel290 murine model, intensity changes over
time exhibited different patterns in liver metastases than in adjacent liver tissue. Tumor region
intensity steadily increased up to 24 h after ProCA32.CXCR4 injection due to in vivo dynamic
binding to CXCR4, followed by a slow wash out after 24 h to 48 h. We measured a transient
increase (at 12 min) immediately after ProCA32 injection due to in vivo distribution, with
subsequent wash out after 3 h. Similar enhancement patterns were observed in the liver regions of
mice injected with both ProCA32.CXCR4 and ProCA32. This unique property of
ProCA32.CXCR4 provides a possibility of acquiring molecular dynamic contrast imaging using
MRI. MDCI provides an additional avenue to non-invasively differentiate tumors from healthy
livers by taking advantage of biomarker binding capabilities. In this study, we also demonstrated
ProCA32.CXCR4 exhibits excellent tumor permeability, which is very different from most
nanoparticles or chelator-based targeting contrast agents that mostly enhance the tumor boundary.
This property allows for mapping heterogeneous CXCR4 expression inside the tumor and may
facilitate monitoring of changes in CXCR4 expression through the tumor tissue during progression
and treatment.
The CXCR4 molecular imaging with MRI is successfully achieved with UM mice models.
In the future, ProCA32.CXCR4 is planned to be tested in the larger animals such as canine and
primate to verify the imaging capability and study the dosage upscale for human translational
usage. Pharmacokinetics study of ProCA32.CXCR4 is initiated and ProCA32.CXCR4 has a
relatively longer half-life and correspondingly longer imaging window. We are going to try
different modification/ PEGylation of ProCA32.CXCR4 to tune the PK/PD properties and tease
out the best way for post-expression modification protein-based MRI contrast agents. Currently,
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we are using lysine PEGylation (multiple sites) and cysteine PEGylation (single site) for
ProCA32.CXCR4

modification.

Both

lysine-PEGylated

and

cysteine-PEGylated

ProCA32.CXCR4 showed good imaging capability. Cysteine-PEGylated ProCA32.CXCR4 is
preferred for now because the site-specific property and homogenous PEGylated product meet the
industrial standard better. Other PEGylation approach for protein contrast agent modification is
ongoing. N-terminus PEGylation can be another approach for ProCA32.CXCR4 modification.
Besides the successful application of ProA32.CXCR4 in UM liver metastases detection.
We expanded our study on ProCA32.CXCR4 to the detection of primary liver cancer and treatment
effect monitoring. HCC is the most common primary liver cancer, and the development of HCC
is through a serious of biomedical incidences. Chronic liver diseases are major risk factors of HCC,
and the surveillance of chronic liver diseases including viral infection, alcoholic and non-alcoholic
fatty liver is highly suggested to monitoring the disease progresses. We tested the imaging
capability of ProCA32.CXCR4 in detecting HCC with a chemical-induced murine model
monitored the CXCR4 expression level changes followed by different treatment groups. The HCC
in the murine model is detected by the administration of ProCA32.CXCR4 and the CXCR4
molecular imaging by ProCA32.CXCR4 can assess the CXCR4 expression level changes. Thus,
the CXCR4 molecular imaging by ProCA32.CXCR4 can not only achieve cancer and metastases
detection in uveal melanoma but also HCC. The value of CXCR4 molecular imaging has been
proved in cancer detection and cancer treatment monitoring.
The tumor microenvironment is a complex environment supporting and facilitating tumor
growth. Angiogenesis and fibrosis are played critical roles in the development of cancers. We
developed contrast agents targeting other biomarkers such as collagen and integrin v3 for cancer
microenvironment imaging. We assessed the Non-PEGylated ProCA32.RGD in a breast cancer
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murine model and the imaging property proved to be dynamic. We observed that the SNR of tumor
regions increase to almost double within a one-hour time frame followed the ProCA32.RGD
administration. This result suggesting the earlier time points followed contrast agent
administration might of great imaging value. Instead of tracing longer time points after injection
as we did with PEGylated protein contrast agents, it could be another option to use non-PEGylated
protein-based contrast agents if the stability, solubility, and toxicity been thoroughly studied and
verified. Thus, one future direction of the protein contrast agent development will be assessing the
influence of different PEGylation on PK/PD property.
Protein-based MRI contrast agents are platform technique that highly transferable to design
and engineer versatile contrast agents. By engineering different targeting peptide into ProCAs, we
can design contrast agents targeting different biomarkers. CXCR4, HER2, EGFR, PSMA, and
collagen targeted contrast agent has been developed and well-studied. Other contrast agents that
targeting biomolecules that play an important role can be designed and develop in future research.
For example, checkpoints biomarkers such as PDL-1 can be good biomarker or imaging in the
future study.
Owing to the safety concern of gadolinium-based contrast agents, MRI contrast agents use
other paramagnetic metals such as manganese have been studied as an alternative of gadolinium.
Manganese is physiologically existing and possesses relatively high relaxivity. Mn-DPDP is a
manganese-based contrast agent approved in clinical usage for liver imaging. We explored the
possibility of developing a manganese-based protein MRI contrast agent in this dissertation. Mn2+ProCA32.CXCR4 was proved to be possess high relaxivity (r1 = 11.94 mM-1s-1, r2 = 142.79 mM1 -1

s , 7.0 T), even higher than Gd3+-ProCA32.CXCR4. The binding affinity of Mn2+ with

hProCA32.collagen1 was measured with competition assay and calculated as 1.13 × 10-20 M. To
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compare the gadolinium-based ProCA32.CXCR4 and manganese-based ProCA32.CXCR4, GdProCA32.CXCR4 has better r1 property and Mn-ProCA32.CXCR4 has better r2 property. These
preliminary data of manganese-based protein contrast agent is promising. In the future, we plan to
further characterize the manganese-based protein contrast agents and modify the metal binding
pockets of scaffold protein to accommodate better for manganese contrast agents.
One of the most challenging tasks of molecular imaging is to differentiate different cell
content. Take uveal melanoma imaging with ProCA32.CXCR4 as an example, CXCR4 has
expressed on the uveal melanoma cells as well as the T lymphocytes. If we can differentiate
CXCR4 from different cells, we can understand better the local tumor microenvironment. Proteinbased MRI contrast agents with different paramagnetic metals provide the possibility of
differentiating different biomarkers by quantitative assessment of concentrations of different
contrast agents. As described in chapter 8, the local concentration of two contrast agents target
different biomarkers can be calculated by the T1 and T2 relaxation time of the tissue. The technical
obstacle is how to acquire the T1 and T2 mapping that provides the T1 and T2 relaxation times at
the same time. The information must be collected in a time-sensitive assay that allows analyzing
the T1 and T2 relaxation times of same region simultaneously to calculate the local concentration
of different contrast agents corresponding to the biomarker distribution. Conventionally, collecting
T1 mapping and T2 mapping is time-consuming procedure. This technical barrier can be overcome
by magnetic resonance fingerprinting (MRF) approach. MRF acquisition is expected to collect
both T1 mapping and T2 mapping with a time-resolved, dictionary-matching fashion. Taking
advantage of MRF acquisition and protein contrast agents targeting different biomarkers that based
on different paramagnetic metals, we are expected to subtype different cell population, quantify,
and mapping the spatial distribution of different biomarkers.
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